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Abstract 
Streptococcus pyogenes (group A streptococcus, GAS) is an obligate human pathogen that 
causes a spectrum of pathologies ranging from superficial infections of the skin and 
oropharynx to severe invasive infections of the soft tissues. Despite a steady rise in the global 
rate of severe GAS disease over the past 30 years, there is currently no licenced vaccine 
available for the prevention of GAS infection. The initial stages of GAS pathogenesis are 
mediated by a repertoire of proteinaceous virulence factors expressed on the bacterial cell 
surface that facilitate colonisation and infection through specific interactions with the host 
extracellular matrix. These proteins are therefore predisposed to recognition by the host 
immune system, which in turn makes them important targets for the development of a novel 
subunit vaccine. The thesis describes the development of a novel approach to the isolation 
and identification of the major surface antigens of GAS using twenty GAS isolates 
representing four serotypes actively circulating within the United Kingdom (M1, M3, M12 
and M89). Antigens were purified by immunoprecipitation using an antibody formulation 
derived from the human clinical blood product IVIG which has been shown to protect against 
severe GAS infection both clinically and in vivo. This “enriched” (E-)IVIG was produced by 
affinity purification using a concentrated GAS cell wall protein fraction and was shown to 
promote neutrophil uptake in an ex vivo opsonophagocytosis assay, and impair dissemination 
of GAS from the nidus of infection in a murine model. A total of eight pan-serotype vaccine 
candidate antigens were identified by E-IVIG immunoprecipitation, seven of which were 
produced recombinantly for use in murine vaccination experiments. This novel approach to 
vaccine candidate identification could be applied to other gram positive pathogens including 
Staphylococcus aureus, and may have wider implications for the field of bacterial 
vaccinology as a whole. 
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1: Introduction 
1.1: The global burden of group A streptococcal disease 
In the western world, Streptococcus pyogenes (group A streptococcus, GAS) is renowned for 
causing outbreaks of tonsillitis and impetigo amongst school aged children and is often 
overlooked as a cause of serious or life-threatening human disease. In reality however GAS is 
responsible for a wide spectrum of disease phenotypes and autoimmune sequelae that often 
stem from these inherently occult infections of the skin and oropharynx (Figure 1.1). 
Notwithstanding marked improvements in hospital sanitation and obstetric care, outbreaks of 
peripartum sepsis remain a leading cause of maternal death within the United Kingdom, 
while acute rheumatic fever continues to be a significant cause of morbidity and mortality 
amongst children and young adults in low income countries (Steer et al., 2009b, Ralph and 
Carapetis, 2013, Turner et al., 2013, Chuang et al., 2002). In addition, despite the continued 
susceptibility of GAS to beta lactam antibiotics, there has been an unexplained resurgence of 
community acquired invasive (i)GAS infections in the UK over the past 30 years. This 
resurgence has tentatively been attributed to the reappearance and/or increased circulation of 
a highly invasive clone of M1T1 GAS, and highlights the need for increased surveillance of 
GAS in the community and more targeted treatments of iGAS disease in a clinical setting 
(Sumby et al., 2005). Above all, the development of a safe, effective GAS vaccine would 
prove invaluable. 
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Figure 1.1: The most common manifestation of group A streptococcal infection .  
Adapted from Ralph and Carapetis 2013.  
1.2: Identification and typing of GAS isolates 
GAS is an obligate human pathogen of the phylum Firmicutes that is primarily transmitted by 
direct person-to-person contact or aerosol spread (Ralph and Carapetis, 2013). In a clinical 
setting, a presumptive identification of GAS is routinely recorded following the formation of 
beta haemolytic, bacitracin sensitive colonies on 5% blood agar plates (Cunningham, 2000). 
If necessary, the organism can be differentiated from other pathogenic streptococci 
serologically using commercially available grouping kits that recognise species specific 
Lancefield antigens present on the streptococcal cell surface (Cunningham, 2000). The “type 
A” antigen of GAS is a highly conserved polysaccharide that is uniquely composed of N-β-
D-acetylglucosamine coupled to a poly-rhamnose backbone (Slade and Slamp, 1962, Krause 
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and McCarty, 1961).  Historically, GAS isolates have been subdivided into serological M 
types based upon the variable antigenic properties of the major surface M protein (discussed 
in detail below) (Lancefield, 1928, Facklam et al., 2002). Contemporary GAS isolates are 
typed genealogically following sequencing of the hypervariable N terminal region of the M 
protein gene (denoted emm typing). This region encodes the heterogeneous N-terminus of the 
mature protein, which broadly appears to provide the basis for differentiating the classical M 
serotypes (Beall et al., 1996).  
1.3: The epidemiology of invasive GAS infection 
The frequency and distribution of the different GAS serotypes varies greatly between 
geographical regions, and the epidemiology of GAS disease in the developed world is vastly 
different from that reported in low resource settings (Steer et al., 2009b). A recent global 
review of GAS epidemiology revealed that 25 distinct emm types accounted for >90% of all 
GAS disease in Europe, North America, Australia, New Zealand and Japan, whilst in 
resource poor settings a much wider diversity of sequence types were reported, none of which 
were overtly dominant (Steer et al., 2009b).  In Europe, the ten most prominent emm types 
(emm1, 3, 4, 5, 12, 28, 81, 83, 87 and 89) purportedly account for >70% of all iGAS 
infections with types 1, 3 and 28 together accounting for approximately one third of all 
reported cases (Figure 1.2A) (Luca-Harari et al., 2009, Schmitz et al., 2003).  
 
Although emm83 and emm87 appeared within the ten most frequently recovered sequence 
types in Europe, the authors noted that the vast majority of the isolates recovered (90% and 
93% respectively) originated from the United Kingdom (Luca-Harari et al., 2009). While 
little UK data exists regarding the frequency of these emm types, one hospital based study has 
reported a high frequency of emm83 recovery amongst injection drug users presenting to one 
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Brighton hospital (Curtis et al., 2007). The authors also reported an unexpectedly high 
prevalence of emm89 recovery in association with invasive bacteraemia in non-drug users, 
suggesting that this sequence type is particularly prevalent within the south east of England. 
This finding is supported by unpublished data from our group showing that emm89 accounted 
for 13% of invasive GAS infections encountered at Hammersmith Hospital between April 
and November 2009, making it the third most common cause of iGAS infection after emm1 
and emm3 (Figure 1.2C). Together, these data suggest that the epidemiology of UK GAS 
disease differs markedly from the rest of Europe. While emm1 and emm3 remain the most 
prevalent causes of sterile site infections, the available data suggests that emm83, emm87and 
emm89 isolates are overrepresented amongst British iGAS cases. 
 
Although no GAS serotype can be uniquely associated with a particular disease outcome, a 
correlation between certain invasive manifestations and a small number of specific M types 
has long been reported (Lamagni et al., 2008, O'Loughlin et al., 2007). The most striking of 
these is the propensity of emm1 and emm3 isolates to cause a clinical syndrome analogous to 
the toxic shock syndrome induced by Staphylococcus aureus, denoted streptococcal toxic 
shock syndrome (STSS, discussed in detail below). Together emm1 and emm3 account for 
>50% of all European STSS cases which normally occur in association with invasive 
infection of the soft tissue (Figure 1.2B). Initially this propensity was widely attributed to the 
presence of phage encoded superantigens (most notably speA and speC) within the accessory 
genome of these two serotypes (Llewelyn and Cohen, 2002, Rantala et al., 2012, Luca-Harari 
et al., 2009). However, several recent studies have suggested that accessory superantigen 
production alone is insufficient to stimulate the symptoms of STSS (Turner et al., 2012, 
Sriskandan et al., 1999, Muller-Alouf et al., 2001).  
5 
 
 
 
Figure 1.2: The epidemiology of invasive GAS infection.  A) The ten most common 
serotypes associated with European iGAS infection (between 2003 and 2004) and B) 
the most common disease manifestations with which they are associated. The vast 
majority of emm87 and emm83 isolates recovered (93% and 90% respectively) 
originated from the United Kingdom. The charts were produced using data from  Laming 
et al 2008. C) Unpublished data from our group showing the most common serotypes 
associated with superficial (Red) and invasive (Blue) GAS infections identif ied within 
the Imperial College Healthcare Trust between April and November 2009. A much 
higher than average frequency of emm12 and emm89 isolates was recovered compared 
to the available Europe wide data.  
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The propensity of emm28 isolates to cause outbreaks of peripartum sepsis and other female 
urogenital tract infections is also widely documented, with rates exceeding 30% in some 
studies (Ben Zakour et al., 2012, Luca-Harari et al., 2009, Plainvert et al., 2012). This 
propensity has tentatively been attributed to the acquisition of a 37 kilobase (kb) mobile 
genetic element (MGE) denoted 6180-RD2 from group B streptococcus (GBS), a leading 
cause of maternal neonatal infections worldwide (Green et al., 2005, Sitkiewicz et al., 2011). 
The 6180-RD2 MGE contains seven putative extracellular virulence factors including the cell 
wall adhesin RD2 which has been shown to mediate GBS adhesion to human vaginal 
epithelial cells (Stalhammar-Carlemalm et al., 1999, Green et al., 2005, Sitkiewicz et al., 
2011). It is therefore conceivable that the acquisition of 6180-RD2 provides emm28 isolates 
with a selective advantage during GAS colonization of the urogenital tract. 
1.4: The pathophysiology of invasive GAS infection 
1.4.1: Transmission 
GAS is an obligate human pathogen with no known environmental reservoir that primarily 
disseminates via discharged respiratory droplets or direct skin-skin contact. In low resource 
settings, the characteristic pustules associated with streptococcal impetigo readily facilitate 
person-person spread if not controlled at a primordial level through stringent attention to 
hygiene and improvement of medical infrastructure (Ralph and Carapetis, 2013, Stulberg et 
al., 2002, Wasserzug et al., 2009). In regions where endemic impetigo is less common, 
clandestine infection of the oropharynx remains a well-documented occurrence with some 
studies reporting GAS carriage rates of 15-20% among school aged children (Ralph and 
Carapetis, 2013, Bessen, 2009, Yagupsky et al., 1995). These persistent carriers represent an 
important reservoir for the spread of GAS infection in a community setting especially in areas 
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of frequent overcrowding such as prisons, schools and military facilities (Wannamaker, 1954, 
Levy et al., 2003a, Cunningham, 2000) 
 
1.4.2: Pharyngitis and acute rheumatic fever 
Acute pharyngitis is one of the most frequent conditions for which primary care physicians 
are consulted. While only ~20-30% of cases can be attributed to GAS infection the economic 
cost of streptococcal pharyngitis annually is estimated in the hundreds of millions (Shulman 
et al., 2012). The classical symptoms of GAS pharyngitis are largely immune mediated and 
include fever and painful inflammation, while involvement of the palatine tonsils (tonsillitis) 
is characterised by enlargement of the lymph nodes and the production of a suppurative 
exudate (Shulman et al., 2012).  
 
In addition to the economic implications of GAS pharyngitis, the condition is associated with 
seasonal outbreaks of acute rheumatic fever (ARF), an immune mediated sequel of long-term 
GAS infection that primarily affects the joints and cardiac tissues (Barash, 2013). In its most 
severe form, ARF can cause aggressive inflammation of the myocardium and heart valves 
resulting in first degree heart block and congestive heart failure (Barash, 2013). Although 
individual cases of ARF can be avoided through the timely administration of antimicrobial 
chemotherapy, this “primary prevention” is not an effective means of controlling the 
condition at the population level and the disease remains endemic in many regions of the 
developing world (Bisno et al., 2005). 
 
While the pathophysiology of ARF remains poorly understood, the characteristic 
inflammation is thought to result from the generation of human cross-reactive antibodies 
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during adaptive immune clearance of the invading organism (Cunningham, 2012, Barash, 
2013). The M protein in particular has been shown to stimulate a myosin-reactive 
autoantibody response owing to the shared alpha helical structure of the two molecules 
(Cunningham, 2012, Quinn et al., 1998, McNamara et al., 2008). This proposed cross-
reactivity prompted fears that M protein based vaccinations may inadvertently precipitate 
ARF, causing a paradigm shift in the field of GAS vaccinology that was historically 
dominated by M protein based approaches (discussed in detail below).  
 
In addition to the M protein, recognition of the group A carbohydrate (GAcar) has also been 
attributed to the generation of human cross-reactive antibodies. Indeed, anti-GAcar antibodies 
derived from rheumatic carditis patients have been shown to cross react with human cardiac 
myosin and valvular laminin (Cunningham, 2012). This data is in keeping with the historical 
observation that rheumatic carditis patients often present with high circulating anti-GAcar 
antibody titres that persist in those with a poor prognosis (Dudding and Ayoub, 1968). 
Importantly however, the lack of an appropriate animal model for ARF, and the inability to 
obtain a homogeneous preparation of GAcar has prevented rigorous evaluation of this 
hypothesis in vivo (Kabanova et al., 2010).  The contribution of anti GAcar antibody to the 
pathogenesis of ARF therefore remains contentious.  
 
1.4.3: Invasive GAS infections 
Invasive GAS infections are defined by the spread of the organism from the initial nidus of 
superficial infection into the deeper host tissues. Such infections are usually associated with 
the soft tissue of the skin, and can result in the development of a spectrum of clinical 
conditions including ecthyma (also known as deep impetigo), cellulitis and necrotising 
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fasciitis. First line treatment for iGAS skin infection is usually oral or parenteral penicillin 
treatment given in concert with an appropriate anti-staphylococcal agent such as 
flucloxacillin where coinfection is considered likely (Gunderson and Martinello, 2012, 
Stulberg et al., 2002) (Table 1.1). In the case of necrotising fasciitis the depth of soft tissue 
involvement usually necessitates drainage or surgical debridement of the afflicted region 
(Bisno and Stevens, 1996). In addition, the purported correlation between soft tissue disease 
and the onset of STSS often necessitates the administration of adjunct antimicrobials such as 
clindamycin and IVIG treatment to control the systemic inflammatory symptoms of the 
underlying iGAS infection (discussed in detail below) (Kaul et al., 1999, Sriskandan et al., 
2006). 
 
Table 1.1: The clinical manifestations of iGAS soft tissue infections. 
Abbreviations: S.C. Sub cutaneous, WBC white blood cell, CRP C-reactive protein, SA 
Staphylococcus aureus .  
 
Condition 
Depth of t issue  
involvement 
Symptoms Treatment 
    
Ecthyma 
(Deep 
impetigo) 
Dermis Painful ulceration Topical 
mupirocin/fusidic acid 
(Localised ulceration)  
Penicil l in + anti-SA 
agent (Systemic 
ulceration) 
    
Cellulit is  Dermis 
S.C. t issue 
Dermal inflammation 
Fever  
Elevated WBC and CRP 
Erythematous welts 
(Erysipelas) 
Penicil l in + anti-SA 
agent 
    
Necrotising 
fasciit is 
Dermis 
S.C. t issue 
Fat 
Fascia 
Diffuse swelling of the 
extremities  
Violaceous fluid f i l led 
bullae 
Pain disproportionate to 
visible injury 
Antimicrobial 
chemotherapy 
Surgical debridement 
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1.4.4: Sepsis and streptococcal toxic shock syndrome 
Sepsis is a fatal inflammatory condition that is triggered in response to a wide range of 
bacterial, viral and fungal pathogens. The symptoms of sepsis are largely immune mediated 
and result from a massive overproduction of pro-inflammatory cytokines in response to a 
severe systemic infection. Initially the condition presents as a series of non-focal symptoms 
including (but not limited too) fever, chills malaise nausea and vomiting. However, if the 
underlying infection remains untreated, the associated inflammation will progress rapidly; 
resulting in reduced organ perfusion, clotting abnormalities and respiratory distress 
(Reglinski and Sriskandan, 2013, Levy et al., 2003b). The ultimate onset of septic shock is 
characterised by a profound drop in arterial blood pressure, and precedes multi organ failure 
(Levy et al., 2003b, Breiman et al., 1993).  
 
Streptococcal toxic shock syndrome (STSS) is clinically defined by a number of criteria that 
largely mirror those that define severe sepsis; coupled with evidence of an ongoing iGAS 
infection (Breiman et al., 1993, Levy et al., 2003b). However, while the systemic 
inflammation associated with severe sepsis occurs transiently in response to a fulminant 
microbial infection, STSS is actively induced through the production of one or more 
superantigenic toxins (Lappin and Ferguson, 2009). These superantigens (SAgs) induce 
systemic inflammation through the non-specific activation of host T-cells, which results in an 
incongruous release of pro-inflammatory cytokines (Murphy et al., 2008). This initial burst of 
cytokines triggers a feedback loop between cytokine release and immune cell activation that 
amplifies exponentially to precipitate the pathophysiological symptoms of streptococcal 
sepsis (Murphy et al., 2008, Lappin and Ferguson, 2009).  
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STSS complicates a reported 10-16% of all iGAS infections and has a case fatality rate 
(CFR) of 35-45% (O'Loughlin et al., 2007, Lamagni et al., 2008). The high CFR associated 
with streptococcal sepsis notwithstanding antimicrobial chemotherapy has prompted many 
clinicians to seek alternative treatments for STSS that go beyond the supportive care 
normally employed upon ICU admission. The observed protection afforded by a strong 
humoral immune response targeted against the SAgs has prompted the adoption of adjunct 
intravenous immunoglobulin G (IVIG) therapy in some institutions however; the benefits of 
this regimen remain controversial (discussed in detail below) (Shah et al., 2009, Norrby-
Teglund et al., 1994, Kaul et al., 1999).  
1.5: The immune response to GAS infection 
1.5.1: Epithelial immunity 
Attachment of GAS to pharyngeal and dermal epithelial cells is the definitive first step 
towards colonisation of a new host. Adherence is a two-step process that requires the 
transmitted bacteria to overcome the natural electrostatic repulsion of the host cell surface 
and form covalent binding interactions with a variety of epithelial cell surface ligands 
(discussed in detail below) (Courtney et al., 2000, Cunningham, 2000). These covalent 
interactions allow the bacteria to resist the mechanical removal that would otherwise occur 
via salivary flow and exfoliation at the superficial nidi of infection (Cunningham, 2000).  
Owing to the narrow range of ecological niches occupied by GAS, a significant degree of 
passive immunity to iGAS infection is afforded by the epithelial barriers of the skin and 
oropharynx. In addition to forming a passive mechanical barrier, the epithelial layer secretes 
a plethora of antimicrobial molecules involved in pathogen recognition, cell-cell signalling 
and bacterial killing (Dale and Fredericks, 2005, Yamasaki and Gallo, 2008). Of particular 
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relevance is the cathelicidin LL-37 which has been shown to be expressed in both anatomical 
locations and to inhibit growth of GAS during colonisation of the cutaneous epithelium 
(Dorschner et al., 2001, Yamasaki and Gallo, 2008, Dale and Fredericks, 2005). Cathelicidin 
(CRAMP) deficient mice have been shown to be more susceptible to iGAS infection than 
their wild type counterparts, indicating a potential role for this class of molecule in containing 
GAS infection to the superficial layers of the epithelium (Nizet et al., 2001). GAS is now 
known to produce at least two proteins that are capable of degrading LL-37 (SpeB and the 
streptococcal inhibitor of complement) suggesting that inactivation of this molecule is 
fundamental during the establishment of iGAS soft tissue infections (Frick et al., 2003, 
Schmidtchen et al., 2002, Johansson et al., 2008). 
 
1.5.2: Innate immunity  
Once the epithelial barrier has been breached, clearance of the infecting GAS population is 
primarily facilitated by cell-mediated immunity. More specifically, clearance of GAS occurs 
following recruitment of phagocytic cells to the site of infection and subsequent destruction 
of the invading cocci by opsonophagocytosis. Early recognition of GAS is facilitated by toll 
like receptor (TLR)-2 signalling which is triggered in response to a number of molecular 
agonists (Gao et al., 2008, Akira and Takeda, 2004). The molecular agonists recognised by 
TLR-2 include the major gram positive cell wall component lipoteichoic acid and several 
members of the bacterial lipoprotein superfamily (discussed in detail below) (Gao et al., 
2008, Akira and Takeda, 2004, Nakayama et al., 2012). Early recognition of GAS may also 
occur following detection of peptidoglycan derived muramyl dipeptide moieties by the 
intracellular pattern recognition receptor (PRR) NOD2 (Travassos et al., 2004). While early 
recognition of GAS is essential for efficient clearance of the invading organism, the targeted 
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release of proinflammatory cytokines and phagocyte chemoattractants which results from 
TLR-2/NOD2 activation also drives the early symptoms of sepsis prior to incongruous 
activation of the adaptive immune response by the streptococcal superantigens (Travassos et 
al., 2004, Fritz et al., 2006, Harter et al., 2004, Armstrong et al., 2004).  
 
In addition to the phagocyte recruitment stimulated by PRR recognition, dissemination of 
GAS from the superficial nidus of infection also triggers activation of the alternative 
complement cascade. Alternative complement activation ultimately results in the formation 
of C3 convertase, an enzyme that splits the plasma protein C3 into two fragments denoted 
C3a and C3b (Murphy et al., 2008). The soluble peptide opsonin C3b is the main effector of 
the complement system and targets the invading bacteria for destruction upon binding to the 
cell surface (Murphy et al., 2008). Bacterial clearance is facilitated by recognition of 
pathogen associated C3b by C3b receptors present on the phagocyte cell surface, which 
promote binding, uptake and ultimate destruction of the invading organism. (Murphy et al., 
2008, Playfair, 2004). Critically the alternative complement pathway does not require 
functional antibody in order to promote efficient opsonisation of the invading organism and 
therefore plays an important role in GAS clearance prior to adaptive immune recognition 
(Murphy et al., 2008). In order to contend with the powerful complement mediated arm of the 
innate immune response, GAS has evolved a number of exoenzymes that sequester and/or 
degrade the soluble components of the complement cascade (Figure 1.3). 
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Figure 1.3: Streptococcal modulation of the classical complement cascade.  GAS is 
capable of preventing complement mediated opsonophagocytosis obstructing the early 
events of the cascade (purple); and degrading or inactivating the major complement 
opsonin C3b (blue). In addition, several exoproteins have been shown to abrogate the 
activity of the soluble peptide mediators of inflammation (red) and inhibit formation of 
the terminal membrane attack complex (MAC, green).  
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1.5.3: Humoral immunity  
While the clearance of superficial GAS infections is primarily mediated by complement 
mediated opsonophagocytosis, resolution of iGAS infections often requires the induction of 
an anti-streptococcal humoral immune response. Surface antibody deposition facilitates 
recognition and uptake of GAS via phagocyte Fc receptors, and through activation of the 
classical complement cascade where C3 convertase is formed following binding of the ‘early’ 
complement proteins to surface associated antibody-antigen complexes (Murphy et al., 2008, 
Sanders et al., 1995, Aderem and Underhill, 1999).  
 
In addition to promoting phagocytic uptake, humoral immunity has been shown to obstruct 
iGAS infection by preventing ECM protein binding, and neutralising the activity of the 
secreted streptococcal exotoxins (Cleary et al., 2004, Kapur et al., 1994, Ulrich, 2008). 
Indeed, infection of rabbits with SpeA producing GAS isolates results in the generation of a 
strong anti-SAg humoral immune response while direct immunisation with SpeA protects 
against iGAS infection through the induction of toxin neutralising antibodies (Knoll et al., 
1985, Knoll et al., 1988). Clinically, sera from iGAS patients reportedly have lower 
neutralising antibody titres than those from uncomplicated pharyngitis cases, suggesting that 
the generation of a strong humoral immune response correlates with protection against iGAS 
disease (Lancefield, 1962, Holm et al., 1992, Norrby-Teglund et al., 1994). Taken together 
these data suggests that efficient priming of the humoral immune response is paramount for 
the prevention and/or resolution of iGAS infection and thus is the definitive requirement of 
any prototype anti-streptococcal vaccine formulation.  
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1.6: IVIG as an adjunct treatment for invasive GAS infection  
1.6.1: Clinical evaluation of IVIG as an adjunct treatment for invasive GAS infection 
Intravenous immunoglobulin G (IVIG) is a purified preparation of polyclonal 
immunoglobulin G that is synthesised from pools of >3000 healthy blood donations (Seite et 
al., 2008). While IVIG is primarily used as a replacement therapy for congenital γ-globulin 
deficiencies, the reagent contains specific antibodies to many pathogenic microorganisms that 
are prevalent within the population and thus is also indicated as a prophylactic treatment for 
several infectious conditions including hepatitis A and measles (Keller and Stiehm, 2000). As 
with the majority therapeutic blood components, IVIG is initially purified by cold ethanol 
precipitation, a method of separating blood plasma into six distinct protein fractions (Cohn 
fractions I-VI) by altering the pH, ionic strength, ethanol content and temperature of the 
starting preparation (Cohn et al., 1944, Menegatti et al., 2012). The reagent is further purified 
by ion exchange chromatography and nanofiltration resulting in a final preparation containing 
90-98% immunoglobulin G (Seite et al., 2008). Although IVIG is obtained from the plasma 
of healthy donors who are pre-screened for the most prevalent blood borne pathogens (e.g. 
HIV and hepatitis B& C), the reagent is routinely subjected to one or more proprietary virus 
inactivation treatments during purification (Seite et al., 2008). These measures are required to 
ensure that the product is free of less common infectious agents such as other hepatitis 
viruses, TT virus and prions which cannot be easily screened for (Seite et al., 2008). 
 
By the early 1990s, the observed protection afforded by a strong humoral immune response 
had led several authors to investigate the effectiveness of IVIG as an adjunct treatment for 
iGAS infection. IVIG had previously been shown to promote opsonophagocytic killing of 
GBS in vitro and to provide passive protection against experimentally induced GBS infection 
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in new born rats (Givner et al., 1985, Miller et al., 1990, Iguchi and Inoue, 1994). In addition, 
IVIG administration had been shown to inhibit staphylococcal SAg mediated T cell 
proliferation, suggesting that the preparation may contain the toxin neutralising antibodies 
necessary for prevention of STSS (Takei et al., 1993).  
 
The publication of several independent case reports indicating that IVIG administration 
correlated with clinical improvement in STSS cases prompted Kaul and colleagues to conduct 
the first comparative observation study into the therapeutic benefits of IVIG administration in 
the treatment of iGAS infection (Kaul et al., 1999, Norrby-Teglund et al., 1996, Barry et al., 
1992, Lamothe et al., 1995). Twenty one STSS patients were treated with a median dose of 2 
g/kg of IVIG in conjunction with a standard does of clindamycin. The 30 day survival of 
these patients was compared to that of a historical control group comprising 32 STSS cases 
who received antimicrobial chemotherapy alone (Kaul et al., 1999). In addition, plasma 
samples were collected from twelve of the enrolled patients before and after IVIG 
administration, and analysed for toxin neutralising activity in vitro (Kaul et al., 1999, Norrby-
Teglund et al., 1996).  
 
The study determined that adjunct IVIG therapy resulted in a significant increase in the 
percentage of patients surviving past thirty days when compared to antimicrobial therapy 
alone (Norrby-Teglund et al., 1996). In addition, post-IVIG plasma was shown to inhibit 
cytokine production by peripheral blood mononuclear cell following incubation with either 
the causative GAS isolate, or one of two purified streptococcal superantigens (SpeA and 
SpeC) (Norrby-Teglund et al., 1996). The ability of patient serum to promote 
opsonophagocytic uptake of M1 GAS also increased markedly following IVIG 
administration, and this increase was attributed to the presence of a detectable amount of 
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polyclonal anti-M1 antibody within the starting IVIG preparation (Basma et al., 1998). 
Together these data suggested that IVIG therapy was an effective adjunct treatment for STSS, 
and conferred some of the protection afforded by a strong, circulating humoral immune 
response. The observed protection most likely resulted from the presence of a detectable 
concentration of polyclonal anti-GAS IgG within the administered reagent; that was targeted 
against the streptococcal SAgs and the M1 protein.  
 
The therapeutic benefits of IVIG have since been evaluated in a randomised, placebo 
controlled trial involving 21 patients, ten of whom received IVIG in conjunction with 
standard antimicrobial therapy (Darenberg et al., 2003). While this trial was prematurely 
terminated due to poor patient recruitment, the available data broadly supported the finding of 
the earlier observational study. On days two and three post-administration, patients receiving 
adjunct IVIG showed reduced organ impairment compared to placebo controls receiving 
antimicrobial therapy alone, suggesting that the reagent was capable of inhibiting the 
characteristic organ dysfunction associated with streptococcal sepsis (Darenberg et al., 2003). 
Furthermore, the toxin neutralising activity of patient plasma was shown to increase post-
infusion, again suggesting that IVIG contains a functional titre of anti-SAg IgG that may 
inhibit incongruous T cell activation. Importantly, while no statistically significant difference 
in primary end point was reported, the 28 day mortality rate in the placebo group was 3.6 fold 
higher than in the treatment group, suggesting that, if the target 120 patients had successfully 
been enrolled , the result may ultimately have favoured adjunct IVIG administration 
(Darenberg et al., 2003). 
 
Despite these initial promising findings, opinions remain divided on the benefits of IVIG 
therapy during iGAS infection. It has been noted that the use of historical control subjects, 
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and the associated differences in antibiotic treatment regimens, invalidates most of the 
conclusions drawn from initial study (Johansson et al., 2010). Indeed, two additional studies 
have since failed to find a statistically significant link between IVIG administration and 
improved clinical outcome, with one group highlighting the significant increase in cost 
associated with adjunct IVIG therapy (Mehta et al., 2006, Shah et al., 2009). Regardless of 
the direct clinical benefit of IVIG administration it is apparent that the reagent is capable of 
neutralising the activity of the streptococcal superantigens and of facilitating 
opsonophagocytosis of GAS through recognition of the M protein. It is also likely that IVIG 
recognises an additional, as yet uncharacterised, repertoire of streptococcal surface antigens 
that facilitate further antibody deposition and bacterial uptake (discussed in detail below). 
 
1.6.2: Evaluation of IVIG therapy in vivo 
In addition to the clinical studies outlined above, the benefits of IVIG administration for the 
treatment of iGAS infection have also been assessed in a murine model. Initially, Patel and 
colleagues reported that treatment with IVIG did not promote clearance of GAS from an 
intramuscular nidus of infection, and thus concluded that administration of the reagent 
provided little benefit to iGAS patients (Patel et al., 2000). While murine models of GAS 
disease are well-established and have previously been used to study alternative antimicrobial 
treatment regimes, the inherent resistance of wild type mice to the pro-inflammatory effects 
of the streptococcal SAgs may limit the effectiveness of IVIG treatment on experimental 
iGAS infections (Sriskandan et al., 2006, Sriskandan et al., 2001).  
 
In order to explore this hypothesis, Sriskandan and colleagues employed a humanised 
transgenic mouse model of streptococcal sepsis (Sriskandan et al., 2001). The mice selected 
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express human MHC class II molecules and are thus highly responsive to the streptococcal 
SAgs (Sriskandan et al., 2001, Sriskandan et al., 2006). In this setting, IVIG administration 
was shown to simultaneously reduce the systemic inflammation associated with SAg 
production, and promote opsonophagocytic clearance of GAS from an intramuscular nidus of 
infection (Sriskandan et al., 2006).  
 
While opsonophagocytic clearance was primarily facilitated by surface antibody deposition, a 
concomitant increase in neutrophil recruitment was also reported. This suggests that, in 
addition to the streptococcal SAgs, IVIG is capable of neutralisation one or more 
immunomodulatory GAS virulence factors that are designed to inhibit phagocyte recruitment 
to the nidus of infection (for example C5a peptidase and SpyCEP) (Sriskandan et al., 2006). 
In addition, this finding supports the earlier hypothesis that IVIG recognises a more diverse 
repertoire of streptococcal surface antigens than was initially reported by Basma and 
colleagues (Basma et al., 1998). Thus while opinions regarding the benefits of clinical IVIG 
administration remain divided, the available data strongly suggests that the reagent is capable 
of reducing the systemic inflammation associated with streptococcal sepsis, while promoting 
bacterial clearance from the nidus of infection. The repertoire of streptococcal surface 
antigens recognised by IVIG has not yet been fully characterised, and such data may prove 
invaluable for the development of novel, serological treatment regimens for iGAS infection 
and STSS.  
1.7: The structure and function of the streptococcal surface antigens 
1.7.1: Microbial surface components recognising adhesive matrix molecules  
The propensity of GAS to cause a diverse range of human infections is facilitated by an 
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impressive repertoire of over 40 secreted and surface expressed virulence factors. These 
proteins are primarily designed to promote colonisation, persistence at the nidus of infection 
and subsequent invasion of the deeper host tissues. Like many gram positive pathogens, 
primary GAS adherence is facilitated by a repertoire of proteins that belong to the microbial 
surface components recognising adhesive matrix molecules (MSCRAMM) superfamily. 
These molecules facilitate host colonization by forming covalent interactions with a variety 
ECM proteins including (but not limited to) fibronectin, fibrinogen, collagen, laminin and 
cytokeratin (Foster and Hook, 1998, Courtney et al., 2002b). Owing to their importance 
during primary colonization, MSCRAMM molecules represent frequent targets of the host 
immune response, and thus are often highlighted as promising vaccine candidate antigens 
(Foster and Hook, 1998, Roche et al., 2003, Guzman et al., 1999, Terao et al., 2005).  
 
Upon translation, mature MSCRAMM molecules are flanked by a long N terminal signal 
sequence required for a Sec-dependent protein secretion and a distinctive C terminal anchor 
peptide that facilitates covalent attachment to the gram positive cell wall (Roche et al., 2003, 
Courtney et al., 2002b). Anchor peptide cleavage is facilitated by one of three sortase 
enzymes which recognise the LPXTG (SrtA and SrtB) or QVPTG (SrtC) motifs, and cross 
link the mature protein into the peptidoglycan of the growing cell wall. Following post 
translational processing, mature MSCRAMM molecules comprise a modular central domain 
that facilitates ECM binding , followed by a hydrophobic membrane spanning domain that 
terminates in the cleaved C-terminal anchor (Figure 1.4) (Foster and Hook, 1998, Barnett et 
al., 2004). The GAS genome encodes at least 20 MSCRAMM molecules many of which are 
capable of interacting with multiple ECM proteins (Table 1.2).  
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Figure 1.4: The structure and domain organisation of the streptococcal 
fibronectin binding proteins.  Fibronectin binding is facil itated by a series of peptide 
repeats (tan) that vary in number between proteins. In some cases a second Fn -binding 
domain is located directly upstream of this  C-repeat region (green). Fibronectin binding 
proteins traff ic to the cell surface via a Sec-dependant signal sequence (grey) where it 
is covalently anchored to the peptidoglycan cell wall via the LPXTG motif (black). 
Ancil lary binding domains are indicated by overbars.  
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Table 1.2: The ligand binding affinities of the streptococcal fibronectin binding 
proteins. 
 
Protein Anchor Ligand Reference 
    
FbaA LPXTG Epithel ial cel ls  (Pandiripal ly et al. ,  2003)  
  Fibronect in  (Terao et al. ,  2001)  
  FHL-1 (Pandiripal ly et al. ,  2003)  
    
Fbp54 Anchorless Fibrinogen (Courtney et al. ,  1994)  
  Fibronect in  (Courtney et al. ,  1994)  
    
PrtF1 LPXTG Epithel ial cel ls  (Rohde et al. ,  2011)  
  Fibrinogen (Katerov et al. ,  1998)  
  Fibronect in  (Hanski and Caparon, 1992)  
(Ozeri et al. ,  1996)  
    
PrtF2 LPXTG Endothel ial 
cel ls  
(Amelung et al. ,  2011)  
  Fibronect in  (Jaffe et al. ,  1996)  
(Ramachandran et al. ,  2004)  
    
SfbX LPXTG Fibronect in  (Jeng et al. ,  2003)  
    
SOF LPXTG Epithel ial cel ls  (Oehmcke et al. ,  2004)  
  Fibrinogen (Courtney et al. ,  2002a)  
  Fibronect in  (Rakonjac et al. ,  1995)  
(Kreikemeyer et al. ,  1999)  
  Fibul in-1 (Courtney et al. ,  2009)  
    
 
In addition to adhesion, the GAS MSCRAMMs are instrumental to a number of bacterial 
immune evasion strategies which are often orchestrated through ECM-protein binding. 
Fibrinogen binding for example has been shown to arrest complement mediated 
opsonophagocytosis by inhibiting surface C3 deposition and recognition of GAS by 
phagocyte C3b receptors (Pandiripally et al., 2002). In addition, sequestration of the 
complement regulatory proteins FHL-1 and C4BP by streptococcal MSCRAMMs has been 
shown to result in incongruous deactivation of the complement cascade prior to phagocyte 
recognition of GAS (Smeesters et al., 2010, Murphy et al., 2008, Friese et al., 1999, Katerov 
et al., 1998, Johnsson et al., 1996). MSCRAMM molecules have also been shown to facilitate 
invasion of epithelial and endothelial cells promoting both bacterial persistence in the face of 
immune clearance, and invasion of the deeper host tissues. Fibronectin binding in particular 
has been shown to mediate epithelial cell invasion through the activation of host cell integrins 
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which results in phagocytic uptake of the fibrinogen molecule, and the attached bacterial cell 
(Schwarz-Linek et al., 2006, Greco et al., 1995). Therefore in addition to promoting direct 
opsonophagocytic clearance of GAS, humoral immune recognition of the streptococcal 
MSCRAMMs may also inhibit primary GAS colonization and prevent evasion of the innate 
immune response.  
 
1.7.2: The lipoproteins 
The lipoproteins are a family of cell surface associated proteins that are heavily modified to 
allow direct covalent attachment to the hydrophobic phospholipid bilayer. As part of the ABC 
transporter system superfamily, the lipoproteins participate in a variety of normal cell 
functions including nutrient acquisition, osmoregulation and the exportation of proteins 
lacking a Sec dependent signal sequence (Liu and Lei, 2005, Kovacs-Simon et al., 2011, van 
Belkum et al., 1997, Hoffmann et al., 2013). The streptococcal lipoproteins are particularly 
important for the acquisition of peptides as the organism is auxotrophic for at least half of the 
amino acids it requires for growth (Davies et al., 1965, Podbielski and Leonard, 1998). Amid 
fulminant infection, the lipoproteins have been shown to facilitate a wide range pathogenic 
functions including ECM protein binding, immunomodulation and antibiotic resistance 
(Kovacs-Simon et al., 2011, Terao et al., 2002, Elsner et al., 2002, Lampen and Nielsen, 
1984). In GAS, the lipoproteins have been shown to mediate laminin binding and epithelial 
cell adherence, suggesting a role for these proteins during primary colonisation of the host 
epithelium (Table 1.2) (Terao et al., 2002, Wahid et al., 2005). 
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Table 1.3: The ligand binding affinities of the streptococcal lipoproteins  
 
Protein Anchor Ligand Reference 
    
Lbp [LVI] [ASTVI][GAS]C Epithel ial cel ls  (Terao et al. ,  2002)  
  Laminin (Terao et al. ,  2002)  
    
Lmb [LVI] [ASTVI][GAS]C Laminin (Wahid et al. ,  2005)  
    
Lsp [LVI] [ASTVI][GAS]C Epithel ial cel ls  (Elsner et al. ,  2002)  
  Laminin (Elsner et al. ,  2002)  
    
 
The lipoproteins are transcribed as long preprolipoprotein molecules that undergo a series of 
post translational modifications designed to facilitate covalent anchoring of the inherently 
hydrophilic protein to the hydrophobic surface of the bacterial cell membrane (Kovacs-Simon 
et al., 2011). Preprolipoproteins possess a distinctive N terminal signal sequence of 
approximately 20 amino acids (aa) in length that comprises a positively charged domain, a 
downstream hydrophobic region and conserved “lipobox” with the consensus sequence 
[LVI][ASTVI][GAS]C (Babu et al., 2006, Kovacs-Simon et al., 2011). Following translation, 
the invariant cysteine that is present within the lipobox is modified to serve as the membrane 
anchor and the signal peptide is cleaved, resulting in the expression of a mature, N-terminally 
tethered surface protein (Figure 1.5) (Babu et al., 2006). To date >30 putative lipoproteins 
have been identified within the GAS genome (Lei et al., 2004). The abundance, degree of 
conservation and surface localisation of these proteins makes them promising vaccine targets 
for the prevention of GAS infection (discussed in detail below). 
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Figure 1.5: Post translational processing of the streptococcal lipoproteins. The N 
terminal signal sequence of the pre-prolipoprotein (grey) is proximal to a highly 
conserved lipobox (green) that contains an invariant cysteine residue (red) at the C 
terminus. Lipid modification of the invariant cysteine results in the formation of the 
prolipoprotein which is subsequently cleaved leaving the cysteine (complete with 
hydrophobic lipid anchor) as the new N terminal residue of the mature lipoprotein. 
Figure adapted from Kovac-Simon et al. 2011. 
 
1.7.3: The M protein 
The streptococcal M protein is a multifaceted virulence factor that has long been known to 
stimulate a strong, type specific immune response following fulminant GAS infection 
(Lancefield, 1962, Lancefield, 1959). The primary structure of the M protein is similar to that 
of the MSCRAMM molecules, and comprises a modular central region that is flanked by an 
N terminal signal sequence and a C terminal anchor motif (Cunningham, 2000, McMillan et 
al., 2013). However, the M protein sequence is interspersed with evenly spaced hydrophobic 
residues which result in the formation of a characteristic irregular coiled-coil secondary 
structure upon translation of the mature protein (McNamara et al., 2008). While the adhesive 
properties of the M protein are well established, the primary structure of the molecule 
contains few recognised binding motifs, leading many authors to suggests that it is this 
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irregular coiled-coil secondary structure that is essential for ligand binding (Cunningham, 
2000, Smeesters et al., 2010). This observation is supported by data showing that targeted 
mutagenesis of the M protein sequence to promote the formation of an idealised coiled-coil 
resulted in a total loss of fibrinogen binding activity. (McNamara et al., 2008). Data 
suggesting that albumin binding is similarly reliant on the irregular coiled-coil formation of 
the M protein has also been reported, together suggesting that an intact secondary structure is 
essential for subsequent interaction with the host ECM (Smeesters et al., 2010, Gubbe et al., 
1997).  
 
The classical type specific immunity that is generated in response to the M protein is targeted 
against a short hypervariable epitope that is located at the extreme N terminus of the mature 
protein (Smeesters et al., 2010). In situ, this hypervariable epitope is thought to facilitate 
adaptive immune evasion across multiple, sequential infections of a single host by promoting 
antigenic diversity (Smeesters et al., 2010, Cunningham, 2000). In addition to the 
hypervariable region, the length and organisation of the molecules modular central domain 
also differs markedly between serotypes, further reducing the number of consistent epitopes 
expressed on the GAS cell surface (Fischetti, 1989, Smeesters et al., 2010, McMillan et al., 
2013). To date three overarching M protein architectures have been described that vary 
dramatically in size and structure (Figure 1.6) (McMillan et al., 2013).  
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Figure 1.6: The structure and domain organisation of the major M protein 
architectures. The M protein traff ics to the cell surface via a Sec -dependant signal 
sequence (grey) where it is covalently anchored to the peptidoglycan cell wall via the 
LPXTG motif (black). The C and D repeat domains (tan and purple respectively) are 
highly conserved between molecules however; the number of C repeat units can range 
from one to f ive. The degeneration and ultimate loss of the A and B repeat domains 
(blue and green respectively) from the latter isoforms is thought to facil i tate adaptive 
immune evasion by reducing the number of potential epitopes expressed on the GAS 
cell surface. Figure adapted from McMillan et al 2013.  
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Table 1.4: The ligand binding affinity of the M protein. 
 
Protein Anchor Ligand Reference 
    
M1 LPXTG Albumin (Gubbe et al. ,  1997)  
  Fibrinogen (Akesson et al. ,  1994)  
  Fibronect in  (Cue et al. ,  2001)  
  Kininogen (Ben Nasr et al. ,  1995)  
  IgG (Akesson et al. ,  1994)  
    
M2 LPXTG C4BP (Morfeldt et al. ,  2001)  
  IgG (Boyle et al. ,  1995)  
    
M3 LPXTG Albumin (Reichardt et al. ,  1995)  
  Fibronect in  (Reichardt et al. ,  1995)  
  Fibronect in  (Reichardt et al. ,  1995)  
    
M4 LPXTG C4BP (Johnsson et al. ,  1996)  
  IgA (Smeesters et al. ,  2010)  
  IgG (Smeesters et al. ,  2010)  
    
M5 LPXTG Albumin (Sandin et al. ,  2006)  
  Fibrinogen (Whitnack et al. ,  1984)  
(Waldemarsson et al. ,  2009)  
  FHL-1 (Kotarsky et al. ,  1998)  
  C4BP (Johnsson et al. ,  1996)  
  CD46 (Price et al. ,  2005)  
  C1q (Koroleva et al. ,  1998)  
    
M6 LPXTG Fibrinogen (Horstmann et al. ,  1992)  
  Fibronect in  (Cue et al. ,  2001)  
  Kininogen (Ben Nasr et al. ,  1995)  
  FHL-1 (Johnsson et al. ,  1998)  
    
M12 LPXTG Albumin (Retnoningrum and Cleary, 1994)  
  IgG (Retnoningrum et al. ,  1993)  
    
M22 LPXTG C4BP (Johnsson et al. ,  1996)  
  CD46 (Price et al. ,  2005)  
  IgG (Smeesters et al. ,  2010)  
    
M24 LPXTG Fibrinogen (Whitnack et al. ,  1984)  
    
M28 LPXTG IgA (Smeesters et al. ,  2010)  
  IgG (Smeesters et al. ,  2010)  
    
M60 LPXTG C4BP (Johnsson et al. ,  1996)  
    
 
In addition to its role in antigenic variation the M protein facilitates immune evasion by 
binding to the complement regulatory proteins FHL-1 and C4BP, resulting in a reduction in 
C3b binding and phagocyte uptake (Smeesters et al., 2010). Certain M protein isoforms have 
also been shown to bind to the soluble complement factor C1q, thus inhibiting formation of 
C3 convertase via the classical complement cascade (Koroleva et al., 1998). Without C3 
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convertase, the classical cascade is incapable of cleaving the complement components C3 and 
C5, resulting in a reduction in phagocyte chemotaxis and bacterial opsonisation (Koroleva et 
al., 1998, Murphy et al., 2008). The M protein also facilitates adaptive immune evasion by 
incongruous binding of human immunoglobulin via the Fc region. However; antibody 
sequestration is not a ubiquitous trait of all M protein isoforms, and the location of the Fc 
binding domain varies between different M protein isoforms (Smeesters et al., 2010). This 
suggests that multiple, convergent antibody binding receptors have arisen during the 
evolutionary history of the M protein molecule. 
 
M protein recognition has long been known to stimulate long lasting immunological memory, 
and many early efforts to develop an effective anti-GAS vaccination were focused around the 
isolation of a safe, homogeneous preparation of the molecule for human administration 
(Lancefield, 1959, Fox et al., 1973, Wolfe et al., 1963). However, attempts to develop an M 
protein based vaccination have been hampered by the serotype specificity of the resulting 
humoral immune response, and the potential of the molecule to stimulate the production of 
human cross reactive autoantibodies (Lancefield, 1959, Lancefield, 1928, Cunningham, 2012, 
Quinn et al., 1998). Despite this several M protein-based vaccine formulations have shown 
promise in preclinical trials (discussed in detail below) (McNeil et al., 2005, Batzloff et al., 
2003).  
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1.7.4: The M-like proteins 
Until the late 1980s the variable antigenic properties of the disparate GAS serotypes was 
thought to result from the expression of a single M antigen (the M protein). However, a 
number of “M-like” proteins have since been described that share many of the properties of 
the M protein proper; including a coiled-coil secondary structure and the ability to facilitate 
adhesion via ECM protein binding (Navarre and Schneewind, 1999, Thern et al., 1998). 
Many M-like proteins also react with the type specific antisera that were traditionally used for 
serotyping of novel GAS isolates, suggesting that these molecules contribute to the long 
lasting, type specific immunity generated following streptococcal infection (Navarre and 
Schneewind, 1999). 
 
Prior to the advent of whole genome sequencing the M-like proteins were differentiated from 
true M protein molecules based upon their purported lack of antiphagocytic activity (Thern et 
al., 1998, Svensson et al., 2002). However, several M-like proteins have since been shown to 
facilitate innate immune evasion through a number of mechanisms common to the M protein, 
including fibrinogen deposition, antibody sequestration and incongruous C4BP activation 
(Thern et al., 1995, Thern et al., 1998). Indeed much of the immunoglobulin binding activity 
that was initially attributed the M protein is in fact facilitated by the M like proteins Sir, Arp 
and Mrp (Table 1.2) (Stenberg et al., 1992, Stenberg et al., 1994). It is therefore possible that 
multiple members of the M protein family are required for adhesion and immune evasion 
during early colonisation of the human host, and that these molecules are frequent targets of 
the adaptive immune response during fulminant GAS infection. 
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Table 1.5: The ligand binding affinities of the M like protein .  
 
Protein Anchor Ligand Reference 
    
Arp LPXTG C4BP (Thern et al. ,  1995) 
  IgA (Johnsson et al. ,  1994)  
  IgG (Stenberg et al. ,  1992)  
    
Mrp LPXTG Fibrinogen (Navarre and Schneewind, 1999)  
  IgG (Stenberg et al. ,  1992)  
    
PAM LPXTG Plasminogen (Ringdahl and Sjobring, 2000)  
    
Protein H LPXTG Albumin (Frick et al. ,  1994)  
  Fibronect in  (Frick et al. ,  1995)  
  IgG (Frick et al. ,  1994)  
    
PRP LPXTG Plasminogen (McKay et al. ,  2004)  
(Sanderson-Smith et al. ,  2007)  
    
Sir LPXTG C4BP (Thern et al. ,  1995)  
  IgA (Stenberg et al. ,  1992)  
  IgG (Stenberg et al. ,  1992) 
    
 
1.7.5: Moonlighting proteins 
Until the mid-1990s, it was widely accepted that the protein product of a single gene 
performed only one biological action. However, it is now well established that many 
purported intracellular proteins also traffic to the bacterial cell surface, where they perform 
adjunct roles during early colonisation and pathogenesis (Henderson and Martin, 2011). The 
capacity of proteins to perform secondary (and tertiary) biological functions is termed 
“moonlighting”, and many highly conserved metabolic proteins have been shown to 
“moonlight” as ligand binding receptors, host cell adhesins and tissue invasins (Henderson 
and Martin, 2011). In GAS the majority of surface exposed moonlighting proteins have been 
identified as part of serological vaccine candidate identification studies, suggesting that they 
are frequent targets of the humoral immune response during fulminant GAS infection 
(discussed in detail below) (Cole et al., 2005, Severin et al., 2007, Rodriguez-Ortega et al., 
2006).  
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In GAS, one of the first  moonlighting proteins to be characterised was streptococcal surface 
dehydrogenase (SDH) which has been shown to bind to a variety of human ECM proteins, 
and to modulate GAS virulence through a hitherto undefined mechanism (Pancholi and 
Fischetti, 1992, Jin et al., 2005). SDH has also been shown to abrogate neutrophil chemotaxis 
through degradation of the complement chemokine C5a, and targeted mutation of SDH to 
prevent surface expression has been shown to attenuate GAS virulence in a mouse peritonitis 
model (Terao et al., 2006, Jin et al., 2005). The appearance of SDH (and many other 
moonlighting proteins) in a multitude of screens utilising convalescent serum from GAS 
infection cases confirms that the molecule is expressed in situ and may therefore be essential 
during bacterial pathogenesis (Severin et al., 2007, Cole et al., 2005, Rodriguez-Ortega et al., 
2006).  
 
Table 1.6: The ligand binding affinities of the streptococcal moonlighting 
proteins. 
 
Protein Anchor Ligand Reference 
    
SDH Anchorless Fibronect in  (Pancholi  and Fischett i ,  1992)  
  Plasminogen (Lottenberg et al. ,  1992)  
  CD87 (Jin et al. ,  2005)  
  C5a (Terao et al. ,  2006) 
    
SEN Anchorless Epithel ial cel ls  (Pancholi  et al. ,  2003)  
  Plasminogen  (Pancholi  et al. ,  2003)  
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1.8: 100 years of GAS vaccinology 
Despite over a century of research there is currently no licenced vaccine available for the 
prevention of GAS infection. The early anti-GAS formulations were predominantly tailored 
towards the prevention of scarlet fever, an inflammatory condition of the oropharynx that is 
associated with superantigen production following tonsillar colonisation (Dick and Dick, 
1924). These trials usually involved the preparation of whole heat killed GAS or crudely 
purified “Dick” antigens (most probably a cocktail of superantigens) for human 
administration. Such preparations often induced a range of aggressive side effects while 
providing little protection against subsequent streptococcal challenges (Rantz et al., 1949, 
Dick and Dick, 1924, Jackson, 1941, Bloomfield and Felty, 1923). 
  
Later attempts to develop a GAS vaccine involved crudely purified cell wall extracts and/or 
M protein preparations of varying purities (Waldman et al., 1975, Polly et al., 1975, Potter et 
al., 1962, Wolfe et al., 1963, Fox et al., 1973). However, as with the scarlet fever trials 
outlined above, these vaccinations proved ineffective and resulted in significant morbidity in 
a series of human vaccination trials. The practise of administrating streptococcal extracts 
directly to human subjects ended abruptly in 1978, following a study in which three subjects 
purportedly developed ARF in response to a partially purified M3 protein vaccine (Massell et 
al., 1969, Bisno et al., 2005). In response the Federal Drug Administration banned the 
uncontrolled administration of vaccines containing GAS or GAS components to human 
subjects citing the obvious safety concerns  and the lack of efficacy of the previously trialled 
formulations (Bisno et al., 2005).  
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The effect of this legislation was two-fold. Firstly there was an immediate shift towards the 
use of animal model for the development and evaluation of GAS vaccinations; and secondly, 
the field of GAS vaccinology became divided into two broad approaches. The first approach 
sought to identify a region of the M protein molecule that was capable of stimulating a strong 
anti-GAS humoral immune response without generating the human cross reactive antibodies 
purportedly responsible for stimulating ARF. In contrast, the second approach involved the 
identification and characterisation of alternative surface proteins that may serve as promising 
candidates for a wide ranging anti-GAS vaccination. These approaches to GAS vaccinology 
still exist today, and are broadly characterised as M protein and non M protein based.  
1.9: Contemporary M protein based vaccines 
1.9.1: The hypervariable N terminus and the multivalent vaccine 
The M protein has long been known to contain type-specific epitopes that promote 
opsonophagocytosis and stimulate long lasting immunological memory (Dale et al., 1996, 
Polly et al., 1975, Lancefield, 1959). By the early 1980s these epitopes had been localised to 
the extreme N terminus of the M protein molecule, and Dale and colleagues had shown that 
immunisation with a synthetic peptide representing the first 20aa of the M5 protein was 
sufficient to evoke protective, type specific immunity in a rabbit model (Dale et al., 1983).  
 
Whilst over 100 distinct M types had already been recorded, the authors hypothesised that a 
multivalent hybrid molecule encoding the amino epitopes of several M protein isoforms 
could be used to elicit broad spectrum immunity against iGAS infection (Dale et al., 1996, 
Dale et al., 1983, Beachey et al., 1986). Over the course of the next ten years, a variety of 
such molecules were constructed containing an increasing number of N terminal epitopes; 
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each of which was shown to evoke the production of type specific antibody in a rabbit model 
(Table 1.3). In parallel, vaccination with the original monovalent fusion molecule 
(encompassing the M5 amino epitope) was shown to provide type specific protection against 
systemic GAS infection, indicating that the induced humoral immunity was sufficient to 
promote adaptive immune clearance of the invading organism (Dale and Chiang, 1995).   
 
Table 1.7: The early evolution of the amino terminal vaccine.  Abbreviations: TT: 
tetanus toxoid, KLH: keyhole limpet hemocyanin.  
 
Year M epitopes Carrier Reference 
1983 M5 TT (Dale et al., 1983)  
1984 M24 TT (Beachey et al., 1984)  
1986 M5, M24 None (Dale and Beachey, 1986) 
1987 M5, M6, M24 KLH (Beachey et al., 1987)  
1993 M5, M6, M19, M24 None (Dale et al., 1993)  
1996 M1, M2, M3, M5, M6, M18, 
M19, M24 
None (Dale et al., 1996)  
 
The most promising multivalent formulation synthesised to date contains a total of 26 amino 
terminal epitope contained within four recombinant fusion proteins (Figure 1.7). The vaccine 
was designed to include 85-90% of serotypes associate with pharyngitis, invasive disease and 
ARF using the data available from a multitude of north American epidemiological studies 
(Hu et al., 2002, McNeil et al., 2005). In addition, one of the fusion proteins (denoted Septa 
B.2) was designed to include the streptococcal protective antigen (Spa), a novel vaccine 
candidate that had previously been shown to provide passive protection against iGAS 
infection in a murine model (Dale et al., 1999).  
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Figure 1.7: A schematic representation of the four recombinant fusion proteins 
comprising the 26-valent vaccine.  Figure adapted from Hu et al. 2002.  
 
The 26-valent vaccine has been shown to evoke type specific antibody against 25 of the 26 
represented serotypes, without inducing the production of human cross reactive antibodies 
(Hu et al., 2002). In addition, supplementation of non-immune human whole blood with 
rabbit antiserum raised against the multivalent formulation inhibited the growth of 84% of the 
represented serotypes in vitro (Hu et al., 2002). Intriguingly, passive immunisation of whole 
blood was also shown to promote opsonophagocytosis of a number of M4 GAS isolates in 
vitro, suggesting that the 26 valent formulation may stimulate the production of functional, 
cross serotype humoral immunity (Hu et al., 2002). The results obtained from later phase I 
and phase II human trials largely mimicked those reported from the earlier animal studies 
with an increase in functional, opsonic antibody titres reported for the majority of the 
represented serotypes (McNeil et al., 2005, McNeil et al., 2006). Importantly no human 
cross-reactive antibodies were detected, and the adverse effects that followed administration 
of the vaccination were only minor (McNeil et al., 2005, McNeil et al., 2006).  
 
To date the 26-valent vaccine is the only anti-GAS vaccination to reach phase II clinical 
trials. The preparation has since been reformulated to include the most prevalent serotypes in 
Europe, potentially increasing the geographical coverage of the vaccination (Dale et al., 
2011). This new 30-valent vaccine has been shown to facilitate opsonophagocytic killing of 
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the majority of the represented serotypes, as well as several that were not included within the 
peptide formulation (Dale et al., 2011, Dale et al., 2013).  
 
Together the data collected over the past twenty years suggests that a multivalent, amino 
terminal vaccine could theoretically provide wide ranging protection against iGAS infection. 
However, this would most likely require the production of a number of multivalent peptides 
covering a wide array of emm types that could be differentially combined according to 
geographical differences in serotype prevalence (Dale et al., 1996). Indeed the epidemiology 
of GAS disease in the developed world is vastly different from that reported in in low 
resource settings where the diversity of emm types is much greater (Steer et al., 2009b, Steer 
et al., 2009a). Furthermore the propensity of the amino terminal epitopes of the M protein to 
mutate in response to adaptive immune pressure and the purported tendency of anti-GAS 
vaccinations to drive the emergence of unusual serotypes may limit the service life of such a 
multivalent formulation. 
 
1.9.2: The C repeat region and the J8 vaccine 
While the N terminus of the M protein molecule contain some of the most immunogenic 
epitopes expressed on the GAS cell surface, in many respects the highly conserved C repeat 
region represents a more promising target for a wide ranging anti-GAS vaccination. Unlike 
the A and B repeat domains, the C repeat region shares a significant degree of sequence 
homology between different M protein isoforms, and is conserved across the three major M 
protein architectures described to date (Smeesters et al., 2010, Fischetti et al., 1991). By the 
late 1980s, vaccination of mice with several peptides derived from the C repeat region had 
been shown to reduce pharyngeal colonisation through the generation of mucosal IgA 
39 
 
(Bessen and Fischetti, 1988, Fischetti et al., 1991). However, these peptides did not provide 
protection against systemic GAS infection, suggesting that the selected epitopes were 
incapable of inducing streptococcal phagocytosis (Bessen and Fischetti, 1988, Fischetti et al., 
1991).  
 
The failing of these peptides to generate a fully functional immune response was 
subsequently attributed to the lack of T cell epitopes within the selected C terminal region 
(Pruksakorn et al., 1992). While adaptive immune clearance of GAS is primary mediated by 
surface antibody deposition, immunoglobulin class switching and the generation of memory 
B cells requires concomitant activation of T helper cells (Wu et al., 2002, Murphy et al., 
2008). Following recognition and internalisation of the protein antigen by the B cell receptor, 
the molecule is degraded and returned to the B cell surface as MHC class II associated 
peptides (T cell epitopes) (Murphy et al., 2008). The resulting peptide:MHC complexes are 
recognised by antigen specific helper T cells which provide the co-stimulatory signal required 
for B cell proliferation (Murphy et al., 2008). Small peptide antigens often lack natural T cell 
epitopes, limiting their capacity to induce B cell proliferation and the production of memory 
B cells (Murphy et al., 2008, Wu et al., 2002). As such, vaccination with small peptides often 
results in the induction of a weak, short lived humoral response; with limited immunological 
memory. To circumvent this problem, such molecules are often conjugated to “carrier” 
molecules which will be recognised by antigen specific T cells and thus providing the co-
stimulation required for efficient B cell proliferation (Pandey et al., 2013, Murphy et al., 
2008). 
 
Alternatively peptides that contain naturally occurring B and T cell epitopes can be carefully 
selected which will simultaneously stimulate a B cell and T helper cell response (Pruksakorn 
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et al., 1992, Pruksakorn et al., 1994). As the T cell epitopes present in such preparations are 
derived from the antigen itself, these vaccines have the added advantage of facilitating 
simultaneous priming of a cognate T cell response (Pandey et al., 2013, Pruksakorn et al., 
1992). This in turn facilitates rapid co-stimulation of the humoral immune response following 
natural infection (provided the challenge serotype expresses the same T cell epitope) and 
therefore increases the levels of protection provided by the vaccine preparation (Pruksakorn 
et al., 1992). While this approach was initially considered during development of the M 
protein vaccine, C terminal peptides containing T cell epitopes were shown to generate heart 
cross reactive T cells that could potentially stimulate rheumatic carditis in situ (Pruksakorn et 
al., 1994, Pruksakorn et al., 1992). 
 
The current incarnation of the C repeat vaccine (denoted J8) is comprised of a minimal B cell 
epitope that is conjugated to a diphtheria toxin carrier (Relf et al., 1996). Owing to the 
conformational nature of the native epitope, the 12 aa peptide is contained within a 16 aa 
sequence derived from a yeast DNA binding protein. This allows the coiled-coil structure of 
the molecule to be maintained, while avoiding the introduction of a human cross reactive T 
cell epitopes (Relf et al., 1996). However, the lack of a dominant T cell epitope means that, 
during natural GAS infection, the T helper cell response will come solely from naïve T cells 
active at the time of challenge (Pandey et al., 2013). Despite this hindrance, immunisation 
with J8 has been shown to stimulate a long lasting memory B cell response that protects 
against lethal GAS challenge in a murine model (Pandey et al., 2013, Pandey et al., 2009).  
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1.10: Non M protein based vaccine strategies 
The inherent problems associated with developing an M protein based vaccine have led to the 
investigation of many alternative streptococcal vaccine candidate antigens, and to the 
development of several alternative vaccine formulations. Initially, research into non-M 
protein vaccine formulations was dominated by the use of previously well characterised 
extracellular virulence factors; such as C5a peptidase, the group A carbohydrate and the 
fibronectin binding proteins (Table 1.4) (Ji et al., 1997, Sabharwal et al., 2006, Guzman et al., 
1999). However, the advent of whole genome sequencing heralded an era of “reverse 
vaccinology” where potential targets are identified in silico by common structures in their 
amino acid sequence, and produced recombinantly for evaluation in a variety of models 
(Rodriguez-Ortega et al., 2006, Bensi et al., 2012, Fritzer et al., 2010). While reverse 
vaccinology facilitates high throughput screening of a large number of antigens, it can be 
very labour intensive and results in the prospective production of many proteins that are later 
shown to have limited or no efficacy in functional immunological studies.  
  
42 
 
Table 1.8: Previously characterised streptococcal vaccine candidate antigens. 
Table produced using information from Steer et al 2009 and Steer et al. 2013. 
 
Vaccine Antigen(s)  Reference 
  
Immune modulators  
C5a Peptidase (Ji et al. ,  1997)  
SpyCEP (Turner et al. ,  2009b)  
  
Streptococcal pyrogenic exotoxins   
SpeA (Roggiani et al. ,  2000)  
SpeA/SpeB (Ulrich, 2008)  
  
Fibronectin binding proteins   
Serum opacity factor  (Schulze et al. ,  2006)  
FBP54 (Kawabata et al. ,  2001)  
SfbI  (Guzman et al. ,  1999)  
FbaA (Ma et al. ,  2009)  
  
Moonlighting proteins  
Streptococcal hist idine tr iad protein  (Kunitomo et al. ,  2008)  
Trigger factor  (Henningham et al. ,  2012)  
  
Misc.  
Group A carbohydrate  (Kabanova et al. ,  2010)  
Streptococcal protect ive ant igen  (Dale et al. ,  1999)  
Streptococcal T ant igen (Pi lus)  (Mora et al. ,  2005)  
  
 
1.11: Previously characterised virulence factors 
1.11.1: C5a peptidase 
C5a peptidase (ScpA) is an extracellular endopeptidase that inhibits phagocyte recruitment by 
cleaving the soluble complement chemotaxin C5a (Wexler et al., 1985). ScpA is expressed 
ubiquitously on the surface of all GAS serotypes as well as in the group B, G and C 
streptococci (Cleary et al., 2004, Chmouryguina et al., 1996, Simpson et al., 1992). Using an 
intradermal airsac model, elimination of scpA was shown to enhance phagocyte influx to the 
site of GAS infection and clearance of the invading organism (Ji et al., 1996). Furthermore, 
scpA disruption was shown to retard murine nasopharyngeal colonisation; suggesting that a 
vaccine formulation incorporating the molecule may protect against both superficial mucosal 
infection and iGAS disease (Ji et al., 1997). 
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Intranasal and parenteral immunisation with recombinant ScpA has since been shown to 
prevent nasopharyngeal colonisation using a multitude of GAS serotypes, and evoke the 
production of mucosal IgA and serum IgG in a murine model (Ji et al., 1997, Cleary et al., 
2004). The induced humoral immunity was shown to inhibit cleavage of C5a suggesting that, 
in addition to facilitating opsonic antibody deposition, the vaccination may restore phagocyte 
recruitment during natural GAS infection (Cleary et al., 2004). This finding supports earlier, 
impuissant data showing that naturally acquired anti ScpA antibody may restore the 
leukocyte chemotactic activity of C5a in vitro (O'Connor et al., 1991).  
 
1.11.2: SpyCEP 
The Streptococcus pyogenes cell envelope protease (SpyCEP) is a highly conserved serine 
protease that facilitates streptococcal immune evasion by cleaving the neutrophil chemotaxin 
IL-8 (Hidalgo-Grass et al., 2006, Edwards et al., 2005). Heterologous expression of SpyCEP 
in non-pathogenic Lactococcus lactis has been shown to promote bacterial dissemination 
from an intramuscular focus of infection and to facilitate persistence in the upper respiratory 
tract in a murine model, together suggesting that the molecule may facilitate bacterial 
colonisation of both the soft tissues and the oropharynx (Kurupati et al., 2010). Furthermore, 
a positive correlation has been reported between measurable SpyCEP activity and the 
recorded severity of disease outcome amongst clinical isolates suggesting that the molecule 
plays an important role in determining the severity of human disease (Turner et al., 2009a). 
These findings echoed earlier observations showing that attenuation of SpyCEP activity 
resulted in a concurrent attenuation of disease severity in a murine model (Zinkernagel et al., 
2008, Hidalgo-Grass et al., 2006).  
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Immunisation with a recombinant amino terminal fragment of the full length SpyCEP 
molecule denoted CEP-5 has been shown to reduce disease severity and inhibit GAS 
dissemination from both an intramuscular and intranasal focus in a murine model (Turner et 
al., 2009b). In addition, functional serum antibody against CEP-5 was shown to inhibit the 
IL-8 cleaving activity of the full length molecule. This suggests that a SpyCEP based vaccine 
may have a similar mode of action to the ScpA based vaccine outlined above, where 
protection is mediated by the combined restoration of phagocyte chemotaxis and increase in 
bacterial opsonisation. This model is supported by the observation that functional SpyCEP is 
shed from the GAS cell surface during normal cell turnover and can therefore act as a soluble 
inhibitor of neutrophil chemotaxis in the absence of neutralising antibody (Edwards et al., 
2005, Chiappini et al., 2012).  
 
1.11.3: Fibronectin binding proteins 
The fibronectin binding proteins are a large family of surface expressed adhesins that 
facilitate bacterial colonisation of the skin and oropharynx. Several groups have therefore 
suggested that neutralisation of the ligand binding activity of one or more of the fibronectin 
binding proteins may provide wide ranging protection against colonisation, and subsequent 
GAS infection (Guzman et al., 1999, Kawabata et al., 2001, Schulze et al., 2006). The high 
degree of conservation amongst these proteins (both in structure and in serotype dependant 
expression) implies that a fibronectin binding protein based vaccine could provide pan 
serotype protection against GAS infection without generating the human cross reactivity 
(Talay et al., 1992, Valentin-Weigand et al., 1994). Indeed, all of the fibronectin binding 
proteins characterised to date have been shown to stimulate a strong humoral immune 
45 
 
response and protect mice against systemic GAS challenge following parenteral and/or 
mucosal inoculation (Schulze et al., 2006, Kawabata et al., 2001, Guzman et al., 1999, Ma et 
al., 2009). 
 
1.11.4: The group A carbohydrate 
The group A carbohydrate antigen (GAcar) is a ubiquitously expressed surface 
polysaccharide consisting of repeating units of N-acetylglucosamine coupled to a poly-
rhamnose backbone (Slade and Slamp, 1962, Krause and McCarty, 1961). As with the short 
peptide antigens described above, carbohydrate antigens stimulate a short lived, T cell 
independent antibody response when recognised in isolation (Astronomo and Burton, 2010). 
However, sera from healthy school aged children have been shown to contain detectable titres 
of anti-GAcar IgG, suggesting that immunoglobulin class switching can occur during GAS 
natural infection. It is likely that in this setting, the required T cell epitopes are supplied by 
the proteinaceous antigens that are co-expressed on the cell surface during fulminant GAS 
infection (Salvadori et al., 1995). Indeed, immunisation with purified GAcar (coupled to a 
tetanus toxoid carrier) has been shown provide protection against systemic GAS challenge in 
a murine model, suggesting that a GAcar based vaccine may be suitably efficacious if 
formulated correctly (Salvadori et al., 1995, Sabharwal et al., 2006). However recent 
evidence suggests that immune recognition of the GAcar molecule also results in the 
generation of human cross reactive antibodies that precipitate the characteristic inflammation 
associated with rheumatic carditis (Cunningham, 2012).  
 
It has been noted that the relatively crude method of GAcar purification utilised in the above 
studies may have resulted in the co purification of a number of proteinaceous antigens, most 
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notably the M protein (Kabanova et al., 2010). The potential presence of M protein within the 
GAcar preparation calls into question the validity of the protection data, and the identity of 
the purported human cross reactive antigen (Kabanova et al., 2010). While these studies were 
being conducted, a novel family of synthetic glycoconjugate were under development. These 
vaccine formulations comprised chemically synthesised GAcar oligosaccharides coupled to 
the proprietary carrier molecule CMR197 (Novartis R&D, Siena, Italy). The formulations were 
shown to provide protection against intraperitoneal GAS challenge in a murine model, again 
suggesting that administration of GAcar with a suitable adjuvant stimulated protective 
humoral immunity (Kabanova et al., 2010). The publication of a novel method for the 
production of synthetic GAcar may allow the questions surrounding human cross reactivity 
antibody generation to be addressed, and analysis of these glycoconjugate vaccines to move 
forward into clinical trials. 
1.12: Vaccine candidate identification in the post genomic era 
1.12.1: Meningitis B: From computer to clinic  
Reverse vaccinology is high throughput screening technique that identifies potential vaccine 
candidate antigens from whole genome sequences, based upon characteristic features in their 
primary amino acid sequence. The concept of interrogating genome data for vaccine 
candidates was first applied to Neisseria meningitidis in the late 1990s, when the genome of a 
virulent serogroup B (MenB) strain was used to identify 570 open reading frames (ORFs) that 
encoded putative exoproteins (Serruto and Rappuoli, 2006, Pizza et al., 2000). From the 570 
exoprotein ORFs identified, 350 recombinant proteins were produced recombinantly and 
used to generate antisera in a murine model. These antisera were subsequently utilised to 
confirm that each protein was antigenic, surface expressed, and conserved amongst a 
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multitude of invasive MenB isolates (Pizza et al., 2000). In addition, each antiserum sample 
was tested for bactericidal activity using a previously described in vitro assay (Pizza et al., 
2000, Peeters et al., 1999).  
 
Using this methodology a total of seven vaccine candidate antigens were identified that 
evoked high titres of bactericidal immunoglobulin following murine vaccination, and were 
highly conserved amongst invasive MenB isolates (Pizza et al., 2000). Three of these 
antigens now form the basis of the licenced 4CMenB vaccine which has been shown to elicit 
effective, long lived protection against meningococcal disease in adults, adolescents and 
infants alike (Serruto et al., 2012). In essence, within 18 months the original reverse 
vaccinology study performed by Pizza and colleagues had laid the groundwork for the first 
licenced MenB vaccine; illustrating the power of this methodology in the development of 
novel protective formulations. Whilst the techniques utilised vary between studies, this basic 
formula for the identification of promising vaccine candidate antigens by reverse vaccinology 
has since been adapted to many other pathogenic bacteria including GAS (Figure 1.8).  
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Figure 1.8: Identification and evaluation of vaccine candidate antigens by reverse 
vaccinology. 
 
1.13: Current approaches to streptococcal reverse vaccinology 
Probably the simplest streptococcal reverse vaccinology study conducted to date focused 
solely on the lipoprotein superfamily. Lei and colleagues identified 30 ORFs encoding 
putative lipoproteins using a serotype M1 GAS reference proteome, 16 of which were 
selected for recombinant production and assessment in a murine model (Lei et al., 2004). 
Convalescent phase serum samples from experimentally infected animals and iGAS infection 
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cases were shown to react with the majority of the resulting recombinant proteins, indicating 
that the lipoproteins identified are expressed during infection, and are capable of stimulating 
a strong humoral immune response in situ (Lei et al., 2004). In addition, blood from mice 
immunised with five of the 16 recombinant proteins was shown to promote opsonophagocytic 
killing of serotype M1 GAS, indicating that the generated antibody was capable of facilitating 
bacterial clearance in vitro (Lei et al., 2004). Despite this study being conducted almost ten 
years ago, no further work has been published regarding the use of these lipoproteins as 
components of a subunit vaccine.  
 
Reverse vaccinology was also employed by Rodriguez-Ortega and colleagues, who utilised 
the protein subcellular localisation program PSORTb to identify the exoprotein ORFs present 
within the proteome of a serotype M23 isolate (Rodriguez-Ortega et al., 2006). PSORTb 
predicts the localisation of an input protein by identifying sequence features known to 
correlate with specific cellular locations (for example cell wall anchor motifs and 
extracellular signal sequences) (Rey et al., 2005). In parallel, the authors trypsinized intact 
M23 GAS cells in a hyperosmotic buffer and analysed the isolated peptides by mass 
spectrometry (Rodriguez-Ortega et al., 2006). This method of surface digestion (denoted 
trypsin shaving) allows the protein composition of the cell surface to be accurately 
catalogued (Rodriguez-Ortega et al., 2006, Severin et al., 2007). Using these two approaches 
the authors identified 17 proteins that were present in the trypsinized fraction and predicted to 
be surface expressed by PSORTb analysis. One of these proteins (SpyCEP) was shown to 
protect against lethal GAS challenge in a murine model following parenteral vaccination 
(Rodriguez-Ortega et al., 2006).  
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Whilst this study was more inclusive than the one conducted by Lei and colleagues, the use 
of PSORTb prediction to inform their choice of candidate antigens may be ill advised, as 
proteins lacking a classical surface expression motif (such as the moonlighting proteins 
discussed above) are instantly overlooked. Furthermore, PSORTb analysis gives no 
indication of the relative levels of expression of each identified protein, or of the molecules 
propensity to stimulate a functional antibody response in situ. Therefore whilst in silico 
analysis provides an initial high throughput screen of potential candidate antigens, a classical 
molecular approach to vaccine candidate identification allows a more informed decision to be 
made regarding the most likely protective targets present within a given genome. 
 
1.13.1: Serological identification of vaccine candidate antigens 
Many of the essential properties of a promising vaccine candidate antigen (cell wall 
localisation, expression during infection and antigenicity) can be confirmed serologically 
using convalescent serum from human patients. It has long been recognised that serological 
analysis of the bacterial surfome is therefore an effective means of identifying potential 
vaccine candidate antigens from crudely purified cell wall fractions (Newhall et al., 1982, 
Erlich et al., 1983). Identification of the major surface immunogens of GAS was first 
undertaken by Cole and colleagues, who utilised two dimensional immunoblot analysis to 
visualise 33 surface antigens that reacted with pooled serum recovered from a region of 
endemic impetigo (Cole et al., 2005, Currie and Carapetis, 2000). Intriguingly only seven of 
the proteins identified were annotated as putative virulence factors; while the vast majority 
played a purported role during normal cell turnover (Figure 1.9) (Cole et al., 2005). Non-
specific biotinylation of intact GAS cells prior to surface protein purification confirmed that 
20 of the 33 identified proteins were expressed on the cell surface in situ. Over half these 
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were purported moonlighting proteins, highlighting the importance of not discounting these 
molecules during the preliminary stages of vaccine candidate antigen selection (Cole et al., 
2005).  
 
 
 
Figure 1.9: The major functional classes of the immunoreactive surface proteins 
identified by Cole and colleagues. Chart produced using data from Cole et al. 2005.  
 
Whilst the study performed by Cole and colleagues represents an important first step in the 
development of a high throughput proteomic screen for GAS vaccine candidate antigens, the 
methodology employed is fraught with potential pitfalls. Firstly, while two-dimensional gel 
electrophoresis is an accepted means of separating complex samples into individual proteins, 
only one sample can be run per gel which severely limits the number of different GAS 
isolates that can be compared within a given time frame. Thus only three GAS isolates were 
examined over the course of the study all of which represented serotypes that are largely 
confined to the Pacific Region (Cole et al., 2005). In addition, the use of pooled serum 
recovered from a region of endemic impetigo calls into question the usefulness of the 
antigens that were identified by immunoblot analysis. The serum was collected from a region 
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where impetigo rates approach 70% within the adolescent population, and where GAS is 
responsible for recurrent outbreaks of ARF and associated rheumatic heart disease (Currie 
and Carapetis, 2000). 
 
The implications of this observation are twofold. Firstly the humoral immunity generated in 
response to primary impetigo in this region is clearly insufficient to prevent subsequent GAS 
re-infection, and thus the antigens identified are unlikely to provide protection against 
streptococcal infection in situ. In addition, the reported prevalence of ARF within the region 
suggests that one or more of the antigens identified is capable of inducing the production of 
human cross reactive autoantibodies, and thus of precipitating the inflammatory symptoms of 
ARF. Together this suggests that the antigens identified by Cole and colleagues are of limited 
value for the development of an effective, wide ranging GAS vaccination. 
 
1.13.2: Antigenome technology 
In addition to reverse vaccinology, the recent advent of whole genome sequencing has led to 
the development of a functional, molecular approach to vaccine design referred to as 
antigenome technology (Etz et al., 2002, Meinke et al., 2005). Antigenome technology, 
involves the mechanical shearing of a target genome into peptide encoding fragments. These 
peptides are frame selected (using commercially available plasmids) and transferred into an 
expression vector encoding a surface associated E.coli carrier protein. The process results in 
the heterologous expression of a library of pathogen derived peptides upon the surface of a 
multitude of E.coli isolates; which together cover the majority of the target proteome (Etz et 
al., 2002). Subsequent serological analysis of the expressed peptides allows all of the linear, 
53 
 
immunoreactive epitopes present within the target proteome to be identified (Etz et al., 2002, 
Meinke et al., 2005).  
 
Unlike a classical reverse vaccinology approach, antigenome technology does not discount 
potential antigens prior to serological analysis; based upon the absence of any recognised 
surface expression motifs within their primary sequence. Antigenome technology therefore 
allows the user to take a wholly indiscriminate look at the immunoreactive protein repertoire 
of a given organism without having to make any prejudgements regarding the most promising 
exoprotein ORFs. Serological analysis of the GAS antigenome resulted in the identification 
of 32 novel antigens that were highly conserved across a multitude of GAS serotypes, and 
contained one or more strongly immunogenic epitopes (Fritzer et al., 2010). Cloning, and in 
vivo analysis of these proteins lead to the identification of nine novel vaccine candidate 
antigens that provided consistent protection against iGAS infection in a murine model 
(Fritzer et al., 2010).  
 
As humoral immunity is paramount to the clearance of GAS infection, the vast majority of 
GAS vaccinology studies focus on the identification of proteins containing highly conserved, 
functional B cell epitopes. However, it has long been reported that most proteinaceous B cell 
epitopes are conformational, and only exist when the molecule is intact and folded correctly 
(Sela-Culang et al., 2014, Hopp and Woods, 1981, Pellequer et al., 1991). Therefore while 
antigenome technology is useful for high throughput analysis of entire pathogen derived 
proteomes, the peptide nature of the expressed antigens introduces a strong bias against the 
recognition of conformational epitopes (Sela-Culang et al., 2014, Pellequer et al., 1991). This 
shortcoming is also shared by the two dimensional immunoblotting approach outlined above; 
where the secondary and tertiary structures of the proteins are disrupted prior to immunoblot 
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analysis (Cole et al., 2005). Thus while Fritzer and colleagues identified nine novel antigens 
using a GAS antigenome, the inability to identify immunogenic conformational epitopes 
using this methodology suggests that many promising targets were unintentionally 
overlooked. 
 
1.13.3: Multiple high throughput approaches. 
Probably the most promising non M protein based vaccine formulation reported to date was 
developed by Bensi and colleagues; using a combination of three high throughput 
technologies (Bensi et al., 2012). Candidate surface antigens were first identified by a 
classical reverse vaccinology approach, and produced recombinantly to allow the generation 
of protein-specific polyclonal serum. Separate pools of promising vaccine targets were then 
identified using three independent approaches. The generated polyclonal sera was used to 
confirm surface expression of the target antigens in situ by flow cytometry, while the 
immunogenicity of the recombinant proteins was confirmed by protein array using serum 
from streptococcal pharyngitis cases (Bensi et al., 2012). In parallel experiments, conserved 
streptococcal exoproteins were identified by trypsin shaving and proteomic analysis, together 
resulting in the generation of three distinct sets of antigens. When these antigen sets were 
mapped onto a Venn diagram, the proteins that were conserved, surface exposed and 
immunogenic fell within the middle area (Figure 1.10). 
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Figure 1.10: The three technologies employed by Bensi and colleagues to identify 
surface exposed, highly conserved vaccine candidate antigens. Figure reproduced 
from Bensi, Mora et al. 2012. 
 
Using this technique, Bensi and colleagues identified 40 prioritised antigens for in vivo 
analysis. Each antigen was used to immunize mice for subsequent intraperitoneal challenge 
with two different GAS serotypes (M1 and M23). These preliminary experiments resulted in 
the identification of six vaccine candidate antigens that induced protection against one or 
both GAS isolates. Using the same model three of these antigens (SpyCEP, streptolysin O 
and the putative surface exclusion protein PrgA), were subsequently shown to provide 
protection against at least one additional GAS serotype (Bensi et al., 2012). These proteins 
now form the basis of the patented “Combo” vaccination (Novartis R&D, Siena, Italy) which 
has been shown to provide consistent protection against a panel of four distinct M serotypes 
using three different murine infection models (Bensi et al., 2012). Whether development of 
the combo vaccine will continue and how the formulation will perform in human clinical 
trials remains to be seen.  
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1.14: The current study 
The current study aims to develop a novel serological approach to the identification of 
bacterial vaccine candidate antigens utilising the clinical blood product IVIG in place of 
patient convalescent serum. The purported efficacy of IVIG as an adjunct treatment for iGAS 
infection, coupled with its proven therapeutic benefit in a transgenic mouse model, suggests 
that the reagent recognises an as yet uncharacterised repertoire of highly conserved, surface 
expressed antigens that are capable of stimulating an effective humoral immune response 
during fulminant GAS infection. This assertion led to the hypothesis that the repertoire of 
antigens recognised by IVIG may form the basis of an effective, multivalent anti-GAS 
vaccination. In order to explore this hypothesis, the repertoire of streptococcal surface 
antigens recognised by IVIG was characterised by proteomic analysis, and the antigens that 
were conserved across four clinically relevant GAS serotypes were identified for downstream 
assessment in a murine vaccination model.  
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2: Materials and Methods 
2.1: Bacterial strains and growth conditions 
The isolates used in this study were recovered from patients referred to the Hammersmith 
Hospital Infectious Diseases Department, or received from the UK national reference 
laboratory (Table 2.1). The isolates were selected to represent the range of clinically relevant 
serotypes that are currently circulating within the United Kingdom (M1, M3, M12 and M89) 
and were recovered from a spectrum of superficial and invasive disease manifestations. 
Serotypes M12 and M89 were included based upon their prevalence amongst GAS cases 
identified within the Imperial College Healthcare Trust between April and November 2009, 
despite the relatively low rate of recovery of these serotypes Europe wide (Figure 1.2C). All 
isolates were received from diagnostic laboratories on nutrient agar slopes and sub cultured in 
Todd-Hewitt broth (THB, Oxoid) prior to storage at -80°C in 20% glycerol. Typing was 
performed using the emm-typing primers emm1 and emm2 under standard conditions (Beall et 
al., 1996). Sequence was obtained using the emm2 primer and emm types (M types) were 
assigned by BLAST analysis. Isolates were cultured from frozen stocks on Columbia horse 
blood agar (CBA, Oxoid) and incubated at 37°C with 5% CO2. Overnight cultures were 
subsequently inoculated with 2-3 single colonies and grown in THB for 16-18 h. Escherichia 
coli isolates were routinely cultured in Luria-Bertani (LB) broth (Sigma-Aldrich) at 37°C 
with agitation at 225 rpm, or on LB-agar pates where necessary. 
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Table 2.1: The isolates used in this study.  Upon storage at -80°C the isolates were 
given a lab identif ication number with the prefix H. Isolates lacking this prefix were 
collected independently as part of an epidemiological study into the prevalence of 
different M types in non-invasive infections.  
 
M type/Isolate Source Disease manifestation 
   
M1   
   
H305 Throat Scarlet fever (type strain) 
H364 Lung Pneumonia/STSS 
H366 Blood Pneumonia/STSS 
H656 Blood - 
H791 Blood Cellulitis 
   
M3   
   
H330 Blood Puerperal sepsis 
H387 Throat STSS 
H413 - - 
H471 Ear STSS 
H672 Throat Tonsillitis 
   
M12   
   
49 Throat Tonsillitis 
67 Throat Tonsillitis 
H529 Blood STSS 
H530 Blood STSS 
H599 Blood - 
   
M89   
   
98 Throat Tonsillitis 
H293 Muscle NF/STSS 
H395 Blood Pneumonia 
H409 - - 
H411 Blood - 
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2.2: IVIG source 
Unless otherwise stated, Endobulin
®
 S/D IVIG (Lot No. 2470799L; Baxter International Inc.) 
was utilised for all experiments. The lyophilised product was reconstituted to a concentration 
of 50 mg/ml in sterile PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
pH 7.4) and stored at 4 °C until required. In the later experiments single batches of 5 mg/ml 
Intratect
®
 IVIG for infusion (Biotest) and 10 mg/ml Privigen
®
 IVIG for infusion (CSL 
Behring) were also utilised. 
2.3: Protein techniques 
2.3.1: Preparation of cell wall extracts 
The cell wall protein fraction was purified from the 20 selected GAS isolates according to the 
protocol of Biswas and colleagues (Biswas et al., 2001). Briefly, overnight GAS cultures 
were diluted 1:10 in fresh THB and grown to an A600 of 0.4-0.8. The bacterial cells were 
pelleted at 1500 xg for 10 min and resuspended in 1/50
th
 volume of 10 mM Tris-HCl (pH 8.0) 
containing 30% raffinose (Sigma-Aldrich), 100 U/ml mutanolysin (Sigma-Aldrich), 1 mg/ml 
lysozyme (Sigma-Aldrich) and 10% Protease Inhibitor Cocktail Set III (Calbiochem). The 
cells were incubated for 3 h at 37°C with occasional agitation by inversion, and pelleted by 
centrifugation at 1500 xg for 10 min. The supernatant (cell wall extract, CWE) was collected, 
clarified by filtration through a 0.2 µm syringe filter (Minisart) and dialysed into PBS  
overnight at 4°C using 12 ml Slide-A-Lyzer Dialysis Cassettes (Pierce) with a molecular 
weight cut-off of 20 kDa. The dialysed cell wall extracts were concentrated using Amicon 
Ultra-15 centrifugal filter units (Merck-Millipore) with a molecular weight cut-off of 10 kDa 
and stored at -20°C. 
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2.3.2: Determination of protein concentration 
The protein concentration of the prepared CWEs was measured using the Coomassie 
(Bradford) protein assay kit (Pierce) according to the manufacturer’s instructions. Briefly, 3x 
5 μl aliquots of each bovine serum albumin (BSA) standard or CWE sample were pipetted 
into triplicate wells of a Costar 96 well flat bottom polystyrene microplate (Corning) and 
combined with 250 μl of the Coomassie Reagent. The reaction was allowed to proceed for 10 
min at room temperature (RT) prior to the absorbance at 595 nm being measured using a 
µQuant universal microplate spectrophotometer (Bio-tek instruments). The mean A595 
measurement from triplicate blank wells (containing PBS in place of the protein sample) was 
subtracted from the absorbance measurements of the individual standard and CWE sample 
replicates. A four-parameter (quadratic) standard curve with a range of 25 µg/ml-2000 µg/ml 
was prepared by plotting the corrected A595 for each standard against its concentration and 
used to determine the concentration of the CWE samples in µg/ml. 
 
2.3.3: Visualisation of proteins by SDS-PAGE 
SDS-PAGE was performed using the Novex NuPAGE SDS-PAGE gel system (Invitrogen) 
according to the manufacturer’s instructions. Protein samples were combined with 4x 
NuPAGE lithium dodecyl sulphate (LDS) sample buffer (Invitrogen) and 0.5 M dithiothreitol 
(DTT, Sigma-Aldrich) in a ratio of 5:2:1 and heated to >70°C for 10 min. The denatured 
samples were separated on NuPAGE precast gels (Invitrogen) comprising either a bis-tris or a 
tris-acetate gel matrix under the conditions outlined in Table 2.2. The separated proteins were 
visualised using InstantBlue (Expedeon) and the molecular weights were estimated by 
comparison with the migration of a pre-stained standard solution (SeeBlue Plus2, Invitrogen). 
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Polyacrylamide gels were dried using the DryEase mini-gel drying system according the 
manufacturer’s instructions (Invitrogen).  
 
Table 2.2: The run conditions employed for SDS-PAGE. Abbreviations: MOPS: 3-(N-
morpholino) propanesulfonic acid; MES: 2-(N-morpholino) ethanesulfonic acid; TA:  
tris-acetate. 
 
Gel matrix Buffer Voltage Run time Separation range 
10% bis-tris MOPS 
MES 
200 V 
200 V 
50 min 
35 min 
200 kDa – 14 kDa 
200 kDa – 2.5 kDa 
7% tr is acetate TA 150 V 60 min 400 kDa – 31 kDa 
 
2.3.4: Visualisation of proteins by immunoblotting 
For immunoblotting, proteins were first separated by SDS-PAGE using an appropriate gel 
system as outlined above and then transferred onto a Hybond-LFP nylon membrane (GE 
Healthcare) by electroblotting at 100 V for 60 min. In the latter protein characterisation 
experiments, 1 µg aliquots of the recombinant streptococcal antigens were spotted directly 
onto a sheet of Hybond-LFP in PBS, or following denaturation in LDS sample buffer and 
DTT as outlined above. The resulting blots were blocked with 5% skimmed milk powder 
(Sigma-Aldrich) in PBS supplemented with 0.1% Tween-20 (Sigma-Aldrich) and 0.1% 
normal goat serum (NGS, Fisher Scientific). The blocked membrane was incubated with an 
appropriate concentration of primary antibody in blocking solution overnight at 4°C. The 
blots were washed three times with 0.05% Tween in PBS and incubated with a 1: 80,000 
dilution of an appropriate HRP-conjugated secondary antibody (Table 2.3). Following a 
further three washes, the reactive bands were detected using Amersham ECL Prime detection 
reagent (GE healthcare) and Amersham high performance chemi-luminescent film (GE 
healthcare) according to the manufacturer’s instructions. 
 
62 
 
Table 2.3: The secondary antibody preparations used in this study.  Abbreviations:  
HRP: Horseradish peroxidase; His: His-tag; LTA: Lipotechoic acid; BSA: Bovine serum 
albumin; GAcar: group A carbohydrate. 
 
Secondary antibody Supplier Target 
HRP-conjugated goat anti-human IgG Sigma Aldrich IVIG/E-IVIG 
HRP-conjugated goat anti-mouse IgG Sigma Aldrich 
 
Mouse anti-his IgG 
Mouse anti-LTA IgG 
HRP-conjugated goat anti-rabbit IgG Invitrogen Rabbit anti-BSA IgG 
HRP-conjugated donkey anti-Goat IgG Abcam Goat anti-GAcar IgG 
 
During the immunoprecipitation experiments, secondary antibody-only control immunoblots 
were routinely utilised to determine the degree of IgG contamination within the recovered 
fractions. Once blocked these control immunoblots were probed with a 1: 80,000 dilution of 
an appropriate HRP-conjugated secondary antibody (Table 2.3), allowing detection of 
desorbed IgG with ECL Prime. 
 
2.3.5: Amido black staining of immunoblot membranes 
During the later one-dimensional gel electrophoresis protein identification experiment, the 
membranes were stained with amido black staining solution (0.1% amido black, 25% 
isopropanol, 10% acetic acid; Sigma Aldrich) following detection of the immunoreactive 
bands. Membranes were incubated with amido black for 30s, rinsed once with dH2O and 
destained for 30 min using an aqueous solution containing 25% isopropanol (Sigma Aldrich) 
and 10% glacial acetic acid (Sigma Aldrich). Upon drying the transferred protein bands 
became visible. 
 
2.3.6: Enzymatic deglycosylation of streptococcal glycoproteins 
Enzymatic deglycosylation was performed using a protein deglycosylation mix (40,000,000 
U/ml O-glycosidase, 4,000 U/ml β-N-acetylglucosaminidase, 500,000 U/ml PNGase F, 
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50,000 U/ml neuraminidase and 8,000 U/ml β1-4 galactosidase; New England Biolabs) 
according to the manufacturer’s instructions. Briefly, 9 µg of CWE or the control protein 
fetuin were heated to 100°C for 10 min in 10 µl of glycoprotein denaturing buffer (0.5% 
SDS, 40 mM DTT). The reaction was chilled and supplemented with 2.5 µl of 10x G7 
reaction buffer (500 mM sodium phosphate, pH 7.5), 2.5 µl of 10% NP40 and 7.5 µl of dH2O 
prior to the addition of 2.5 µl of deglycosylation enzyme cocktail. Digestion was allowed to 
proceed for 4 h at 37 °C and the reaction was stored at 4 °C for analysis by SDS-PAGE and 
immunoblotting. In the glycosylated controls 2.5 µl of dH2O was added in place of the 
deglycosylation enzyme cocktail. 
 
2.3.7: Glycoprotein staining of streptococcal cell wall extracts 
Glycoproteins were stained using a glycoprotein detection kit (Sigma Aldrich) according to 
the manufacturer’s instructions. Briefly, the target proteins were separated by SDS-PAGE 
immersed in 50% methanol for 1 h at RT. Following 2x 20 min washes in dH2O, the gels 
were immersed in oxidation solution (periodic acid) and incubated for 1 h at RT. The gels 
were washed twice in dH2O and incubated in Schiff reagent overnight at 4°C. The following 
morning the gels were immersed in reduction solution (sodium metabisulphite) and incubated 
for a further 2 h at RT. Staining was intensified through incubation of the reduced protein 
gels in dH2O overnight at 4°C.  
 
2.3.8: Proteolytic digestion of streptococcal cell wall extracts 
For the proteolytic digestion experiments, 5 µg aliquots of CWE or BSA were combined with 
SET buffer (75 mM NaCl, 35 mM EDTA, 20 mM Tris, pH 7.5) to yield a final reaction 
volume of 15 µl. The reactions were supplemented with 1.5 µl of 10% SDS (Sigma Aldrich) 
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and 1.5 µl of 500 µg/ml proteinase K (Sigma Aldrich), and incubated at 55°C for 2 h. The 
reaction was halted through the addition of 6 µl of LDS sample buffer and 3 µl of 0.5 M DTT 
and incubation at >70 °C for 10 min. In the undigested controls 1.5 µl of dH2O was added in 
place of the proteinase K solution. 
2.4: Identification of immunoreactive proteins by SDS-PAGE and 
proteomic analysis 
2.4.1: Preparation of samples and separation by SDS-PAGE 
For analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS), 13 µl 
aliquots of each protein sample were combined with 5 µl of 4x LDS buffer and 2 µl of 0.5 M 
DTT and heated to >70°C for 10 min. The denatured samples were allowed to cool, 
combined with 5 µl of freshly prepared 1 M iodoacetamide (Sigma-Aldrich) and incubated in 
the dark for 20 min prior to separation by SDS-PAGE as described above. The separated 
proteins were visualised using InstantBlue (Expedeon) and the molecular weights were 
estimated using SeeBlue Plus2. 
 
2.4.2: Extraction of protein bands and preparation for LC-MS/MS 
The protein gels were washed with Milli-Q water (Millipore) and the individual protein bands 
were excised and placed into LoBind Eppendorf tubes (Eppendorf).  The gel slices were 
destained using 1 ml of 200 mM ammonium bicarbonate (Sigma-Aldrich) supplemented with 
50% acetonitrile (Sigma-Aldrich), washed with Milli-Q water and dehydrated with 0.5 ml of 
100% acetonitrile. The acetonitrile was aspirated and the proteins were incubated in 1.2 
mg/ml of trypsin (Sigma-Aldrich) in 1 M ammonium bicarbonate supplemented with 200 
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mM acetic acid at 37°C overnight. The trypsinized peptides were extracted with 250 µl of 2% 
acetonitrile in 0.1% formic acid (Sigma-Aldrich) for 1 h at RT, lyophilised and dissolved in 
30 µl of 0.1% trifluroacetic acid (Sigma Aldrich) in LC-MS grade water (Sigma Aldrich). 
The solubilised samples were loaded into the wells of an LC microplate ready for LC-MS/MS 
analysis (Agilent). 
 
2.4.3: Analysis of trypsinized peptides by LC-MS/MS and protein identification 
Reverse phase LC-MS/MS was performed by Magdalena Gierula, a research technician 
employed by the department of experimental medicine and toxicology, according to the 
protocol of Edwards and colleagues (Edwards et al., 2005).The prepared samples were 
analysed using a high resolution LTQ-instrument (Thermo Finnigan) fitted with an Agilent 
1200 series LC system. Peptides were separated on a 75 µm Picofrit C18 column (LC 
Packings) using a 20 min, 5%-50% acetonitrile gradient in 0.1% formic acid and ionised by 
positive mode electrospray. Proteins were identified using the publically available proteomes 
for the GAS reference strains SF370 and MGAS5005 and correlation of the MS/MS peptide 
data with the in silico trypsin fragmentation patterns predicted using the using BioWorks 3.3 
and the SEQUEST algorithm (Thermo Scientific). Peptides generating ions of 200-2000 amu, 
with a cross correlation score >1.5, 2.0, or 2.5 where z (the number of elementary charges 
carried by the peptide ion) = 1, 2 or 3 were mapped onto the GAS proteome allowing the 
peptide coverage of each identified protein to be calculated (Figure 2.1). To increase the 
stringency of this protein identification technique, only peptides with a probability >0.01 
were mapped onto the GAS proteome during the immunoprecipitation experiments. 
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A) 
 
M protein type 1 
 
        10         20         30         40         50         60  
MAKNNTNRHY SLRKLKTGTA SVAVALTVLG AGFANQTEVK ANGDGNPREV IEDLAANNPA  
  ↑    ↑     ↑↑ ↑                         ↑        ↑              
 
        70         80         90        100        110        120  
IQNIRLRYEN KDLKARLENA MEVAGRDFKR AEELEKAKQA LEDQRKDLET KLKELQQDYD  
    ↑ ↑    ↑  ↑ ↑          ↑  ↑↑      ↑ ↑       ↑↑     ↑ ↑        
 
       130        140        150        160        170        180  
LAKESTSWDR QRLEKELEEK KEALELAIDQ ASRDYHRATA LEKELEEKKK ALELAIDQAS  
  ↑      ↑  ↑  ↑    ↑ ↑            ↑   ↑      ↑    ↑↑↑            
 
       190        200        210        220        230        240  
QDYNRANVLE KELETITREQ EINRNLLGNA KLELDQLSSE KEQLTIEKAK LEEEKQISDA  
    ↑      ↑      ↑      ↑       ↑          ↑      ↑ ↑     ↑      
 
       250        260        270        280        290        300  
SRQSLRRDLD ASREAKKQVE KDLANLTAEL DKVKEDKQIS DASRQGLRRD LDASREAKKQ  
 ↑   ↑↑      ↑  ↑↑    ↑           ↑ ↑  ↑       ↑   ↑↑      ↑  ↑↑  
 
       310        320        330        340        350        360  
VEKDLANLTA ELDKVKEEKQ ISDASRQGLR RDLDASREAK KQVEKALEEA NSKLAALEKL  
  ↑           ↑ ↑  ↑       ↑   ↑ ↑     ↑  ↑ ↑   ↑        ↑     ↑  
 
       370        380        390        400        410        420  
NKELEESKKL TEKEKAELQA KLEAEAKALK EQLAKQAEEL AKLRAGKASD SQTPDTKPGN  
 ↑     ↑↑    ↑ ↑      ↑     ↑  ↑     ↑       ↑ ↑  ↑               
 
       430        440        450        460        470        480  
KAVPGKGQAP QAGTKPNQNK APMKETKRQL PSTGETANPF FTAAALTVMA TAGVAAVVKR  
↑    ↑              ↑    ↑  ↑↑                                 ↑↑ 
 
KEEN 
↑    
 
Figure 2.1: Identification of trypsinized peptides by LC-MS/MS and determination of protein 
coverage. 
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B) 
 
 
Figure 2.1 (Continued) 
  
Trypsin fragment Position Coverage (%) 
 
Trypsin fragment Position Coverage (%) 
EVIEDLAANNPAIQNIR 49 - 65 3.51 
 
EQLTIEK 222 - 228 1.45 
ARLENAMEVAGR 75 - 86 2.48 
 
RDLDASR 247 - 253 1.45 
LENAMEVAGR 77 - 86 2.07 
 
DLANLTAELDK 262 - 272 2.27 
RAEELEK 90 - 96 1.45 
 
RDLDASR 289 - 295 1.45 
AKQALEDQR 97 - 105 1.86 
 
DLANLTAELDK 304 - 314 2.27 
QALEDQR 99 - 105 1.45 
 
VKEEKQISDASR 315 - 326 2.48 
QALEDQRK 99 - 106 1.65 
 
RDLDASR 331 - 337 1.45 
LKELQQDYDLAK 112 - 123 2.48 
 
LAALEK 354 - 359 1.24 
ESTSWDR 124 - 130 1.45 
 
LNKELEESK 360 - 368 1.86 
ELEEKKEALELAIDQASR 136 - 153 3.72 
 
KLTEKEK 369 - 375 1.45 
KEALELAIDQASR 141 - 153 2.69 
 
EKAELQAK 374 - 381 1.65 
EALELAIDQASR 142 - 153 2.48 
 
ALKEQLAK 388 - 395 1.65 
ALELAIDQASQDYNR 171 - 185 3.1 
 
QAEELAK 396 - 402 1.45 
ANVLEK 186 - 191 1.24 
 
ASDSQTPDTKPGNK 408 - 421 2.89 
ELETITR 192 - 198 1.45 
 
PGNKAVPGK 418 - 426 1.86 
NLLGNAK 205 - 211 1.45 
 
AVPGKGQAPQAGTK 422 - 435 2.89 
LELDQLSSEK 212 - 221 2.07 
 
GQAPQAGTKPNQNK 427 - 440 2.89 
68 
 
C) 
 
M protein type 1 
 
        10         20         30         40         50         60  
MAKNNTNRHY SLRKLKTGTA SVAVALTVLG AGFANQTEVK ANGDGNPREV IEDLAANNPA  
 
        70         80         90        100        110        120  
IQNIRLRYEN KDLKARLENA MEVAGRDFKR AEELEKAKQA LEDQRKDLET KLKELQQDYD  
 
       130        140        150        160        170        180  
LAKESTSWDR QRLEKELEEK KEALELAIDQ ASRDYHRATA LEKELEEKKK ALELAIDQAS  
 
       190        200        210        220        230        240  
QDYNRANVLE KELETITREQ EINRNLLGNA KLELDQLSSE KEQLTIEKAK LEEEKQISDA  
 
       250        260        270        280        290        300  
SRQSLRRDLD ASREAKKQVE KDLANLTAEL DKVKEDKQIS DASRQGLRRD LDASREAKKQ  
 
       310        320        330        340        350        360  
VEKDLANLTA ELDKVKEEKQ ISDASRQGLR RDLDASREAK KQVEKALEEA NSKLAALEKL  
 
       370        380        390        400        410        420  
NKELEESKKL TEKEKAELQA KLEAEAKALK EQLAKQAEEL AKLRAGKASD SQTPDTKPGN  
 
       430        440        450        460        470        480  
KAVPGKGQAP QAGTKPNQNK APMKETKRQL PSTGETANPF FTAAALTVMA TAGVAAVVKR  
 
 
KEEN 
 
Total coverage: 35% 
 
Figure 2.1 (Continued): A) The primary amino acid sequence of each protein present 
within the util ized GAS proteome was automatically subjected to theoretical trypsin 
digest by Xcalibur. Arrows indicate predicted trypsin digestion sites. B -C) Fragments 
generating peptide ions of 200-2000 amu were tabulated producing a comprehensive 
list of all of the identif iable fragments produced by trypsinization of the GAS proteome. 
Peptides that were posit ively identif ied with a cross correlation score >1.5, 2.0, or 2.5 
where z = 1, 2 or 3 (yellow) were mapped onto the GAS proteome and the percentage 
of each protein covered was calculated. The digestion map of the M protein and the 
trypic peptides recovered from a single sample are displayed.  
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2.5: Cloning of recombinant streptococcal proteins into pET-19b 
2.5.1: Streptococcal genomic DNA extraction 
Genomic DNA (gDNA) was extracted according to the protocol of Pospiech and Neumann 
(Pospiech and Neumann, 1995). Cells from a 50 ml overnight culture were pelleted at 2500 
xg for 10 min at 4°C and incubated in 1 ml of PBS supplemented with 200 U/ml mutanolysin 
and 2 mg/ml lysozyme, for 10 min at 37°C. The cells were pelleted at 200 xg and 
resuspended in 500 µl of SET buffer supplemented with 1% SDS (Sigma-Aldrich) and 250 
µg/ml proteinase K (Sigma-Aldrich). The reaction was incubated at 55°C for 2 h, combined 
with 175 µl of 5 M NaCl (Sigma-Aldrich) and 500 µl of chloroform (Sigma-Aldrich) and 
incubated for a further 30 min. Following centrifugation at 16,000 xg for 15 min, the aqueous 
layer was transferred to a microcentrifuge tube (Star Labs), and the purified DNA was 
precipitated by addition of 1 volume of 100% isopropanol (Fisher Scientific). The DNA was 
pelleted at 16, 000 x g, rinsed with 1 volume of 70% ethanol and re-pelleted. The ethanol was 
aspirated and the purified DNA allowed to air dry for 20 min at RT. Purified DNA was 
dissolved in 500 µl of molecular grade water (VWR) and stored at -20°C. 
 
2.5.2: PCR amplification of inserts 
Primers were designed using the publically available genome sequences of the serotype M1 
GAS isolates SF370 and MGAS5005 (Table 2.4). Target genes were amplified using Gotaq 
DNA polymerase (Promega) in 100 µl reaction volumes comprising 20 µl of 5x reaction 
buffer, 2 µl of a 10 mM deoxynucleotide triphosphates (dNTP) stock solution, 2 µl of each 
primer at a concentration of 10 mM, 2 µl of purified genomic DNA, 0.5 µl of Gotaq 
polymerase and 70.5 µl of dH2O. All of the gene products were amplified using H305 
genomic DNA with the exception of clpE which was produced using both H305 and H366 
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gDNA. In the latter experiments, primers were designed to exclude the cell wall anchor 
domain from each target gene using the pSORTB algorithm described above. In addition, the 
signal sequences were excluded using SignalP, an algorithm that predicts the location of 
signal peptide cleavage sites within the amino acid sequences of gram positive proteins 
(Emanuelsson et al., 2007). The thermocycler program comprised an initial denaturation step 
at 95°C for 2 min, followed by 30 cycles of; 95°C for 1 min, 50°C for 1 min and 72°C for 2 
min 30 s, followed by a final extension step at 72°C for 5 min. The resulting PCR products 
were visualised by electrophoresis, using 1% agarose/tris-acetate EDTA (TAE) gels that were 
supplemented with a 1:10,000 dilution of SYBR® Safe (Invitrogen) and run at 100 V for 40 
min in TAE buffer.  
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Table 2.4: Primer sequences used in this study. 
 
Primer Sequence Gene UniProt Identifier Protein product 
     
DltA-F 
a
 
DltA-R 
a
 
GAGGATCCGATGATTAAGGATATGATTGACAG 
AAGGATCCATCATCGGTTATTGACCTC 
dltA Q99ZA6 D-alanine--poly(phosphoribitol) ligase subunit 1 
     
GapN-F 
a
 
GapN-R 
a
 
GAGGATCCGTTGGCAAAACAATATAAAAATTT 
TTGGATCCATTACTGGATATCAAATACAACAG 
gapN Q99Z67 NADP-dependent glyceraldehyde-3-phosphate dehydrogenase 
     
Clp-F 
Clp-R 
Clp_seq-F 
Clp_seq-R 
GCTCGGATCCTATGCTGTGTCAAAATTG 
CTGCGGATCCGTTAATCGAGAGAC 
GCCGTGGTGCTATAATATGAA 
GATAGAAAAAGAGAGAGTCTCCTT 
clpE Q48XR7 ATP-dependent clp protease ATP-binding subunit 
     
ABC-F 
a
 
ABC-R 
a
 
GGGGATCCATTGCTTACAGTTTCTGAT 
CAGGATCCTTTATTTCCAAAGTTCAGCAAC 
SPy_2210 Q99XH2 ABC transporter ATP-binding protein 
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Table 2.4 (Continued) 
 
Primer Sequence Gene UniProt Identifier Protein product 
     
GuaA-F 
a
 
GuaA-R 
a
 
AGGGATCCAATGACTGAAATTTCAATTTTG 
TTGGATCCGTTATTCCCATTCAACTG 
guaA P64299 GMP synthase [glutamine-hydrolyzing] 
     
CSP-F 
CSP-R 
CCGGATCCAGAAACTTCTGGCCCTGTTGATGATACAG 
CCGGATCCTTGCAGAGTGTCGTCCTCTATTCGT 
Spy_0843 Q9A0C0 Cell surface protein 
     
HMAP-F 
HMAP-R 
CCGGATCCAAGTCCGATTGAAACCTATACGCATAG 
CCGGATCCTTTATTTTTTGGTGGTTGTCAACTGAACG 
Spy_1037 Q99ZW9 Hypothetical membrane associated protein 
     
NBP-F 
NBP-R 
CCGGATCCAGTTGCAATGGTTACCGATACTGGTGGTG 
CCGGATCCTCTATTTTTCAGGAACTTTAATGTCACC 
M5005_Spy0942 Q99ZH4 Nucleoside binding protein 
     
OppA-F 
OppA-R 
CCGGATCCAGGAACGACTGATGTGATAACACAAATG 
CCGGATCCTTTATTTTTCAACGTGATCAGCTAACTTCTC 
oppA Q490V0 Oligopeptide binding protein 
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Table 2.4 (Continued) 
 
Primer Sequence Gene UniProt Identifier Protein product 
     
PrgA-F 
PrgA-R 
CCGGATCCAGGAGAAACGAAGGCGAGTAATACTCACG 
CCGGATCCTTCACTTAGATTCCTTACGGAACCTAAATCC 
prgA Q9AH1 Putative surface exclusion protein 
     
PulA(N)-F 
PulA(N)-R 
CCCATATGGATGGCAATGCTAAATCTGGTGATGG 
CCCATATGCGGTAGCAATTGAACGTGGGTAAC 
pulA Q99XX8 Putative pullulanase 
     
ScpA-F 
ScpA-R 
ScpA(SDM)-F 
ScpA(SDM)-R 
ScpA_seq-F 
ScpA_seq-R 
CCGGATCCAACCAAAACCCCACAAACTC 
CCGGATCCTAGAGTGGCCCTCCAATAGC 
TTTGCTATCATAGATTGGTTTTTATAAGGCTGACAGATTGCCAAAAT 
ATTTTGGCAATCTGTCAGCCTTATAAAAACCAATCTATGATAGCAAA 
CGTTCCAATCGATGCTAGTCG 
GGCAATCTTGCCTTTGACATCC 
scpA C5AP_STRP1 C5a peptidase 
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Table 2.4 (Continued):  Primers included a BamHI or NdeI digestion site (underlined) to facil itate cloning of the amplif ied gene 
products into the pET-19b overexpression vector. 
a
Primers were designed by Daryl Beckford, a Masters student in the section of 
infectious disease and immunity, under supervision. Abbreviations: MCS: multiple cloning site. Clp_seq -F and clpE_seq-R were used 
for automated fluorescent sequencing of the full length clpE inserts. 
 
Primer Sequence Gene UniProt Identifier Protein product 
     
MalE-F 
MalE-R 
CCGGATCCAATGGGTTTGTCATGTATTTCG 
CCGGATCCTTTATTTTGTTGCAGCGATATC 
malE Q48Y96 Maltose/maltodextrin-binding protein 
     
T7 promoter 
T7 terminator 
TAATACGACTCACTATAGGG 
GCTAGTTATTGCTCAGCGG 
pET-19b MCS   
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2.5.3: Restriction digestion of Vector/Insert DNA  
The amplified inserts were digested with BamHI or NdeI (New England Biolabs) for 3 h at 
37°C and cloned into digested pET-19b overexpression vector (Novagen). The digestions 
were performed using 100-1000 ng aliquots of vector or insert DNA and 20 U of enzyme in 
10 µl of NEB Buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, pH 7.9) 
supplemented with 1 μg/μl of BSA.  
 
Digested inserts were purified using the QIAquick PCR purification kit (Qiagen) according to 
the manufacturer’s instructions. Briefly, the digested DNA was combined with 5 volumes of 
buffer PB and applied to a QIAquick column by centrifugation at 16,000 xg for 1 min. Bound 
DNA was washed with 0.5 ml of buffer PB and 0.75 ml of buffer PE, then eluted in 50 µl of 
molecular grade water and stored at 4°C until use. The concentration of the purified DNA 
was measured by UV-Vis Spectrophotometry (A260, 50 ng-cm/µl, 1 mm path length) and 
application of Beer’s law using a Nanodrop ND-1000 Spectrophotometer (NanoDrop).  
 
The digested vector reactions were supplemented with 5 U Antarctic Phosphatase (AP, New 
England Biolabs) and 1 µl of 10x AP reaction buffer (500 mM bis-tris-propane-HCl, 10 mM 
MgCl2, 1 mM ZnCl2, pH 6) and incubated for a further 40 min at 37°C. Following 
dephosphorylation, the digested pET-19b DNA was resolved on a 0.5% agarose/TAE gel, 
supplemented with a 1:10,000 dilution of SYBR Safe and purified using the QIAquick gel 
extraction kit (Qiagen) according to the manufacturer’s instructions. Briefly, gel slices 
containing the linearized plasmid were extracted, weighed and incubated with 3 volumes of 
buffer QG at 55°C for 15 min. The solubilised DNA was supplemented with 1 volume of 
isopropanol and applied to a QIAquick column by centrifugation at 16, 000 xg for 1 min. The 
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bound DNA was washed with 0.75 ml of buffer PE, eluted in 50 µl of molecular grade water 
and stored at 4°C until use. The concentrated of the purified DNA was measured using a 
Nanodrop ND-1000 Spectrophotometer. 
 
2.5.4: Re-ligation of Vector/Insert DNA and transformation into chemically 
competent E.coli cells 
Ligation reactions were performed using a 3:1 molar ratio of insert:vector and 400 U of T4 
DNA ligase (New England Biolabs) in 10 µl of T4 DNA Ligase Reaction Buffer (50 mM 
Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, pH 7.5). The reaction was allowed to 
proceed for 20 min at RT prior to transformation of the re-ligated vector into One Shot 
TOP10 chemically competent E. coli cells (Invitrogen) according to the manufacturer’s 
instructions. Briefly, 5 µl of the re-ligated plasmid reaction was inoculated into 50 µl of 
competent cells and incubated on ice for 30 min. The cells were heat shocked at 42°C for 30 s 
and allowed to recover in 250 µl of SOC medium (2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose, Invitrogen) for 1 h 
at 37°C with agitation. Once recovered, the cells were plated onto LB agar plates 
supplemented with 100 µg/ml of ampicillin (Sigma-Aldrich) and incubated overnight at 
37°C. 
 
The presence and orientation of the cloned inserts was verified by PCR and BamHI digestion. 
An initial screen of the transformed colonies was performed by colony PCR, where a small 
percentage of each colony was resuspended in 10 µl of molecular grade water, boiled for 10 
min and used as the template for a Gotaq PCR reaction. The T7 promoter primer and T7 
terminator primer (Novagen) were used to amplify across the pET-19b multiple cloning site 
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(MCS), yielding a product of ~180 bp from the empty plasmid or a larger product from a 
plasmid containing a cloned insert (Figure 2.2).  
 
 
 
Figure 2.2: The pET-19b overexpression vector.  Vector maps of A) the full length 
vector, and B) the multiple cloning site were produced using the data sheet provided by 
the manufacturer. Abbreviations: His – His-tag; Entero. – Enterokinase cleavage 
domain.  
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Colonies yielding a product that was equivalent to the size of the expected insert were 
cultured overnight in LB broth supplemented with 100 µg/ml of ampicillin (LBAmp100) and the 
loaded plasmid (i.e. plasmid containing an insert) was purified using the QIAprep spin 
miniprep kit (Qiagen) according to the manufacturer’s instructions. Briefly, a 5 ml overnight 
culture was pelleted at 1500 x g, resuspended in 250 µl of buffer P1 and lysed by sequential 
addition of 250 µl of buffer P2 and 350 µl of buffer N3. Cellular debris was pelleted by 
centrifugation at 16,000 xg for 10 min and the supernatant was applied to a QIAprep spin 
column by centrifugation at 16, 000 xg for 1 min. Bound DNA was washed with 0.5 ml 
buffer PB and 0.75 ml buffer PE, then eluted in 50 µl of molecular grade water and stored at 
4°C until use. To confirm the presence of the insert, a 5 µl aliquot of the purified plasmid was 
digested with BamHI for 1 h at 37°C and visualised on a 1% agarose/TAE gel. The 
orientation of the insert was confirmed by Gotaq PCR using the T7 promoter primer, and an 
insert-specific reverse primer ensuring that amplification would only occur if the product was 
in the correct orientation (Figure 2.3). Prior to expression of the protein, the frame of the 
insert was routinely confirmed by automated-fluorescent sequencing of the purified plasmid 
using the T7 promoter/terminator primer pair. Sequencing was performed by the MRC CSC 
genomics core laboratory, Imperial College London. Sequence alignments were performed 
using ClustalW2 (Larkin et al., 2007). 
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Figure 2.3: The PCR strategy used to determine the orientation of the cloned 
inserts. Using the T7 promoter primer and an insert specif ic reverse primer, only 
plasmid constructs containing an insert in the correct orientation produced a DNA 
fragment following PCR amplif ication. Thus plasmid constructs that were fit for purpose 
could easily be identif ied using PCR amplif ication and agarose gel electrophoresis.  
 
2.5.5: Site directed mutagenesis of pET-19b(scpA) 
Site directed mutagenesis (SDM) was performed using the QuikChange II site-directed 
mutagenesis kit (Agilent Technologies) according to the manufacturer’s instructions. Briefly, 
primers were designed using the QuikChange primer design program and used to introduce a 
premature stop codon into the scpA sequence (Table 2.4). Synthetic pET-19b(ScpA) was 
amplified using in 50 µl reaction volumes comprising 5 µl of 10x reaction buffer, 1 µl of 
dNTP mix, 1.25 µl of each primer at a concentration of 100 mM, 2 µl of purified plasmid, 1 
µl of PfuUltra HF DNA polymerase and 38.5 µl of dH2O. The thermocycler program 
comprised an initial denaturation step at 95°C for 30 s, followed by 18 cycles of; 95°C for 30 
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s, 55°C for 1 min and 68°C for 10 min, followed by a final extension step at 72°C for 30 min. 
The resulting PCR products were supplemented with 1 µl of DpnI and incubated at 37 ºC for 
1 h to digest the parental, non-mutated plasmid DNA.  
 
For transformations, 1 µl of the Dpn I-treated DNA was inoculated into 50 µl of XL-10 Gold 
ultracompetent cells and incubated on ice for 30 min in a prechilled 14-ml BD Falcon 
polypropylene round-bottom tube. The cells were heat shocked for 45 seconds at 42°C and 
placed on ice for 2 min prior to the addition of 0.5 ml of NZY
+
 broth (10 g NZ amine; 5 g 
yeast extract; 5 g NaCl; 12.5 mM MgCl2; 12.5 mM MgSO4; 20 mM glucose, Invitrogen) 
prewarmed to 42°C. Once recovered, the cells were plated onto LB agar plates supplemented 
with 100 µg/ml of ampicillin and incubated overnight at 37°C. Insertion of the premature stop 
codon was confirmed by purification of pET-19b(scpA) from overnight XL-10 cultures and 
automated fluorescent sequencing of the scpA insert using the primers outlined in Table 2.4. 
 
2.5.6: Overexpression of recombinant proteins in One Shot BL21 E. coli cells 
Recombinant proteins were overexpressed in One Shot BL21 (DE3) chemically competent E. 
coli cells (Invitrogen) according to the manufacturer’s instructions. Briefly, loaded pET-19b 
was purified from 5 ml overnight cultures of TOP10 E. coli cells and transformed into BL21 
cells via heat shock at 42°C. Following recovery in SOC medium, the transformed cells were 
inoculated into 10 ml of LBAmp100 and incubated overnight at 37°C. The overnight culture 
was diluted 1:50 in fresh LBAmp100 and cultured to an A600 of 0.4-0.6 prior to the addition of 
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Sigma-Aldrich) and incubation for a 
further 3 h. The cells were pelleted at 1500 xg in 50 ml aliquots and stored at -20°C until 
required. 
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2.6: Purification of His-tagged recombinant proteins by immobilized metal 
affinity chromatography 
2.6.1: Preparation of soluble and insoluble protein fractions 
Histidine (His) tagged proteins were purified using the Ni-NTA Purification System 
(Invitrogen). The pelleted BL21 cells were resuspended in 2.5 ml of native binding buffer (50 
mM NaH2PO4 monobasic, 0.5 M NaCl, 10 mM imidazole, pH 8) containing 250 µl 10x 
BugBuster (Novagen) and 2.5 µl Benzonase Nuclease (Novagen). Following 20 min of gentle 
agitation at RT, the cellular debris was pelleted and the supernatant (containing the soluble 
protein fraction) was pooled and aspirated into a sterile 30 ml universal tube (VWR) for 
storage at -20°C. The cellular debris (containing the insoluble protein fraction) was dissolved 
in 2.5 ml of denaturing lysis buffer (6 M guanidine hydrochloride, 20 mM NaH2PO4, 500 
mM NaCl, pH 7.8) by incubation at 55°C with gentle agitation, pooled and stored at -20°C. 
The fraction containing each recombinant protein was identified by SDS-PAGE and 
InstantBlue staining. In place of 4x LDS loading buffer, the insoluble protein fractions were 
supplemented with 4x DNA loading dye (30% glycerol, 0.25% bromophenol blue) prior to 
incubation at >70°C with DTT. 
 
2.6.2: Immobilized metal affinity purification of soluble recombinant proteins 
Immobilized metal affinity chromatography (IMAC) was performed according to the 
manufacturer’s instructions. Briefly, a 2 ml aliquot of a 50% Ni-NTA agarose resin slurry in 
30% ethanol (Invitrogen) was resuspended by gentle agitation and pipetted into a 5 cm 
Econo-column (Bio-Rad). The resin was washed with 10 column volumes (CV) of distilled 
water followed by 10 CV of native binding buffer and incubated with a 5 ml aliquot of the 
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soluble protein fraction for 30 min at RT with gentle agitation. The resin was washed 
extensively with native wash buffer (50 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, pH 8) 
and the purified recombinant protein was fractionated into 10x 1 ml fractions of native 
elution buffer (50 mM NaH2PO4, 0.5 M NaCl, 250 mM imidazole, pH 8) for analysis by 
SDS-PAGE. The column was stripped with 20 CV of 0.5 M NaOH (Sigma-Aldrich), re-
equilibrated into PBS and stored in 1 CV of PBS supplemented with 0.1% sodium azide 
(Sigma-Aldrich). Eluted fractions containing purified recombinant protein were pooled and 
dialysed into PBS overnight at 4°C. The dialysed samples were subjected to centrifugal 
concentration and the protein concentration was measured by Coomassie protein assay prior 
to storage at -20°C. 
 
2.6.3: Immobilized metal affinity purification of insoluble recombinant proteins 
Denaturing IMAC was performed as above however, after washing with 10 CV of distilled 
water, the column was flushed with 10 CV of denaturing binding buffer (8 M urea, 20 mM 
NaH2PO4, 500 mM NaCl, pH 7.8) and incubated with a 5 ml aliquot of the insoluble protein 
fraction for 30 min at RT with gentle agitation. The resin was washed sequentially with 
denaturing binding buffer, denaturing wash buffer 1 (8 M urea, 20 mM NaH2PO4, 500 mM 
NaCl, pH 6) and denaturing wash buffer 2 (8 M urea, 20 mM NaH2PO4, 500 mM NaCl, pH 
5.3) and the purified recombinant protein was fractionated into 10x 1 ml fractions of 
denaturing elution buffer (8 M urea, 20 mM NaH2PO4, 500 mM NaCl, pH 4) for analysis by 
SDS-PAGE. The column was stripped with 20 CV of 0.5 M NaOH, re-equilibrated into PBS 
and stored in 1 CV of PBS supplemented with 0.1% sodium azide.  
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2.6.4: Solubilisation of insoluble recombinant proteins 
Eluted fractions containing each purified insoluble recombinant protein were pooled and 
solubilised by stepwise dialysis into decreasing concentrations of urea (Sigma-Aldrich). 
Dialysis was performed using 2 L of 8 M urea that was diluted by 1 M twice daily until a 
concentration of 1 M was reached. Following dialysis into 0.5 M urea, the solubilised 
samples were dialysed into PBS overnight at 4°C and subjected to centrifugal concentration. 
The protein concentration of the samples was measured by Coomassie protein assay prior to 
storage at -20°C. 
 
2.7: Purification of streptococcal antigens by IVIG immunoprecipitation 
using a protein G agarose matrix 
IVIG immunoprecipitation was initially performed using Pierce Protein G agarose (Thermo 
Scientific) according to the manufacturer’s instructions. Briefly, 75 µg of CWE was 
combined with 25 µg of IVIG and diluted to a final reaction volume of 50 µl in molecular 
grade water. Following 2 h of gentle agitation at RT, the mixture was supplemented with 100 
µl of 50% protein G resin slurry in 0.02% sodium azide and incubated for a further 2 h. The 
resin was gently pelleted by centrifugation at 2500 xg for 2 min and the supernatant 
(containing the unbound protein fraction) was collected and saved for analysis. The resin was 
washed 3 times with 250 µl of immunoprecipitation buffer (25 mM Tris, 150 mM NaCl, pH 
7.2) and denatured in 100 µl of LDS loading buffer supplemented with 50 µl of 0.5 M DTT at 
>70°C for 10 min. The resin was pelleted by centrifugation at 16,000 xg and the supernatant 
(containing the bound protein fraction) was analysed by SDS-PAGE. 
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2.8: Enrichment of IVIG with anti-GAS antibody 
2.8.1: Coupling of streptococcal cell wall extract to cyanogen bromide-activated 
agarose 
Streptococcal CWE was coupled to cyanogen bromide (CNBr)-activated agarose (Sigma-
Aldrich) at an approximate concentration of 1 mg/ml. CWE was dialysed into coupling buffer 
(0.1 M NaHCO3, 0.5 M NaCl, pH 8.3) overnight at 4°C. Lyophilised CNBr-activated agarose 
was swollen in cold 1 mM HCl (200 ml/g dry gel), pipetted into a 5 cm Econo-column and 
washed sequentially with 10 CV of distilled water and 5 CV of coupling buffer. The dialysed 
CWE was immediately added and incubated with the swollen CNBr-activated agarose 
overnight at 4°C. The resin was washed extensively with coupling buffer and incubated with 
0.2 M glycine (Sigma-Aldrich) at RT for 2 h with gentle agitation. The resin was washed 
sequentially with 10 CV of coupling buffer and 10 CV of sodium acetate buffer (0.1 M 
CH3COONa, 0.5 M NaCl, pH 4). This high/low pH wash cycle was repeated five times and 
the resulting affinity purification column was equilibrated into PBS supplemented with 0.1% 
sodium azide and stored at 4°C. 
 
2.8.2: Affinity purification of anti-GAS IgG from IVIG 
Anti-GAS IgG was purified from commercially available IVIG by affinity chromatography. 
A 5 ml aliquot of reconstituted IVIG was incubated with a 2 ml streptococcal CWE column 
for 2 h at RT with gentle agitation. The column was washed extensively with PBS and the 
bound antibody was eluted in 10x 790 µl aliquots of 0.5 M acetic acid (pH 3, Sigma-Aldrich) 
that were neutralised immediately using  210 µl aliquots of 3 M Tris-HCl (pH 8.8). The 
eluted fractions (EF) were pooled, dialysed into PBS overnight at 4°C and subjected to 
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centrifugal concentration. The concentration of the resulting “enriched” IVIG (E-IVIG) was 
measured by UV-Vis Spectrophotometry (A280, 1.37 mg-cm/ml, 1 mm path length) and 
application of Beer’s law using a Nanodrop Spectrophotometer. The column was re-
equilibrated into PBS supplemented with 0.1% sodium azide and stored at 4°C. 
 
2.8.3: Comparison of the reactivities of E-IVIG and IVIG by ELISA 
For ELISA, triplicate wells of a 96 well flat bottom polystyrene microplate were incubated 
with 50 µl of a 20 µg/ml GAS CWE solution in PBS o/n at 4°C. The coated wells were 
washed three times with 0.05% Tween in PBS using an ELx50 plate washer (Bio-tek 
instruments) and blocked with immunoblot blocking solution for 1 h at RT. The blocked 
wells were incubated with an appropriate concentration of primary antibody (either IVIG or 
E-IVIG) in blocking solution for 1 h at RT and washed three times with 0.05% Tween in 
PBS. The bound antibody was detected following incubation with a 1: 80,000 dilution of 
horseradish peroxidase (HRP) conjugated goat anti-human IgG in blocking solution for 1 h at 
RT. The wells were washed three times to remove the unbound detection antibody and 
incubated with 50 µl of 3,3′,5,5′-tetramethylbenzidine liquid substrate solution (Sigma-
Aldrich) in the dark for 10 min at RT. The reaction was halted by addition of 50 µl of 1 M 
sulphuric acid (Sigma-Aldrich) and the mean A450 measurement from triplicate blank wells 
(incubated with PBS in place of CWE) was subtracted from the A450 measurements of the 
individual IgG sample replicates. 
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2.9: Purified neutrophil opsonophagocytosis assays 
2.9.1: Neutrophil extraction 
Neutrophils were extracted from 20 ml aliquots of heparinised blood collected from healthy 
human donors in accordance with the appropriate ethical approval. Blood was combined 1:1 
with 3% dextran (MW >100,000) in 0.9% saline and allowed to separate on ice for 30 min. 
The supernatant layer was aspirated and centrifuged at 1000 xg for 10 min. The pelleted cells 
were resuspended in 20 ml of 0.9% saline, layered onto 10 ml of Ficoll-paque plus (VWR) 
and centrifuged at 700 xg for 40 min. The liquid and the buffy coat layer were discarded, and 
the pelleted cells were resuspended in 20 ml of 0.2% saline in order to lyse the red blood cells 
(RBC). After 30 s, 20 ml of 1.6% saline was added and the cell solution was mixed by 
inversion to adjust the overall saline concentration back to 0.9%. The cells were pelleted at 
1000 xg for 6 min at 20°C and the RBC lysis step was repeated. The purified neutrophils 
were pelleted and resuspended in 2 ml of 0.9% saline. A small aliquot of the resulting 
neutrophil suspension was combined 1:1 with 0.4% trypan blue solution (Sigma-Aldrich) and 
10 µl of the stained cell solution was loaded onto a Neubauer improved haemocytometer 
(VWR). The number of cells present in 20 nl was counted and used to calculate the cell 
density per ml. Purified neutrophils were adjusted to a density of 2 x 10
6
 cells/ml with 0.9% 
saline, stored on ice and used within 2-4 h. 
 
2.9.2: Bacterial preparation 
Bacterial cells from a 5 ml overnight culture were pelleted, washed once in PBS and 
resuspended in 490 µl 0.1 M sodium carbonate buffer (pH 9) supplemented with 10 µl of 1 
mg/ml fluorescein isothiocyanate (FITC, Sigma-Aldrich). The cells were incubated at 37°C 
with agitation for 30 min, washed twice and resuspended to an A600 to 0.35 in PBS. FITC 
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labelled bacteria were stored on ice until required. All FITC incubation steps were performed 
in the dark to prevent photobleaching.  
 
2.9.3: Opsonophagocytosis assay 
Opsonophagocytosis assays were performed in 1 ml reaction volumes containing 100 µl of 
resuspended bacteria and 1 x 10
6
 neutrophils. The resuspended bacteria were incubated with 
an appropriate concentration of E-IVIG, IVIG or PBS at 37°C for 30 min with agitation prior 
to addition of the neutrophil suspension. After a further 30 min, 400 µl of the GAS/neutrophil 
suspension was aspirated into a BD Falcon round-bottom polystyrene FACS tube (Fisher 
Scientific) containing 400 µl of ice cold 0.02% ethylenediaminetetraacetic acid (EDTA, 
Sigma-Aldrich) in 0.9% saline. Immediately prior to cytometric analysis the extracellular 
fluorescence was quenched through addition of 400 µl of trypan blue. 
 
2.9.4: Cytometric analysis 
The quenched samples were analysed using a FACS Calibur flow cytometer (BD 
Bioscience), pre-calibrated using Calibrite 3 Beads (BD Bioscience). Neutrophils were gated 
based upon their size (forward scatter) and granularity (side scatter) and 20,000 events were 
assessed for green fluorescence by excitation at 488 nm and absorbance at 515-545 nm. Cells 
were independently gated for positive green fluorescence during each experiment due to 
varying levels of auto fluorescence between donor neutrophils. Gating was defined by 
analysis of the positive and negative control groups prior to analysis of the experimental 
populations (Figure 2.4).  
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Figure 2.4: Gating of FITC positive neutrophils. A) The neutrophil population was 
identif ied based on the size (FSC-H) and granularity (SSC-H) of the cells. B) FITC 
posit ive cells were identif ied by excitation at 488 nm and absorbance at 515-545 nm; 
and gated for posit ive green fluorescence (dotted line) by analysis of the posit ive and 
negative control populations.  
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2.10: Purification of streptococcal antigens by E-IVIG 
immunoprecipitation using a protein G agarose matrix 
2.10.1: Cross-linking of E-IVIG to protein G agarose  
A 1 ml aliquot of protein G agarose slurry was resuspended by gentle agitation and pipetted 
into a 5 cm Econo-column (giving a 500 µl resin bed). The resin was washed with 10 CV of 
PBS and incubated with 4 CV of 0.5 mg/ml E-IVIG or rabbit anti-BSA IgG (Invitrogen) in 
PBS for 2 h at RT with gentle agitation. The resin was washed extensively with PBS and 
incubated with 10 CV of 20 mM dimethyl pimelimidate dihydrochloride (DMP, Sigma-
Aldrich) in 0.1 M sodium borate (pH 9) for 30 min at RT with gentle agitation. Following a 
second incubation with fresh DMP solution, the protein G IP columns were washed 
extensively with 50 mM glycine (pH 2.5), re-equilibrated into PBS and stored in 1 CV of 
PBS supplemented with 0.1% sodium azide.  
 
2.10.2: Purification of streptococcal antigens 
For immunoprecipitation, 9 ml aliquots of dialysed streptococcal CWE were incubated with 
the E-IVIG and control anti-BSA immunoprecipitation columns for 2 h at RT with gentle 
agitation. The unbound protein flow through (FT) was collected and saved for analysis, and 
the columns were washed extensively with PBS. The bound protein was eluted in 10x 790 µl 
aliquots of 0.5 M acetic acid (pH 3) that were neutralised immediately using  210 µl aliquots 
of 3 M Tris-HCl (pH 8.8). The EFs were pooled, dialysed into PBS o/n at 4°C and 
concentrated using Amicon Ultra-15 centrifugal filter units. The concentration of the FT and 
pooled EF samples was measured by Coomassie protein assay prior to storage at 4°C. The 
columns were equilibrated into PBS supplemented with 0.1% sodium azide and stored at 4°C. 
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2.11: Purification of streptococcal antigens by E-IVIG 
immunoprecipitation using a cyanogen bromide activated agarose 
matrix 
2.11.1: Preparation of column and purification of streptococcal antigens 
E-IVIG and goat control IgG (Abcam) were each coupled to CNBr activated agarose at an 
approximate concentration of 1 mg/ml as outlined above. For immunoprecipitation, 1-2 mg 
aliquots of dialysed M1 GAS CWE were incubated with the resulting columns for 2 h at RT 
with gentle agitation. The unbound protein FT was collected and saved for analysis, and the 
columns were washed extensively with PBS. The bound protein was eluted in 10x 1 ml 
aliquots of 1 M acetic acid (pH 3) that were neutralised immediately using  1 ml aliquots of 3 
M Tris-HCl (pH 8.8). The EFs were pooled, dialysed into PBS overnight at 4°C and 
subjected to centrifugal concentration. The concentration of the FT and pooled EF samples 
was measured by Coomassie protein assay prior to storage at 4°C. The columns were 
equilibrated into PBS supplemented with 0.1% sodium azide and stored at 4°C.  
 
2.11.2: Comparative immunoprecipitation experiments 
For comparative the immunoprecipitation experiments, 1 mg aliquots of E-IVIG prepared 
using Endobulin, Intratect or Privigen IVIG were coupled to 1 ml aliquots of swollen CNBr 
resin. CWE was prepared using 2 representative strains from each serotype and applied to 
each column in 1-2 mg aliquots. The concentration of the FT and pooled EF samples was 
measured by Coomassie protein assay prior to storage at 4°C. The columns were equilibrated 
into PBS supplemented with 0.1% sodium azide and stored at 4°C.  
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2.12: Murine treatment experiments 
2.12.1: Pre-treatment with E-IVIG 
Age matched (7-8 week old) female C57BL/6 mice were purchased from Charles River 
Laboratories International and housed in 3 cages of 8 mice. The groups were pre-treated with 
800 µg of E-IVIG or IVIG in 100 µl of PBS by intraperitoneal injection and allowed to 
recover for 16 h. A control group of mice was pre-treated with PBS alone.  
 
2.12.2: Infection 
The mice were challenged intramuscularly with 5x 10
6
 CFU of the M1 GAS isolate H305. A 
250 ml overnight culture was pelleted by centrifugation at 1500 x g, washed twice with PBS 
and resuspended in PBS to an A600 of 12. The CFU/ml of the inoculum was calculated by 
serial dilution of the bacterial suspension and plating onto CBA. After 24 h the mice were 
culled and exsanguinated by cardiac puncture. The blood was aspirated into 10 µl of 
preservative free heparin and 50 µl was plated onto CBA to assess the bacterial load. The 
spleen, liver and infected thigh were removed and homogenised in PBS at a dilution of 10 
µl/mg (spleen) or 5 µl/mg (liver and thigh). The superficial inguinal lymph node was also 
excised and homogenised in 500 µl of PBS regardless of the organ weight. Bacterial loads at 
the infection site and the degree of dissemination was assessed by plating serial dilutions of 
each organ homogenate onto CBA. 
92 
 
2.13: Murine vaccination experiments 
2.13.1: Vaccination schedule 
Age matched (5-6 week old) female BALB/c mice were purchased from Charles River 
Laboratories International and housed in 5 cages of 6 mice. The groups were vaccinated 
intramuscularly with 15 µg of M1 GAS immunoprecipitate, 15 µg of M1 GAS CWE, 50 µg 
of recombinant protein in 25 µl of PBS, emulsified 1:1 with Freund’s complete adjuvant. 
Booster immunisations were given at 21 and 35 days in Freund’s incomplete adjuvant. A 
control group of mice was immunised and boosted with PBS and adjuvant alone. Tail bleeds 
were performed on day 40 to obtain uninfected serum for analysis by ELISA. 
 
2.13.2: Murine seroconversion ELISAs 
The wells of a 96 well microplate were coated with a 20 µg/ml solution of each vaccine 
formulation as outlined above. The coated wells were incubated with a 1:500 dilution of the 
serum obtained by tail bleeding and the bound antibody was detected using a 1: 80,000 
dilution HRP-conjugated goat anti-mouse IgG as outlined above. The initial colorimetric 
reaction was allowed to proceed for 1 h prior to the addition of 1 M sulphuric acid. The mean 
A450 measurement from triplicate blank wells (incubated with normal mouse serum in place 
of vaccinated mouse serum) was subtracted from the A450 measurements of the individual IgG 
sample replicates. Each vaccine formulation was probed using serum from the relevant 
vaccination group, and from the PBS vaccinated control group.  
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2.13.3: Infection 
The mice were challenged intramuscularly with 5.6 x 10
6
 CFU of the M1 GAS strain H305 as 
outlined above. After 24 h the mice were culled and exsanguinated by cardiac puncture. In 
order to determine bacterial load, 5 µl of aspirated blood was diluted 1:10 with preservative 
free heparin (Wockhardt) and plated onto CBA. The remaining blood was centrifuged at 2000 
xg for 30 min and the serum was aspirated and stored at -20°C. The spleen, liver, superficial 
inguinal lymph node and infected thigh were removed and homogenised as outlined above. 
Bacterial loads at the infection site and the degree of dissemination was assessed by plating 
serial dilutions of each organ homogenate onto CBA. 
 
2.14: Ethics 
All animal procedures were approved by the local ethical review process and were conducted 
in accordance with the relevant, UK Home Office sanctioned, project licence.  
 
2.15: Statistical analysis 
All data were analysed using GraphPad Prism (GraphPad Software Inc.) by application of the 
appropriate statistical test. Statistical significance was recorded where P < 0.05. Where 
appropriate, curve fits were calculated by non-linear regression and Kd values determined 
using the equation                    . 
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3: Results and Discussion 
3.1: Recognition of streptococcal surface antigens by IVIG 
3.1.1: Visualization of antigens by immunoblot analysis 
The starting hypothesis of this study was that IVIG recognises an as yet uncharacterised 
repertoire of streptococcal surface antigens that may form the basis of an effective, 
multivalent vaccine formulation. In order to explore this hypothesis, streptococcal cell wall 
extracts (CWEs) were prepared as outlined in section 2.3.1 of the methods, and the proteins 
recognised by IVIG were visualised by immunoblot analysis. In order to determine the 
diversity of antigens recognised by IVIG, and their degree of conservation within the GAS 
population, the CWEs were prepared from 20 isolates that together represented four clinically 
relevant serotypes currently circulating within the United Kingdom (M1, M3, M12 and M89, 
Table 2.1).  
 
When subjected to SDS-PAGE and InstantBlue staining, the separated CWEs looked 
remarkably similar with the majority of protein bands migrating to an apparent molecular 
weight of 97 kDa to 19 kDa (Figure 3.1A). However, immunoblot analysis revealed that the 
repertoire of IVIG reactive proteins differed markedly between disparate GAS serotypes 
(Figure 3.1B). The serotype M1 strains reacted with the most intensity and produced a series 
of high molecular weight smears in addition to a paucity of lower molecular weight bands. 
This smearing was thought to result from the relatively poor separation of the high molecular 
weight region (HMR) that stemmed from the use of a bis-tris gel system with a reported 
separation range of 200 kDa to 14 kDa. Indeed, the apparent molecular weight range of the 
immunoreactive surface proteins was between >190 kDa and 50 kDa, suggesting that IVIG 
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predominantly interacts with high molecular weight GAS surface antigens, possibly as a 
result of a concomitant increase in protrusion from the bacterial cell surface. With the 
exception of the M12 samples, the banding patterns recovered from the five CWEs of the 
same serotype were broadly similar however; no overarching homogeneity was apparent. 
This suggests either that the different GAS serotypes produce disparate repertoires of 
immunoreactive proteins, or that the reactive proteins have mutated in certain serotypes in 
response to adaptive immune pressure. 
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Figure 3.1: Extraction and visualisation of the streptococcal surfome. CWE was 
prepared from 20 GAS isolates representing four clinically relevant serotypes after 
growth to mid log phase (A600 0.4 - 0.8) in Todd-Hewitt broth as described in the 
methods. For SDS-PAGE, 5 µg of each CWE was separated using 10% bis-tris gels, 
and (A) stained with InstantBlue or (B) subjected to immunoblot analysis using 1 µg/ml 
of IVIG as the primary antibody. Molecular mass markers to show the migration 
patterns of the protein bands are given in kilodaltons.  
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As the previous experiment had determined that all of the detectable IVIG-reactive proteins 
present upon the GAS cell surface resolved to a molecule mass of >50 kDa, the gel matrix 
and buffer system utilized for SDS-PAGE were optimized for the resolution of high 
molecular weight proteins. The M1 CWEs were resolved in duplicate using 7% tris-acetate 
gels with a separation range of 45 kDa–250 kDa and subjected to InstantBlue staining and 
immunoblot analysis (Figure 3.2). In addition, the concentration of IVIG that was used as a 
primary antibody was increased from 1 µg/ml to 4 µg/ml in an attempt to increase the signal 
strength of the protein bands present between 64 kDa and 51 kDa.  
 
 
 
Figure 3.2: Separation of the M1 streptococcal CWEs using tris-acetate gels. In 
order to determine if it  was possible to improve the resolution of the immunoreactive 
bands, 5 µg of each M1 CWE was separated in duplicate using 7% tr is-acetate gels as 
outlined in section 2.3.3 of the methods.  (A) The resulting gels were stained with 
InstantBlue or (B) subjected to immunoblot analysis using 4 µg/ml of IVIG as the 
primary antibody. Molecular mass markers to show the migration patterns of the protein 
bands are given in kilodaltons.  
 
While the reactivity of the high molecular weight region was still prominent, the separation 
of the remaining immunoreactive proteins improved markedly, making it easier to discern 
individual reactive bands in the resulting immunoblot. In addition, the increase in IVIG 
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concentration resulted in a comprehensive increase in the signal strength of the lower 
molecular weight bands. Together this data demonstrates that IVIG recognizes a repertoire of 
streptococcal surface antigens that resolve to a molecular mass range of between 111 kDa and 
40 kDa. In addition, the preparations appears to contain one or more strongly antigenic 
molecules that predominantly resolve to >111 kDa and are evenly dispersed across a broad 
molecular weight range.  
 
3.1.2: The surface antigens recognised by IVIG are not glycosylated 
In an attempt to identify the highly immunogenic antigen(s) present within the HMR of the 
resolved CWE samples, a series of experimental approaches were devised to further 
characterise the molecular composition of the reactive material. In the initial experiments, the 
possibility that the antigen(s) represented a protein that had undergone extensive post 
translational modification (PTM) was explored. PTM can result in the addition of 
carbohydrates and various prosthetic groups that may increase the molecular mass of the 
mature protein (Walsh and Jefferis, 2006). While bacterial proteins can be post translationally 
modified in a variety of ways, one of the most common is glycosylation, which introduces 
considerable structural heterogeneity through the attachment of glycans that vary in length, 
monosaccharide composition, and structure (Benz and Schmidt, 2002, Walsh and Jefferis, 
2006). The presence of such glycans may retard the electromobility of the associated protein, 
resulting in the characteristic HMR smearing reported in the preliminary experiments. In 
addition, it is possible that the glycan moieties themselves (if present) may be capable of 
stimulating a functional humoral immune response; if recognised in conjunction with the T 
cell epitopes present within the peptide component of the molecule. 
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In order to explore this hypothesis the streptococcal CWEs were enzymatically 
deglycosylated using a commercially available enzyme preparation, and subjected to 
immunoblot analysis using IVIG as the primary antibody (Figure 3.3). The decrease in 
molecular mass that can occur following enzymatic deglycosylation was elegantly 
demonstrated by incorporation of the positive control glycoprotein fetuin, which migrated 
further though the polyacrylamide gel matrix following removal of its glycan flourish (Fetuin 
(d), Figure 3.3A). However, enzymatic deglycosylation had no detectable effect on the 
immunoreactivity of the HMR suggesting that the presence of glycosylated proteins did not 
account for the smearing, or intense IVIG reactivity of this region (Figure 3.3B). In addition, 
deglycosylation did not reduce the apparent molecular mass of the resolved proteins bands, 
suggesting that these molecules are not glycosylated prior to surface localisation. The 
apparent lack of detectable glycoproteins within the streptococcal CWEs was confirmed 
using a glycoprotein detection kit as outlined in section 2.3.7 of the method. While the 
control protein fetuin stained strongly following periodate oxidation, no glycoprotein bands 
were detected within the streptococcal CWEs (Figure 3.3C).  
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Figure 3.3: The effect of enzymatic deglycosylation on the immunoreactivity of 
the streptococcal CWEs. A) The posit ive control protein fetuin was enzymatically 
deglycosylated (d) and compared in size to a comparative aliquot of glycosylated fetuin 
by SDS-PAGE and InstantBlue staining. B) The effect of enzymatic deglycosylation (d) 
on the immunoreactivity of  the streptococcal CWEs was assessed by immunoblot 
analysis using 4 µg/ml of IVIG as the primary antibody. In both experiments 4 µg 
aliquots of each protein were separated on 7% tr is acetate gels. C) The absence of 
detectable glycoproteins within the streptococcal CWE was confirmed by periodic acid-
Schiff staining using 5 µg aliquots of each sample and a 10% bis tris gel.  Molecular 
mass markers to show the migration pattern of the protein bands are given in 
kilodaltons. 
 
3.1.3: IVIG recognises a non proteinaceous, high molecular weight component of 
the streptococcal cell wall 
Having established that the intense reactivity of the HMR did not result from surface protein 
glycosylation, the possibility that IVIG may react with one or more non-proteinaceous 
components of the GAS cell wall was next explored. Indeed, to date only one streptococcal 
surface protein with a predicted molecular weight of >190 kDa (extracellular protein factor, 
Epf) has been reported within the literature which would be expected to resolve to form a 
discrete band when subjected to SDS-PAGE (Linke et al., 2012). In contrast, fragmentation 
of the peptidoglycan cell wall following enzymatic digestion may result in the 
release/exposure of one or more immunogenic surface carbohydrates such as lipotechoic acid 
(LTA), peptidoglycan and the group A carbohydrate (Mc and Lancefield, 1955, Fischer, 
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1988, Stewart-Tull, 1980). If these conserved components were indeed IVIG reactive, a lack 
of uniformity in the fragment size generated by enzymatic peptidoglycan digestion may 
account for the smearing detected within the HMR of the resulting immunoblot. 
 
In order to explore this possibility, the proteinaceous components of the streptococcal CWEs 
were degraded using proteinase K, and the reactivity of the samples was determined by 
immunoblot analysis using IVIG as the primary antibody (Figure 3.4). Pre-treatment of the 
samples with proteinase K resulted in a loss of immunoreactivity within the resolved 
proteinaceous bands, presumably as a result of the marked disruption in primary structure. 
While proteinase K digestion resulted in a significant reduction in the signal strength of the 
HMR, a small amount of residual immunoreactivity was still apparent in some of the 
samples. This residual reactivity was particularly apparent within the H656 CWE which 
produced the most intense reaction prior to proteinase K treatment. This suggests that the 
while the antigenic components of the HMR are primarily proteinaceous in nature, the region 
also contains one or more non-proteinaceous cell wall antigens. 
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Figure 3.4: The effect of proteinase K digestion on the immunoreactivity of the 
streptococcal CWEs. A) The undigested and B) digested CWEs (4 µg each) were 
separated on 10% bis tris gels and subjected to immunoblot analysis using 4 µg/ml of 
IVIG as the primary antibody. As a posit ive control 4 µg aliquots of A) undigested and 
B) digested BSA were subjected to immunoblot analysis using a 1:1000 dilution of 
rabbit anti-BSA IgG as the primary antibody. Molecular mass markers to show the 
migration pattern of the protein bands are given in kilodaltons.  
 
3.1.4: LTA resolves to a defined molecular weight following enzymatic digestion of 
the streptococcal cell wall 
In order to determine if the residual reactivity of the HMR resulted from the presence and 
recognition of surface associated LTA, the streptococcal CWEs were subjected to 
immunoblot analysis using an anti-LTA primary antibody (a kind gift from Dr Angelika 
Gründling, Imperial College London) as outlined in section 2.3.4 of the methods. The 
resulting immunoblot showed that while LTA was indeed present within the samples, the 
molecule resolved to form discreet bands when subjected to SDS-PAGE. In four of the five 
M1 isolates examined, the LTA band resolved to an apparent molecular mass of <28 kDa 
placing it outside of the established molecular weight range of detectable IVIG reactivity 
(Figure 3.5). Interestingly, the LTA band produced by strain H791 resolved to an apparent 
molecular weight of ~62 kDa suggesting that this strain produces a higher molecular weight 
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LTA polymer than the other M1 isolates examined. Nevertheless the data indicates that, 
while enzymatic digestion of the gram positive cell wall indeed resulted in a release of LTA, 
the molecule migrates to form uniform bands following SDS-PAGE and thus does not 
explain the intense reactivity of the HMR.  
 
 
 
Figure 3.5: Visualisation of streptococcal LTA by immunoblot analysis. For 
immunoblot analysis, 5 µg aliquots of the streptococcal CWEs were separated on a 
10% bis-tr is gel and probed with a 1:5000 dilution of mouse anti -LTA IgG. Molecular 
mass markers to show the migration pattern of the protein bands are given in 
kilodaltons. 
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3.1.5: Resolution of the group A carbohydrate is not confined to the HMR 
In order to determine if the residual reactivity of the HMR resulted from the presence and 
recognition of the group A carbohydrate (GAcar) molecule, the streptococcal CWEs were 
subjected to immunoblot analysis using an anti-GAcar primary antibody (Abcam) as outlined 
in section 2.3.4 of the methods. The resulting immunoblot showed that the presence of GAcar 
was not confined to the HMR, and that the molecule appeared throughout the molecular 
weight range displaying IVIG reactivity (Figure 3.6). This ubiquitous distribution suggests 
that while IVIG recognition of the GAcar molecule cannot be ruled out, it is unlikely that this 
recognition is the cause of the HMR smearing reported in the previous experiments.  
 
 
 
Figure 3.6: Visualisation of the group A carbohydrate by immunoblot analysis. For 
immunoblot analysis, 5 µg aliquots of the streptococcal CWEs were separated on a 7% 
tris-acetate gel and probed with a 1:2000 dilution of goat anti -GAcar IgG. Molecular 
mass markers to show the migration pattern of the protein bands are given in 
kilodaltons. 
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3.1.6: Summary of section 3.1 
Taken together the above data indicates that IVIG recognises a diverse range of streptococcal 
surface antigens, the majority of which resolve to an apparent molecular mass of between 110 
kDa and 40 kDa. While serological analysis of the bacterial surfome is a well-established 
method of vaccine candidate identification, to the author’s knowledge this is the first study to 
utilise IVIG in place of patient convalescent serum. Several previous studies have adopted a 
wholly or partially serological approach to the identification of streptococcal vaccine 
candidate antigens however, the sera utilised in these studies was often recovered from 
hospitalised patients or regions of endemic impetigo (Cole et al., 2005, Fritzer et al., 2010, 
Bensi et al., 2012). The apparent lack of protection provided by these sera calls into question 
the usefulness of the antigens that were identified in these studies.  
 
In contrast, IVIG is prepared from pooled human plasma collected from healthy donors at 
licenced plasmapheresis centres. While the possibility of prior donor hospitalisation for 
streptococcal infection cannot be ruled out, it is likely that the anti-GAS IgG in this reagent 
was generated during successful clearance of a fulminant GAS infection. Together with the 
purported protective efficacy of the reagent against iGAS infection (both clinically and in a 
transgenic mouse model) this suggests that these antigens recognised by IVIG may form the 
basis of a multivalent anti-GAS vaccination.  
 
The data also indicates that the highly immunoreactive antigens present within the HMR are 
predominantly proteinaceous in nature. This hypothesis is supported by the marked reduction 
in signal strength following proteinase K treatment, and the migration patterns recovered for 
LTA and the GAcar molecule. If this is indeed the case, it is possible that the purported 
retardation of electromobility results from a retention of covalently bound peptidoglycan by 
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the protein upon enzymatic digestion of the streptococcal cell wall. While some residual 
reactivity remained within the region following proteolysis of the streptococcal CWEs, it is 
possible that one or more of the protein antigens present upon the streptococcal cell wall are 
resistant to proteinase K digestion. Indeed the defining characteristic of the Lancefield T 
antigen (now recognised as the backbone subunit of the streptococcal pilus) is the molecules 
resistance to proteolytic digestion by the enzyme trypsin (Lancefield and Dole, 1946, Johnson 
et al., 2006). It is therefore possible that the streptococcal surfome includes one or more 
proteinaceous antigens that are resistant to proteinase K digestion and thus retained their 
reactivity following enzymatic treatment. 
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3.2: Identification of resolved immunoreactive surface proteins by 
immunoblotting and proteomic analysis 
3.2.1: Proteomic analysis of the conserved, reactive surface protein bands 
Having established that IVIG recognizes a diverse repertoire of streptococcal surface 
antigens, the identity of the resolved proteins was next investigated. In order to determine if 
the different banding patterns recovered from the 20 GAS isolates could result from 
differences in their extracellular protein repertoire; several regions of variable reactivity were 
identified and characterized by proteomic analysis. The CWEs were separated on duplicate 
polyacrylamide gels; which were subjected to InstantBlue staining and immunoblot analysis 
using IVIG as the primary antibody. The resulting immunoblot was used to identify regions 
of variable reactivity, two of which were subsequently excised from the duplicate InstantBlue 
stained matrix (Figure 3.7). In the preliminary experiment, the regions of the gel selected 
displayed detectable immunoreactivity in some isolates but not in others (71 kDa region) or 
conserved reactivity across all 20 of the isolates examined (55 kDa region). The regions of 
M12 reactivity could not be accurately identified and accordingly these samples were omitted 
from downstream proteomic analysis. 
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Figure 3.7: Identification of highly conserved IVIG-reactive proteins by 
immunoblotting and proteomic analysis:  The immunoreactive proteins present in the 
prepared CWE were visualised by immunoblot analysis and identif ied by proteomic 
analysis. (A) For immunoblot analysis 5 µg aliquots of each CWE were separated on 
7% tr is-acetate gels and probed with 3 µg/ml of IVIG. Regions of conserved reactivity 
(red boxes) were extracted from replicate InstantBlue stained gels for analysis by LC-
MS/MS. Molecular mass markers to show the migration patterns of the protein bands 
are given in k ilodaltons.  
 
Proteomic analysis of excised gel slices revealed the overwhelming molecular complexity of 
the selected regions. An average of nine and 16 proteins were present in each of the 71 kDa 
and 55 kDa bands respectively, none of which were overtly dominant or represented 
previously characterized streptococcal surface antigens (Tables 3.1 and 3.2). Despite this 
apparent complexity only one protein was identified that was present within the 
immunoreactive, 71 kDa gel slices but absent from those lacking detectable reactivity. This 
protein was the ATP-dependent caseinolytic protease ClpE, a highly conserved heat shock 
protein that has been shown to function as a regulator of virulence factor expression in S. 
pneumoniae (Zhang et al., 2009). ClpE knockout mutants display reduced adherence to 
human epithelial cells, leading the authors to suggest that the molecule modulates the 
expression of one or more streptococcal colonization factors (Zhang et al., 2009). However, it 
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is also possible that ClpE moonlights as a minor surface adhesin during streptococcal 
pathogenesis, and is therefore targeted by the host humoral immune response. 
 
In addition to ClpE, the experiment identified a single protein that was ubiquitously present 
within the excised, immunoreactive bands of the 55 kDa region. This protein represented the 
ATP binding component of a hitherto unnamed ABC transporter; a large family of surface 
expressed macromolecules that facilitate binding and uptake of many essential growth factors 
during normal cell turnover (Higgins, 1992, Janulczyk et al., 1999). While the ATP binding 
subunits of ABC transporters are primarily located within the cell cytoplasm, the diverse 
functionality of the proteins that moonlight on the GAS surface during early pathogenesis 
suggested that further analysis of this proteins was also warranted (Henderson and Martin, 
2011, Pancholi and Fischetti, 1992). 
. 
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Table 3.1: The proteins identified within the 71 kDa region of the CWE gel:  The proteins present within the excised 71 kDa gel 
slices were identif ied by proteomic analysis using the SEQUEST algorithm and an M1-GAS reference proteome. The identif ied proteins 
were tabulated with numbers representing the percentage of the protein sequence covered by the identif ied peptides (see Figure 2.1 in 
the methods section). A single protein (ATP-dependent clp protease ATP-binding subunit) was identif ied that was present within the 
immunoreactive, 71 kDa gel slices but absent from those lacking detectable reactivity (Highlighted).  
 
 71 kDa region 
M type   M1     M3     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 98 H293 H395 H409 H411 
Reactivity R R NR R R NR NR NR R NR R R R R R 
60 kDa chaperonin       10 6           
ATP-dependent clp protease ATP-binding subunit 13 9   12 13       7   14 13 16 12 5 
Cell division protein 12 17 15 19 12             
Cell division protein ftsY             12 12 14 19   
Chaperone protein DnaK 21 25 33 21 20 32 14 35 19 19 11 15 9 8 14 
Elongation factor G 63 76 70 71 68 54 74 52 69 59 66 65  68 66 
Elongation factor Tu  11 5 14 11  8  20   8 27 19 13 13 
Enolase              43 19 19 17 
Formate acetyltransferase 20 35 40 22 35       39 39 38 24 35 
Glyceraldehyde 3-phosphate dehydrogenase       7   7 15     8 
GTP-binding protein     11        4     
Leucyl-tRNA synthetase  5        5 16    6 11 
Lysyl aminopeptidase / alanine aminopeptidase  11 8     5 27 14 31  3 4 7 17 
Phosphorylase 8 8 24 6   23 14 40 11 27       
Polyribonucleotide nucleotidyltransferase     9  7           
Putative pyruvate formate-lyase       25 46 24 27 44       
Putative signal recognition particle-docking protein       7 17  17 10       
Putative transketolase   6  15 28  13  17     4 
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Table 3.2: The proteins identified within the 55 kDa region of the CWE gel:  
 
 55 kDa region 
M type   M1     M3     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 98 H293 H395 H409 H411 
Reactivity R R R R R R R R R R R R R R R 
60 kDa chaperonin 59 67 64 55 48 74 75 83 77 74 
     
67 kDa Myosin-crossreactive streptococcal antigen 
 
15 11 6 
 
25 26 15 42 33 
     
ABC transporter ATP-binding protein 48 53 55 49 48 45 18 7 6 18 28 23 27 24 20 
Arginyl-tRNA synthetase 25 39 43 30 24 25 54 
 
67 14 
    
4 
Aspartyl-tRNA synthetase 
   
3 
  
5 
 
18 
      
Cell division protein 
 
10 13 8 10 
          
Chaperone protein DnaK 18 16 19 13 12 17 15 13 18 17 
  
5 
  
CTP synthase 
  
5 
   
23 
 
18 
      
Dextran glucosidase 
  
10 6 
           
Dihydrolipoamide dehydrogenase 
          
13 17 20 9 17 
Elongation factor G 19 28 30 12 16 10 11 
 
4 
 
24 21 32 19 31 
Elongation factor Tu 14 23 14 14 11 
   
32 
  
6 
 
34 
 
Enolase 
 
14 
      
4 
 
9 18 16 61 
 
Formate--tetrahydrofolate ligase 1 
 
7 
        
7 9 9 
 
9 
GMP synthase [glutamine-hydrolyzing] 9 17 
        
43 40 37 35 39 
Inosine-5'-monophosphate dehydrogenase 12 31 16 9 
      
43 33 28 36 12 
Lysyl-tRNA synthetase 19 36 8 28 19 
     
14 11 13 14 
 
Nicotinate phosphoribosyltransferase 
          
29 27 31 31 22 
Peroxiredoxin reductase (NAD(P)H) / NADH oxidase 
          
10 24 29 35 35 
Phosphoenolpyruvate-protein phosphotransferase 12 
 
8 
            
Phosphoglucomutase / Phosphomannomutase 27 46 53 35 16 
     
12 7 16 9 12 
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Table 3.2 (Continued):  The proteins present within the excised 55 kDa gel slices were identif ied by proteomic analysis u sing the 
SEQUEST algorithm and an M1-GAS reference proteome. The identif ied proteins tabulated with numbers  representing the percentage 
of the protein sequence covered by the identif ied peptides (see Figure 2.1 in the methods section). A single protein (ABC transporter 
ATP-binding protein) was identif ied within all of the excised, immunoreactive gel slices (Hig hlighted). 
  
 55 kDa region 
M type   M1     M3     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 98 H293 H395 H409 H411 
Reactivity R R R R R R R R R R R R R R R 
Putative 42 kDa protein 5 9 9 9 
           
Putative endopeptidase 5 
 
5 
  
5 7 21 32 33 
     
Putative oligoendopeptidase 
       
13 21 17 
     
Putative oligopeptidase 
         
5 
     
Putative phosphoenolpyruvate:sugar phosphotransferase 
     
6 42 34 34 32 
     
Putative phosphoglucomutase 
     
71 64 72 73 80 
     
Putative phosphomannomutase 17 12 20 8 3 9 
         
Pyruvate kinase 22 34 32 7 9 
 
7 
 
4 
 
10 7 59 
 
8 
Q1JBD3 D-alanine-activating enzyme 
          
14 20 12 15 22 
Q1JBD4 D-alanine-activating enzyme 
          
40 36 34 33 46 
Q1JDN8 Glutamyl-tRNA synthetase 
          
23 16 26 22 
 
Q1JDN9 Glutamyl-tRNA synthetase 
          
17 28 25 24 12 
Ribonuclease Y  
             
3 3 
Trigger factor 8 11 5 
       
7 25 
  
11 
Trigger factor, ppiase  
          
46 62 63 40 41 
Zn-dependent hydrolase 
 
9 
 
8 
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Having established that proteomic analysis is a viable means of identifying potential antigens 
from a complex protein preparation, the above experiment was repeated, and a more systemic 
analysis of the immunoreactive regions was undertaken (Figure 3.8). Proteomic analysis of 
the excised gel slices again revealed that each region comprised an extensive repertoire of 
streptococcal proteins that varied in composition between isolates (Table S1, supplementary 
information). Unlike in the previous experiment, no proteins were identified that were present 
within the immunoreactive gel slices but absent from those lacking detectable reactivity. In 
addition, despite the ubiquitous presence of the ABC transporter ATP-binding protein within 
the 55 kDa slices, both the H305 and H387 bands were devoid of detectable 
immunoreactivity. The correlation between the presence of ClpE and immunoreactivity was 
also weakened, with the protein appearing two 71 kDa bands that lacked detectable reactivity 
(recovered from isolates 49 and H529).  
 
 
Figure 3.8: Visualisation of highly conserved IVIG-reactive antigens by 
immunoblotting.  Aliquots of the twenty prepared CWEs were separated on 7% tr is -
acetate gels and subjected to immunoblot analysis using 3 µg/ml o f IVIG as the primary 
antibody. Regions of conserved reactivity (blue boxes) were extracted from replicate 
InstantBlue stained gels for proteomic analysis. Molecular mass markers to show the 
migration patterns of the protein bands are given in kilodaltons.  
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The relatively low intensity of the 55 kDa H305 and H387 bands in Figure 3.7 indicates that 
even a minor decrease in the concentration of the causative antigen may be sufficient to place 
the molecule below the detection limit of immunoblot analysis. In contrast, the same drop in 
antigen concentration would be insufficient to prevent identification of the molecule by LC-
MS/MS. It is therefore conceivable that the concentration of the ATP-binding protein 
identified above was below the detection limit of immunoblotting in this experiment, but was 
still high enough for the molecule to be identified by LC-MS/MS analysis. In contrast the 
presence of ClpE in two regions of undetectable immunoreactivity may imply that the 
molecule has mutated in isolates 49 and H529; in response to significant adaptive immune 
pressure. If this is indeed the case, it is likely that the mutated protein would still be detected 
by LC-MS/MS despite the resulting loss of immunogenic epitopes. 
 
To ensure that such events did not result in otherwise promising vaccine candidates being 
overlooked, the data in Figure S1 was reassessed, and the proteins whose presence within a 
given molecular weight range correlated with immunoreactivity >90% of the time were 
tabulated (Figure 3.9). This analysis resulted in the identification of five potential 
immunogens (ClpE, the ABC transporter ABC binding protein, GMP-Synthase, NADP-
dependent glyceraldehyde-3-phosphate dehydrogenase and D-Alanine--polyphosphoribitol 
ligase 1) four of which were recovered from the 55 kDa region. Whilst four other proteins 
were identified that fitted the outlined criteria (60 kDa chaperonin, elongation factor G, 
glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase), these proteins were present 
almost ubiquitously within the excised gel slices (see Figure S1, supplementary information) 
and were therefore excluded from downstream analysis.  
 
115 
 
 
 
Figure 3.9: Identification of highly conserved IVIG-reactive antigens by proteomic 
analysis. The proteins present within the gel slices excised in Figure 3.8A were 
identif ied by proteomic analysis using the SEQUEST algorithm and an M1 -GAS 
reference proteome. Proteins that were present within regions of immunoreactiv ity, but 
absent from the surrounding regions were tabulated with numbers representing the 
percentage of the protein sequence covered by the identif ied peptides (see Figure 2.1 
in the methods section). N/A indicates that the gel slice was lost prior to proteomic 
analysis. Coverage levels are scaled from highest to lowest using progressively l ighter 
shades of grey, indicating >66% (darkest), >33%, >10% and <10%.  
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3.2.2: Cloning, expression and analysis of recombinant streptococcal proteins 
To determine which (if any) of the molecules identified by proteomic analysis represented the 
55 kDa and 71kDa antigens present within the streptococcal CWEs, the five proteins were 
expressed recombinantly in E. coli and subjected to immunoblot analysis using IVIG as the 
primary antibody. Target genes were amplified from H305 gDNA and cloned into the pET-
19b overexpression vector as outlined in section 2.5 of the methods. Four of the target genes 
were cloned by Daryl Beckford as part of an MRes in translational medicine under the 
author’s supervision (Table 3.3). Routine automated fluorescent sequencing revealed that an 
insert that was thought to encode the sixth protein (D-alanine--poly (phosphoribitol) ligase 
subunit 1) in fact encoded phosphopentomutase, a protein that was being cloned in parallel 
for an unrelated study (Figure S2, supplementary material). Accordingly this target was 
excluded from downstream production and analysis. 
 
Table 3.3: The five targets selected for recombinant production by 
immunoblotting and proteomic analysis.  Abbreviations: MR: Mark Reglinski; DB: 
Daryl Beckford. 
 
Protein name Gene SF370 ORF Cloned by 
ABC transporter ATP-binding protein  N/A Spy_2210 DB 
ATP-dependent clp protease ATP-binding subunit  clpE Spy_1509 MR 
D-alanine—poly (phosphorib itol) l igase subunit  1  dltA Spy_1312 DB 
GMP synthase [glutamine-hydrolyzing]  guaA Spy_1204 DB 
NADP-dependent -glyceraldehyde-3-phosphate dehydrogenase gapN Spy_1371 DB 
 
In addition to the five targets cloned from H305, PCR analysis revealed the presence of a 
clpE homolog within the H366 genome (Figure 3.10A). In order to determine if the absence 
of ClpEH366 from the 71 kDa region and/or the proteins purported lack of immunogenicity 
resulted from one or more strain specific genetic mutations, clpEH366 was cloned into pET-
19b for further analysis. Recombinant ClpEH305 and ClpEH366 were produced in BL21 cells by 
IPTG overexpression, and purified by IMAC under denaturing conditions as outlined in 
117 
 
section 2.6 of the methods. Visualization of the purified recombinant proteins by SDS-PAGE 
revealed that clpEH366 encoded a truncated form of the mature protein that migrated to a 
molecular mass of only 39 kDa (Figure 3.10B). Subsequent automated fluorescent 
sequencing of the full length clpEH366 insert revealed a premature stop codon approximately 
800 base pairs into the nucleotide sequence that accounted for this reduction in size (Figure 
3.10C). This truncation clearly explains the absence of ClpEH366 from the 71 kDa region and 
may account for the lack of immunogenicity of the 71 kDa H366 band. 
 
 
 
Figure 3.10: Cloning and expression of recombinant ClpE.  (A) The H305 and H366 
clpE genes were amplif ied by PCR and cloned into the pET-19b overexpression vector. 
Recombinant ClpE was produced by overexpression of clpE
+
 pET-19b in BL21 cells and 
purif ied by IMAC as outlined in section 2.6 of the methods. (B) Recombinant production 
of ClpE was confirmed by SDS-PAGE, where 5 µg of the purif ied recombinant samples 
were resolved on a 10 % bis-tr is gel and stained using InstantBlue. (C) Automated-
fluorescent sequencing of ClpEH366  revealed the presence of a premature stop codon 
within the gene sequence (yellow) that accounted for the reduction in molecular mass 
that was apparent following analysis by SDS-PAGE and InstantBlue staining. Molecular 
mass markers and DNA sequence length markers to  show the migration patterns of the 
bands, and are given in kilodaltons and base pairs respectively.  
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The three remaining inserts (GMP-Synthase, NADP-dependent glyceraldehyde-3-phosphate 
dehydrogenase and the ABC transporter ATP binding protein) were produced in BL21 cells 
by IPTG overexpression and purified by IMAC. In tandem, a previously identified antigenic 
SpyCEP fragment (CEP-5) was purified for use as a positive control in the subsequent 
experiments (Turner et al., 2009b). The concentration of the purified recombinant proteins 
was determined by Bradford assay, and 250 ng aliquots were separated on adjacent lanes of a 
10% bis-tris gel for immunoblot analysis using mouse anti-his IgG and IVIG as primary 
antibodies. While the positive control protein CEP-5 reacted strongly with both antibody 
preparations, none of the putative vaccine candidate antigens identified by proteomic analysis 
produced a detectable signal when probed with IVIG (Figure 3.11). This suggests that these 
proteins are not recognized by IVIG, and therefore do not account for the reactivity of the 71 
kDa and 55 kDa regions in the preliminary experiments.  
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Figure 3.11: Immunoblot analysis of the putative IVIG-reactive antigens. The H305 
gapN , guaA and SPy_2210 genes were cloned into the pET-19b overexpression vector 
and purif ied from BL21 cells by IMAC as outlined in section 2.6 of the methods. For 
immunoblot analysis, 250 ng of (A) CEP-5, (B) ABC transporter ATP-binding protein 
(ABC), (C) NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (N-GAPDH), 
(D) GMP synthase (GMPS), (E) ClpEH305 and (F) ClpEH366 were separated on 10 % bis-
tris gels and probed with a 1: 100,000 dilution of murine anti-his IgG (MaH) or 5 µg/ml 
of IVIG. Molecular mass markers to show the migration patterns of the protein bands 
are given in kilodaltons. 
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3.2.3: Summary of section 3.2 
Taken together the above data indicates that proteomic analysis of the separated CWEs is an 
ineffective means of identifying the resolved IVIG reactive antigens that were visualised by 
immunoblot analysis in the preliminary experiments. It had previously been noted that the 
classical GAS virulence factors (for example M protein, C5a peptidase and SpyCEP) were 
rarely identified within the excised gel slices, regardless of the molecular weight range 
examined or the immunoreactivity of the region. Indeed the vast majority of the proteins 
identified were purported housekeeping proteins, including a number of elongation factors 
and chaperonins (Table S1, supplementary material). While it is possible that all of these 
molecules moonlight as streptococcal surface antigens, it is more likely that the relatively 
crude method of surface protein purification employed results in a significant degree of 
intracellular protein carryover following digestion of the peptidoglycan cell wall. The 
incongruous presence of intracellular proteins would result in a bolus increase in the 
complexity of the excised protein bands, which may impede identification of any IVIG 
reactive antigens that are present at relatively low concentrations.  
 
In contrast to the current study, Cole and colleagues utilised two-dimensional gel 
electrophoresis to separate crudely extracted cell surfome fractions into homogeneous protein 
spots prior to immunoblotting and proteomic analysis (Cole et al., 2005). The reported 
homogeneity of the excised protein spots suggests that two dimensional gel electrophoresis 
provides better resolution of complex protein samples; and thus allows immunoreactive 
surface antigens to be readily identified from crude cell surface preparations by 
immunoblotting and proteomic analysis. While this approach could be employed in the 
current study, the procedure requires each protein sample to be run on a separate gel; making 
the comparison of twenty separate CWEs a costly and time consuming exercise. 
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While proteomic analysis of the separated CWEs proved an ineffective means of identifying 
novel vaccine candidate antigens, the experiments did reveal that one of the isolates selected 
(H366) may encode a truncated version of the purported virulence regulator ClpE (Zhang et 
al., 2009). Currently, the possibility that clpE mutated following insertion into the pET-19b 
overexpression vector cannot be ruled out, as only the cloned version of clpEH366 was 
sequenced during the course of the study. Nonetheless assuming the truncation exists within 
native clpEH366, it would be interesting to determine what effect (if any) it has on global gene 
regulation within GAS.  
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3.3: Development of an immunoprecipitation-based method for the 
isolation of streptococcal surface antigens 
3.3.1: Purification of streptococcal antigens by IVIG immunoprecipitation using a 
protein G agarose matrix 
Working from the hypothesis that the complexity of the crudely purified CWEs was 
preventing reliable detection of the IVIG reactive antigens by LC-MS/MS, the study protocol 
was modified several times to promote purification of the target antigens prior to proteomic 
analysis. Ultimately an immunoprecipitation based method for the isolation of reactive 
antigens from crudely purified CWE was developed; using IVIG as a source of immobilized 
antibody.  
 
In the preliminary experiments, IVIG was pre incubated with pooled streptococcal CWE for 
two hours prior to the bolus addition of protein G agarose. The resin was pelleted and the 
supernatant fraction (containing the unbound streptococcal proteins) was saved for 
downstream analysis. The sequestered antibody was denatured as outlined in section 2.7 of 
the methods (causing a release of the bound, cell wall derived antigens) and the fractions 
were visualized by immunoblot analysis using IVIG as the primary antibody (Figure 3.12A). 
In order to assess the degree of antibody contamination within the collected fractions, the 
immunoglobulin bands were visualized using a secondary only control immunoblot as 
outlined in section 2.3.4 of the methods (Figure 3.12B).  
 
Preliminary analysis of the IVIG immunoblot revealed a number of reactive protein bands 
that were uniquely present within the bound protein fraction, suggesting that the 
immunoprecipitation protocol may have successfully isolated a small number of IVIG 
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reactive antigens from the starting CWE preparation. However, subsequent examination of 
the secondary only control immunoblot revealed that all of these bands reacted directly with 
the HRP conjugated secondary antibody (goat anti-human IgG), indicating that they 
represented desorbed antibody rather than affinity purified antigen.  
 
 
 
Figure 3.12: Purification of streptococcal surface antigens by IVIG 
immunoprecipitation using a protein G agarose matrix . H305 CWE was subjected to 
immunoprecipitation using protein G agarose resin as outlined in section 2.7 of the 
methods. (A) Aliquots of the bound and unbound fractions were separated on a 10% 
bis-tris gel and subjected to immunoblot analysis using 1 µg/ml of IVIG as the primary 
antibody. (B) Immunoreactive bands representing desorbed antibody were identif ied 
using a secondary only control immunoblot as outlined in  section 2.3.4 of the methods. 
Molecular mass markers to show the migration patterns of the protein bands are given 
in kilodaltons. 
 
The implications of these initial finding were twofold. Firstly, the interaction between the 
protein G agarose and the Fc region of the IVIG molecules was clearly insufficient to ensure 
retention of the IgG molecules under denaturing conditions. Based on data collected in 
section 3.2, it was surmised that the presence of desorbed IgG within the bound fraction was 
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likely to inhibit identification of the target antigens by LC-MS/MS. It was therefore 
concluded that the binding interaction between the antibody and the solid support required 
strengthening, and that a milder elution step was necessary to ensure retention of the antibody 
following release of the associate antigen. In addition, it was hypothesized that the 
concentration of anti-GAS IgG within the starting IVIG preparation may be too low to 
facilitate efficient purification of the target antigens by immunoprecipitation. It was therefore 
concluded that the starting IVIG preparation required enrichment with anti-GAS IgG prior to 
further modification of the immunoprecipitation protocol. 
 
3.3.2: Affinity purification of anti-GAS IgG from IVIG 
Having concluded the anti-GAS IgG titre of the starting IVIG preparation may be too low to 
facilitate immunoprecipitation of the reactive streptococcal surface antigens, the reagent was 
subjected to affinity purification as outlined in section 2.8 of the methods. Covalent 
attachment of the purified M1 CWE to the CNBr-activated agarose was confirmed by 
measuring the protein concentration of the solution before and after incubation with the 
swollen resin (Table 3.4). The result of the initial coupling experiment was a 1.8 ml anti-GAS 
IgG affinity purification column, with the immunogen bound at an approximate concentration 
of 900 µg/ml. 
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Table 3.4: Covalent attachment of streptococcal CWE to CNBr activated agarose:  
Attachment of streptococcal CWE to the CNBr activated agarose matrix was confirmed 
by measuring the concentration of the protein sample before and after incubation with 
the prepared resin. These measurements also allowed for the concentration at which 
the protein was bound to the prepared column to be determined. Protein concentrations 
were measured by Coomassie protein assay as outlined in section 2.3.2 of the 
methods. 
 
Starting concentration 830 µg/ml 
Starting volume 8 ml 
Final concentration 386 µg/ml 
Final volume 8 ml 
Total bound protein  3552 µg 
Resin volume 4 ml 
Bound concentration 890 µg/ml 
 
In order to increase the anti-GAS IgG titre of the starting IVIG preparation, 500 mg of the 
reagent was subjected to affinity chromatography using the prepared streptococcal CWE 
column as outlined in section 2.8.2 of the methods. Following extensive washing the bound 
IgG was gently eluted using 0.5 M acetic acid that was neutralized instantly using 3 M Tris-
HCl. This rapid neutralization was designed to prevent denaturation of the desorbed 
antibodies, and thus ensure that the activity of the enriched IVIG preparation was maintained 
following affinity purification. The eluted antibody was concentrated and analyzed by 
Bradford assay allowing the total amount of anti-GAS IgG purified to be measured, and the 
proportion of anti-GAS IgG in the starting IVIG preparation to be estimated (Table 3.5). As 
this estimate assumes a 100% efficient purification of anti-GAS IgG from the starting 
preparation, the recorded proportion of 0.15% may be a slight underestimation. Nonetheless, 
the assertion that less than 1% of the antibody in IVIG recognizes the streptococcal surfome 
provided strong support for enrichment of the reagent prior to further modification of the 
immunoprecipitation protocol. 
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Table 3.5: Affinity purification of anti-GAS IgG from IVIG: The proportion of anti-
GAS IgG in IVIG was estimated by measuring the volume and protein concentration of 
the preparation following affinity purif ication. Protein concentrations were measured by 
Coomassie protein assay as outlined in section 2.3.2 of the methods. 
 
Starting IgG concentration 50 mg/ml 
Starting volume 10 ml 
Total IgG 500 mg 
Final IgG concentration 485 µg/ml 
Final volume 1.5 ml 
Total anti-GAS IgG 727.5 µg 
Proportion of anti-GAS IgG  
in starting preparation 
~0.15% 
 
In order to confirm that the affinity purification protocol had successfully increased the anti-
GAS IgG titre of the starting IVIG preparation, the activity of the resulting “enriched” (E)-
IVIG was first assessed by ELISA. In the initial experiments, E-IVIG was shown to have a 
much higher affinity for pooled M1 CWE than IVIG, and bound to apparent saturation at a 
concentration of ~1.25 µg/ml (Figure 3.13A). Calculated half maximal binding (Kd) values 
of 86 ng/µl for E-IVIG and >3000 ng/µl for IVIG confirmed that the anti-GAS IgG titre of 
the affinity purified reagent was more than 100 times higher than that of the starting 
preparation. The increased affinity of E-IVIG for streptococcal CWE was subsequently 
shown to be serotype independent, suggesting that the preparation was interacting with one or 
more highly conserved streptococcal surface antigens Figure 3.13B).  
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Figure 3.13: Characterisation of E-IVIG by ELISA. Commercially available IVIG was 
enriched with anti-GAS IgG as outlined in section 2.8 of the methods. (A) The binding 
affinity of the result ing E-IVIG (blue) for pooled M1 cell wall extract was compared with 
that of IVIG (red) in a concentration dependent manner as outlined in section 2.8.3 of 
the methods. Representative results (n = 3) are expressed as absorbance readings at 
450 nm minus the background absorbance, measured by incubating one set of CWE 
coated wells with PBS in place of antibody. Curve fits and equilibrium binding 
constants (Kd) were calculated by non-linear regression using GraphPad Prism. (B) 
The serotype specif icity of the reagents was compared using 2500 ng/ml of E -IVIG or 
IVIG and tr iplicate wells coated with CWE from each of the twenty isolates selected for 
study. For each strain, one set of CWE coated wells was incubated with PBS in place 
of antibody, in order to determine the background absorbance  (typically <0.02). 
Representative results (n = 3) are expressed as absorbance readings at 450 nm minus 
background levels of absorbance. Error bars indicating standard deviation and 
asterisks indicate a statistically signif icant difference between wells incubated with E -
IVIG or IVIG (P<0.05, two-way ANOVA with Bonferroni’s correction).  
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Having established that E-IVIG has a much higher affinity for streptococcal CWE than IVIG, 
the repertoire of antigens recognized by the two reagents was next compared by 
immunoblotting. The banding patterns of the resulting immunoblots were remarkably similar, 
indicating that the E-IVIG preparation recognizes a similar repertoire of proteins to IVIG 
(Figure 3.14). Taken together these data suggest that affinity purification of IVIG using a 
streptococcal CWE column is sufficient to markedly increase the anti-GAS IgG titre of the 
starting preparation. Furthermore, the resulting E-IVIG preparation binds to the resolved 
IVIG-reactive surface antigens with high affinity, and thus may facilitate downstream 
purification of these targets by immunoprecipitation. Finally, it was noted that the high 
molecular weight smearing recorded in Figure 3.7 and 3.8 was also present on the E-IVIG 
immunoblot, suggesting that E-IVIG immunoprecipitation may provide a viable means of 
isolating the causative immunogen(s) for downstream identification. 
 
129 
 
 
 
Figure 3.14: Recognition of antigenic proteins by E-IVIG and IVIG.  The repertoire of 
GAS proteins recognised by IVIG and E-IVIG was compared by immunoblot analysis. 
For immunoblot analysis, 5 µg aliquots of each CWE were separated on 7% tris-acetate 
gels and probed with (A) 3 µg/ml of IVIG or (B) 300 ng/ml of E-IVIG. Molecular mass 
markers to show the migration patterns of the protein bands are given in kilodaltons.  
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3.3.3: E-IVIG promotes opsonophagocytic uptake of GAS by human neutrophils 
Having established that E-IVIG recognises a diverse range of IVIG-reactive streptococcal 
surface antigens, the ability of the reagent to promote opsonophagocytic uptake of GAS in 
vitro was subsequently assessed. In the initial experiments, FITC labelled M1 GAS cells were 
pre-treated with a range of concentrations of E-IVIG or IVIG and incubated with freshly 
isolated human neutrophils as outlined in section 2.9 of the methods. The percentage of 
FITC
+
 neutrophils was subsequently determined by flow cytometry, indicating the degree of 
opsonophagocytic uptake that had occurred in each reaction. After a 30 min co-incubation, 
the percentage of FITC
+
 neutrophils was significantly higher in the E-IVIG group for all 
concentrations >10 µg/ml, indicating that E-IVIG is a much more efficient streptococcal 
opsonin than commercially available IVIG (Figure 3.15A).  
 
The ability of E-IVIG to promote opsonophagocytic uptake of M3, M12 and M89 GAS was 
subsequently assessed using a single concentration of antibody and two representative 
isolates from each serotype. E-IVIG was shown to promote sporadic uptake of two additional 
serotypes, with detectable phagocytosis occurring in the H471 (M3) and H530 (M12) 
reactions (Figure 3.15B). Uptake of these isolates was much less pronounced than that 
reported for the M1 strains H364 and H366; suggesting that an overarching serotype 
specificity exists within the E-IVIG preparation. This serotype specificity most likely results 
from the use of pooled M1 CWE for the affinity purification of E-IVIG in the above 
experiments. 
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Figure 3.15: E-IVIG facilitates neutrophil mediated opsonophagocytosis  of GAS.  
FITC labelled GAS was coated with E-IVIG (blue) or IVIG (red) and incubated with 
freshly isolated neutrophils at a ratio of 1:200. In control groups 5 mg/ml of IVIG 
(green) or PBS (grey) was used as an opsonin. Results (n = 3) are expressed as 
percentage of FITC
+
 neutrophils after a 30 min co-incubation as determined by FACS. 
(A) Decreasing antibody concentrations were used to opsonise H364 cells prior to 
neutrophil incubation. (B) In order to assess the serotype specif icity of the reagent, 40 
µg/ml of E-IVIG was used to opsonise 8 of the selected GAS isolates.  In control groups 
5 mg/ml of IVIG (green) or PBS (grey) was used as an opsonin. Error bars indicate  
standard deviation and asterisks indicate a statistically signif icant difference between 
cells incubated with E-IVIG or PBS (P<0.05, two-way ANOVA with Bonferroni’s 
correction). Bar represent tr iplicate experiments conducted using whole blood 
extracted from three different donors.  
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3.3.4: Purification of streptococcal antigens by E-IVIG immunoprecipitation using 
a protein G agarose matrix 
Having established that E-IVIG binds to streptococcal CWE with a much higher affinity than 
IVIG, the immunoprecipitation protocol itself was next examined. In an attempt to prevent 
desorption of the bound antibody upon release of the associated antigens, E-IVIG was first 
cross linked to the protein G agarose support using dimethyl pimelimidate dihydrochloride 
(DMP), according to the protocol of Trinkle-Mulcahy and colleagues (Trinkle-Mulcahy et al., 
2008). DMP is a flexible, bifunctional coupling reagent which binds nonspecifically to free 
amino groups present within protein molecules (Harlow and Lane, 1988). Simultaneous 
binding of one or more DMP molecules to the Fc region of the antibody and the resin-
associated protein G molecule will greatly enhance the strength of the overall interaction 
between the antibody and the agarose substrate (Harlow and Lane, 1988). 
 
Under these conditions, 500 µl of immunoprecipitation resin with a bound E-IVIG 
concentration of approximately 1 mg/ml was produced. In order to identify any proteins that 
were incongruously purified by non-specific IgG binding, a negative control column was also 
prepared using rabbit anti-BSA IgG (Sigma Aldrich) in place of E-IVIG. The 
immunoprecipitation protocol was also modified to include a mild acid elution step, similar to 
that utilized during affinity purification of the E-IVIG. It was hypothesized that this milder 
means of dissociating the antibody-antigen interactions would prevent uncoupling of the 
antibody from the cross linked protein G column.  
 
These newly designed columns were utilized to immunoprecipitate the IVIG-reactive surface 
antigens from two aliquots of M1 CWE from a single preparation. The flow through from 
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each column (containing the unreactive protein fraction) was collected and visualized by 
immunoblot analysis alongside the eluted fraction which should contain the immunoreactive 
streptococcal antigens. Immunoprecipitation of H305 CWE resulted in the successful 
purification of a single IVIG-reactive protein band of approximately 80 kDa in size that was 
present in the applied CWE and eluted fraction, but absent from the unbound flow through 
(Figure 3.16A and B). Secondary only control immunoblot analysis (using the goat anti-
rabbit and goat-anti human secondary antibodies alone) was insufficient to visualize this 80 
kDa band, indicating that it did not represent desorbed IgG (Figure 3.16C). In contrast, the 
surrounding regions of reactivity were present on both the IVIG and secondary only control 
immunoblots indicating that a large amount of IgG had desorbed from the column despite the 
chemical cross linking step. Therefore while it would appear that E-IVIG has a high enough 
anti-GAS IgG titre to permit affinity purification of the target streptococcal antigens, the 
binding interaction afforded by cross linked protein G agarose is still not strong enough to 
prevent uncoupling of the absorbed antibodies. 
 
Furthermore, InstantBlue staining revealed that the anti-BSA IgG eluted fraction contained a 
number of protein bands, many of which were present on both the IVIG and secondary only 
control immunoblots. While the origin and means of purification of these proteins is difficult 
to predict, it is clear that their interaction with the coupled immunoglobulin occurs non-
specifically as evidenced by their presence on the secondary only control immunoblot.  
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Figure 3.16: Purification of streptococcal surface antigens by E-IVIG 
immunoprecipitation using a protein G agarose matrix. E-IVIG and anti-BSA IgG 
were cross linked to settled protein G resin and incubated with H305 CWE as outlined 
in section 2.10 of the methods. Aliquots of the applied CWE (CWE On), the column flow 
through (FT) and the eluted fractions (EF) were separated on 7% tris-acetate gels and 
(A) stained with InstantBlue or (B) subjected to immunoblot analysis using 2 µg/ml of 
IVIG as the primary antibody. (C) Immunoreactive bands representing desorbed 
antibody were identif ied using a secondary only control immunoblot as outlined in 
section 2.3.4 of the methods. A single IVIG-reactive protein band of approximately 80 
kDa in size that was present in the applied CWE and eluted fraction but was absent 
from the unbound flow through was identif ied (red boxes) . Molecular mass markers to 
show the migration patterns of the protein bands are given in kilodaltons.  
 
3.3.5: Purification of streptococcal antigens by E-IVIG immunoprecipitation using 
a cyanogen bromide activated agarose matrix 
In a further attempt to inhibit dissociation of antibody during the elution step of the 
immunoprecipitation protocol, the protein G agarose substrate was abandoned, and the E-
IVIG was instead coupled to CNBr activated agarose as outlined in section 2.11.1 of the 
methods. Additionally, in response to the non-specific binding that occurred in the previous 
experiment, the negative control column was prepared using goat control IgG (Abcam) with 
no known specificity in place of the rabbit anti-BSA IgG utilized previously. In order to 
confirm that both antibodies had successfully coupled to the resin, the concentration of the 
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antibody solutions was measured before and after CNBr coupling (data not shown), and 
aliquots of the initial and unbound antibody solutions were visualized by SDS-PAGE (Figure 
3.17A).  
 
Once prepared, the E-IVIG and goat control IgG columns were used to immunoprecipitate 
the IVIG-reactive surface antigens from two aliquots of M1 CWE from the same preparation 
as outlined in section 2.11.1 of the methods. The applied extract was analyzed by Coomassie 
protein assay along with the flow through and eluted fractions recovered from each column 
(Table 3.6). A small amount of protein was detected within five of the twelve eluted fractions 
collected from the E-IVIG column suggesting that a small fraction of the protein present 
within the M1 CWE had bound to the immunoprecipitation resin. The absence of detectable 
protein within the goat IgG eluent suggested that the purported binding occurred specifically 
and thus most likely resulted from a finite number of antibody-antigen interactions.  
 
Table 3.6: Detection of antigenic proteins within the E-IVIG and goat IgG eluted 
fractions. Protein concentrations were measured by Coomassie protein assay as 
outlined in section 2.3.2 of the methods and are given in µg/ml. 
 
  Eluted fractions 
 CWE On FT 1 2 3 4 5 6 7 8 9 10 11 12 
E-IVIG 761 496 / / 51 58 38 30 25 25 / / / / 
Goat IgG 761 510 / / / / / / / / / / / / 
 
To confirm the presence of one or more antigens within the E-IVIG eluent, eluted fraction 
three (EF-3) was visualized by SDS-PAGE and InstantBlue staining (Figure 3.17A). While 
there was no discernable difference between the banding patterns recovered from the E-IVIG 
and control flow through, EF-3 contained a number of faint protein bands that were 
apparently absent from the corresponding negative control sample. This disparity was 
confirmed by consolidation, and 10x concentration of the twelve eluted fractions prior to 
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reanalysis of the E-IVIG and control eluents by SDS-PAGE and InstantBlue staining (Figure 
3.17B). 
 
 
 
Figure 3.17: Purification of streptococcal surface antigens by E-IVIG 
immunoprecipitation using a CNBr activated agarose matrix . Goat control IgG and 
E-IVIG were coupled to CNBr activated agarose and incubated with H364 CWE as 
outlined in section 2.11.1 of the methods. Aliquots of the applied antibody solutions, 
the unbound antibody solutions and the applied CWE were saved for analysis along 
with the flow through (FT) and pooled eluted fractions (EF). (A) For SDS-PAGE, 5 µl 
aliquots of each goat control IgG fraction ( left panel) and E-IVIG fraction (r ight panel) 
were separated on 7% tr is-acetate gels and stained with InstantBlue. (B) The eluted 
fractions were concentrated and reanalysed by SDS-PAGE. Molecular mass markers to 
show the migration patterns of the protein bands are given in kilodaltons . 
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The presence of a number of protein bands within the E-IVIG eluent that were absent from 
the negative control samples strongly suggests that the CNBr/E-IVIG immunoprecipitation 
column was capable of isolating the IVIG-reactive surface proteins present within 
streptococcal CWE. In order to confirm this hypothesis, aliquots of the applied CWE, the 
column flow through, and the concentrated eluent were analyzed by immunoblot analysis 
using IVIG as the primary antibody (Figure 3.18). Of the four major IVIG-reactive bands that 
were present within the applied CWE sample, all four appeared in the E-IVIG eluent 
(hereafter referred to as the immunoprecipitate) whilst remaining in the flow through of the 
goat control IgG column. This strongly suggests that E-IVIG immunoprecipitation is a viable 
means of purifying the antigenic surface proteins present within the crudely extracted 
streptococcal CWEs for downstream proteomic analysis. 
 
 
 
Figure 3.18: Immunoblot analysis of the E-IVIG immunoprecipitates. E-IVIG and 
goat control IgG were coupled to cyanogen bromide activated agarose and incubated 
with H364 CWE as outlined in section 2.11.1 of the methods . For immunoblot analysis, 
5 µl aliquots of the applied CWE and the flow through (FT), and 16 µl aliquots of the 
pooled eluted fractions (EF) were separated on 7% tr is-acetate gels and probed with 2 
µg/ml of IVIG. Molecular mass markers to show the migration patterns of the protein 
bands are given in kilodaltons. 
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It was also noted that the banding pattern recovered from the E-IVIG immunoprecipitate by 
InstantBlue staining was much more complex than that visualized by immunoblot analysis, 
suggesting that IVIG/E-IVIG may recognize a wider array of antigens under native 
conditions than was apparent by denaturing PAGE. The concentration of these proteins 
within the starting CWE was remarkably low as evidenced by the initial concentration of the 
five E-IVIG fractions containing the eluted antigens (Table 3.6). This finding supports the 
earlier hypothesis that the complexity of the excised protein bands in Figures 3.7 and 3.8 
prevented conclusive identification of the immunoreactive antigens which were thought to be 
present at relatively low concentrations. 
 
3.3.6: Purification of conserved M1-GAS antigens by E-IVIG immunoprecipitation 
In an attempt to identify the IVIG-reactive surface antigens that are conserved across the five 
M1 isolates selected for study, CWEs from the four remaining strains of this serotype were 
subjected to immunoprecipitation using the E-IVIG column as outlined in section 2.11.1 of 
the methods. As a negative control, an aliquot of pooled cell wall extract (prepared using an 
equivalent concentration of CWE from each M1 isolate) was incubated with the goat control 
IgG column. Following immunoprecipitation, the applied cell wall extract, the flow through 
and the immunoprecipitate were subjected to immunoblot analysis using IVIG as the primary 
antibody (Figure 3.19). 
 
The results mirrored those reported during the preliminary experiment; with all of the IVIG-
reactive bands present within the applied CWE sample appearing in the E-IVIG 
immunoprecipitate, whilst remaining in the flow through of the goat control IgG column. The 
banding patterns that were produced by the five isolates were remarkably similar indicating 
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that a number of conserved antigens had been recovered that merit downstream 
characterization by proteomic analysis. In addition secondary only control immunoblot 
analysis of the collected fraction revealed that a minimal amount of E-IVIG had desorbed 
from the column during elution of the associated antigens. Owing to the strength of the 
covalent binding interaction between the E-IVIG and the CNBr matrix, it is likely that this 
antibody was released as a result of GAS-mediated proteolytic cleavage rather than through 
contiguous uncoupling upon incubation with acetic acid. Importantly the apparent 
concentration of desorbed IgG was much lower than in the previous immunoprecipitation 
experiments; and the molecules had migrated to form discrete bands within the 
polyacrylamide gel matrix, limiting their proposed impact on downstream proteomic analysis.  
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Figure 3.19: Purification of streptococcal surface antigens by E-IVIG 
immunoprecipitation.  Antigenic proteins were purif ied from the five M1 isolates 
selected for study using an E-IVIG IP column as outlined in section 2.11.1 of the 
methods. (A) Aliquots of the applied CWE (On), the column flow through (FT) and the 
eluted fractions (EF) were separated on 7% tris-acetate gels and subjected to 
immunoblot analysis using 2 µg/ml of IVIG as the primary antibody. (B) Immunoreactive 
bands representing desorbed antibody were identif ied using a secondary only control 
immunoblot as outlined in section 2.3.4 of the methods. Molecular mass markers to 
show the migration patterns of the protein bands are given in kilodaltons.  
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3.3.7: Summary of section 3.3 
The above data indicates that E-IVIG immunoprecipitation is a viable means of purifying the 
IVIG-reactive surface proteins that are present within the crudely extracted streptococcal 
CWE preparations. Initial attempts to isolate the antigens recognised by IVIG were hampered 
by the propensity of the antibody to dissociate from the protein G agarose solid support 
during the elution step of the immunoprecipitation protocol. Protein G agarose was initially 
selected as the specificity of the resin for the IgG Fc region ensures that the antigen binding 
Fab region of the molecule remains unoccluded, allowing maximal antigen binding to occur 
(Harlow and Lane, 1988). Therefore this problem was first addressed by modification of the 
immunoprecipitation protocol rather than through the selection of an alternative solid support. 
To this end, the antibody was cross linked to the protein G agarose using the bifunctional 
coupling reagent DMP, while the immunoprecipitation itself was modified to include a mild 
acid elution step. However, these measures proved insufficient to prevent elution of the 
absorbed antibody with the target antigens. 
 
In addition to the problems associated with the choice of solid support, the preliminary data 
suggested that the concentration of anti-GAS IgG within the starting IVIG preparation was 
too low to facilitate immunoprecipitation of the antigenic proteins from the prepared CWEs. 
The anti-GAS was therefore affinity purified using streptococcal cell wall extract that was 
covalently coupled to a CNBr activated agarose solid support. The affinity of the resulting E-
IVIG for the target streptococcal surface antigens was shown to be much higher than that of 
the starting preparation by ELISA, while the range of antigens recognized (as determined by 
immunoblot analysis) was comparable between the two reagents. E-IVIG was thus employed 
for isolation of the IVIG-reactive surface proteins in the proceeding immunoprecipitation 
experiments.  
142 
 
Despite the comparable reactivity observed when the 20 CWEs were subjected to ELISA 
using E-IVIG as the primary antibody, the overarching serotype specificity of the reagent 
became apparent when uptake of the isolates was examined using a purified neutrophil 
opsonophagocytosis assay. Uptake of the M1 isolates was much more pronounced than that 
reported for the other strains suggesting that this M type expresses one or more IVIG reactive 
antigens that are not expressed by the other serotypes examined. For example, it is likely that 
the use of M1 CWE in the affinity purification of E-IVIG resulted in the isolation of a 
significant amount of serotype specific IgG targeted against the hypervariable region of the 
M1 protein. However, it is also possible that the other serotypes produce a different repertoire 
of surface antigens to M1 GAS. In order to explore this hypothesis it would be desirable to 
enrich separate preparations of IVIG using serotype M3, M12 and M89 affinity purification 
columns, and use the resulting serotype specific E-IVIG preparations to identify and compare 
the contrasting repertoires of IVIG reactive proteins. Alternatively, a single, pan serotype 
affinity purification column could be constructed that incorporates and equal concentration of 
CWE from each of the twenty streptococcal isolates selected for study. Nevertheless, the 
ability of IVIG to recognises all 20  CWEs suggests that one or more highly conserved 
vaccine candidate antigens exists within the preparations that may be isolated by E-IVIG 
immunoprecipitation.  
 
The affinity purification protocol highlighted the ability of CNBr activated agarose to retain 
the absorbed antibody during the mild acid elution step of the immunoprecipitation protocol. 
While CNBr binding is non-specific and thus results in many antigen binding sites being lost 
where antibodies becomes attached via their Fab domain, the binding interaction between the 
resin and the antibody is much stronger than can be achieved through the use of protein G 
agarose (Harlow and Lane, 1988). It was therefore concluded that while less total antigen 
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would be purified using CNBr activate agarose, the recovered immunoprecipitate would be 
cleaner than that purified using a protein G agarose column. Furthermore it was thought that 
the use of E-IVIG, which contains a much higher anti-GAS IgG titre than the starting IVIG 
preparation, may offset the loss of antigen binding sites that was inevitable when CNBr 
agarose was employed.  
 
The preliminary serotype M1 immunoprecipitation experiments confirmed that the newly 
constructed CNBr/E-IVIG immunoprecipitation column was indeed capable of isolating the 
IVIG-reactive surface antigens present within the streptococcal CWEs despite the purported 
reduction in exposed Fab domains. While a small amount of antibody was present within the 
eluted fractions, it was much less pronounced than in the previous experiments and resolved 
to a defined molecular weight when subjected to SDS-PAGE. Therefore although the 
peptides generated by trypsinisation of the desorbed antibody will be detected during LC-
MS/MS analysis of the CNBr/E-IVIG immunoprecipitates, their relative abundance should be 
low enough to permit identification of the target streptococcal antigens.  
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3.4: Identification of vaccine candidate antigens by E-IVIG 
immunoprecipitation and proteomic analysis 
3.4.1: Identification of the conserved M1-GAS surface antigens purified by E-IVIG 
immunoprecipitation 
Having developed a robust protocol for the immunoprecipitation of IVIG-reactive surface 
antigens from crude streptococcal CWE preparations, the antigens present within the M1 
immunoprecipitates were next identified by proteomic analysis as outlined in section 2.4 of 
the methods. A total of 162 gel slices were excised representing 27 distinct rows that 
decreased sequentially in molecular mass (Figure 3.20A). The distribution of each of the 
proteins identified was tabulated with numbers representing the percentage of the protein 
sequence covered by the identified peptides (see Figure 2.1 in the methods section). Initially, 
heat maps were generated for three previously identified vaccine candidate antigens (C5a 
peptidase, SpyCEP and the M-protein) in order to validate the method, and assess the likely 
coverage that could be expected from a novel promising candidate antigen (Figure 3.20B). 
Analysis of the negative control immunoprecipitate (recovered from the goat control IgG 
column) revealed that a detectable quantity of C5a peptidase and the M protein was present 
within several of the excised gel slices. While it is possible that these proteins display weak 
affinity for the goat control IgG present on the negative control column, it is more likely that 
a modicum of protein carryover from the adjacent regions of the gel occurred when these 
slices were being excised.  
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Figure 3.20: Identification of the immunoprecipitated streptococcal surface antigens by LC-MS/MS. Streptococcal surface 
antigens were identif ied by LC-MS/MS as outlined in section 2.4 of the methods. (A) For SDS-PAGE, 5 µg of each immunoprecipitate 
was separated using a 7% tr is-acetate gels, stained with InstantBlue and sectioned for analysis by LC -MS/MS. (B) Peptides were 
identif ied using the SEQUEST algorithm and a serotype M1 reference proteome. The distr ibution of all of the proteins identif ied was 
tabulated with numbers representing the percentage of the protein sequence covered by the identif ied peptides  (see Figure 2.1 in the 
methods section). Coverage levels are scaled from highest to lowest using progressively l ighter shades of grey, indicating >66% 
(darkest), >33%, >10% and <10%. The heat maps that were generated for three previously characterised vaccine candidate antigens 
(C5a peptidase, SpyCEP and the M protein) are displayed.  
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Encouraged by the data recovered for the previously characterized vaccine candidate 
antigens, heat maps were subsequently generated for each of the remaining proteins identified 
(data not shown). The proteins recovered from all five GAS isolates, or from four isolates 
with a coverage of >10% were tabulated, and an extensive literature search was conducted to 
identify any antigens that had not previously been trialled using a suitable in vivo vaccination 
model (Table 3.7). A total of 16 proteins were identified that satisfied these criteria, some of 
which had been identified by previous high throughput vaccine candidate antigen 
identification studies, but had not subsequently been evaluated in vivo. The heat maps 
generated for these proteins are displayed in Figure 3.21. 
 
Table 3.7: The conserved antigens present within the M1 immunoprecipitates.  
 
Protein name Gene name SF370 locus Prior reference 
60 kDa chaperonin groEL Spy_2070 (Lemos et al., 2000) 
Adenylosuccinate synthase purA Spy_0160 None found 
C5a peptidase scpA Spy_2010 (Ji et al., 1997) 
Cell surface protein - Spy_0843 (Rodriguez-Ortega et al., 2006) 
Chaperone protein DnaK dnaK Spy_1760 (Lemos et al., 2000) 
DNA polymerase III subunit beta dnaN Spy_0003 None found 
Elongation factor G fus Spy_0273 None found 
Elongation factor Ts tsf Spy_2093 None found 
Endonuclease/exonuclease/phosphatase - Spy_0747 (Bensi et al., 2012) 
Enolase eno Spy_0731 None found 
Extracellular hyaluronate lyase hylA Spy_1032 (Bensi et al., 2012) 
Fibronectin-binding protein cpa Spy_0125 (Mora et al., 2005) 
Glyceraldehyde-3-phosphate dehydrogenase gap, gapA, plr Spy_0274 None found 
Hypothetical membrane associated protein - Spy_1037 (Bensi et al., 2012) 
M protein type 1 emm Spy_2018 (Fox et al., 1973) 
Maltose/maltodextrin-binding protein malE Spy_1294 (Lei et al., 2004) 
Maltose/maltodextrin-binding protein malX Spy_1306 None found 
Metal ABC transporter substrate-binding 
lipoprotein 
mtsA Spy_0453 (McMillan et al., 2004) 
Multimodular transpeptidase-transglycosylase 
PBP 
pbp1b Spy_0097 None found 
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Table 3.7 (Continued): Proteins recovered from all f ive GAS isolates, or identif ied 
within four isolates with a coverage of >10% are displayed. Where targets have been 
previously evaluated in vivo  the relevant reference is displayed.  
 
Protein name Gene name SF370 locus Prior reference 
N-acetylneuraminate-binding protein - Spy_0252 (Lei et al., 2004) 
Nicotine adenine dinucleotide glycohydrolase nga, spn Spy_0165 None found 
Nucleoside-binding protein - Spy_1228 (Lei et al., 2004) 
Nucleoside-binding protein - M5005_Spy0137 None found 
Oligopeptide-binding protein  sarA, oppA M5005_Spy0249* (Bensi et al., 2012) 
Periplasmic component of efflux system - Spy_2032 None found 
Phosphoglycerate kinase  pgk Spy_1881 None found 
Phosphoglycerol transferase - Spy_0807 None found 
Pilin - Spy_0128 (Mora et al., 2005) 
Probable dipeptidase B pepDB Spy_2066 (Bensi et al., 2012) 
Putative 42 kDa protein  - Spy_0469 (Rodriguez-Ortega et al., 2006) 
Putative pullulanase  pulA Spy_1972 (Fritzer et al., 2010) 
Putative secreted protein sibA Spy_0019 (Bensi et al., 2012) 
Putative surface exclusion protein prgA Spy_0269 (Bensi et al., 2012) 
Putative transcription regulator lytR  Spy_1733 None found 
Putative uncharacterized protein - Spy_0130 (Mora et al., 2005) 
Putative uncharacterized protein - Spy_0836 (Rodriguez-Ortega et al., 2006) 
Putative uncharacterized protein - Spy_1643 None found 
Putative uncharacterized protein - Spy_1591 None found 
SpyCEP prtS Spy_0416 (Turner et al., 2009a) 
Streptococcal histidine triad protein - Spy_2006 (Kunitomo et al., 2008) 
Streptolysin O  slo Spy_0167 (Bensi et al., 2012) 
Streptopain  speB Spy_2039 (Ulrich, 2008) 
Sugar-binding protein - Spy_1592 (Lei et al., 2004) 
Trigger factor  tig Spy_1896 (Henningham et al., 2012) 
Zinc-binding protein adcA, znuA Spy_0714 (Bensi et al., 2012) 
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Figure 3.21: Identification of novel vaccine candidate antigens by E-IVIG 
immunoprecipitation. 
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Figure 3.21: (Continued) 
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Figure 3.21 (Continued):  Conserved vaccine candidate antigens were identif ied within 
the M1 immunoprecipitates by LC-MS/MS and SEQUEST analysis as outlined in section 
2.4 of the methods. Following an extensive literature search, the previously 
uncharacterised vaccine candidate antigens were tabulated with numbers representing 
the percentage of the protein sequence covered by the identif ied peptides  (see Figure 
2.1 in the methods section) . Coverage levels are scaled from highest to lowest using 
progressively lighter shades of grey, indicating >66% (darkest), >33%, >10% and 
<10%. 
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Proteomic analysis also revealed the presence of a number of distinct proteins within the 
HMR of the separated CWEs, the majority of which were noted to contained sortase 
dependent cell wall anchor motifs (Figure 3.22). It is likely that the covalent interaction 
between these proteins and the cell wall remained intact following proteolytic digestion; 
resulting in the variable accession of peptidoglycan fragments at the C terminus of the 
released molecules This observation supports the earlier hypothesis that the high molecular 
weight smearing reported in the preliminary experiments resulted from the presence of 
several highly immunogenic surface proteins whose migration was being retarded by the 
retention of covalently bound peptidoglycan upon release from the cell wall. 
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Figure 3.22: The high molecular weight smearing may result from a  retardation of surface antigen migration by peptidoglycan.  
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Figure 3.22 (Continued): A) The proteins present within the HMR of the M1 immunoprecipitate samples were identif ied by LC -MS/MS 
and SEQUEST analysis and tabulated with numbers representing the percentage of the protein sequence covered by the identif ied  
peptides (see Figure 2.1 in the methods section). Coverage levels are scaled from highest to lowest using progressively l ighter shades 
of grey, indicating >66% (darkest), >33%, >10% and <10%. B) C terminal sortase anchor motifs (yellow) were identif ied from the 
primary amino acid sequences using ClustalW. Abbreviations: UP; Uncharacterized protein, FNBP; Fibronectin binding protein. Stars 
denoted the presence of identical residues within the idealised anchor motif (LPXTG and QVPTG) and the primary sequence of th e 
respective antigen. 
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3.4.2: Identification of pan-serotype vaccine candidate antigens by E-IVIG 
immunoprecipitation and proteomic analysis 
In order to identify the IVIG-reactive streptococcal surface antigens that were conserved 
across the four serotypes selected for study, the 15 remaining CWEs were subjected to E-
IVIG immunoprecipitation for downstream proteomic analysis. To confirm that one or more 
antigenic proteins had been purified, the resulting immunoprecipitates were subjected to 
immunoblot analysis using IVIG as the primary antibody (Figure 3.23A). The diverse 
banding pattern that was recovered included two bands that were present within all fifteen of 
the immunoprecipitates examined, suggesting that E-IVIG immunoprecipitation had 
successfully purified one or more pan-serotype IVIG-reactive antigens. As in the preliminary 
experiments, InstantBlue staining of the separated immunoprecipitates revealed a more 
complex banding pattern than was evident following immunoblot analysis (Figure 3.23B). 
This finding further suggests that IVIG/E-IVIG recognizes a wider array of streptococcal 
surface antigens under native conditions than is apparent by denaturing PAGE. The separated 
samples were subjected to proteomic analysis, and the resulting data was combined with that 
recovered from the preliminary serotype M1 antigen identification experiments. The proteins 
that were recovered from all 20 isolates were tabulated, resulting in the identification of eight 
highly conserved vaccine candidate antigens (Figure 3.24).  
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Figure 3.23: Purification of M3, M12 and M89 surface antigens by E-IVIG 
immunoprecipitation. Antigenic proteins were purif ied from the remaining isolates 
selected for study as outlined in section 2.4 of the methods. For SDS-PAGE, 5 µg 
aliquots of each immunoprecipitate were separated using a 7% tr is-acetate gels, and 
(A) subjected immunoblot analysis using 3 µg/ml of IVIG as the primary antibody or (B) 
stained with InstantBlue, sectioned for analysis  by LC-MS/MS.  
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Figure 3.24: Identification of pan-serotype streptococcal antigens by E-IVIG 
immunoprecipitation and proteomic analysis.   
 
C5a peptidase
M1 M3 M12 M89
H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411
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Maltose/maltodextrin-binding protein
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Figure 3.24 (Continued) 
 
Oligopeptide-binding protein
M1 M3 M12 M89
H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411
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Putative pullulanase
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Figure 3.24 (Continued)  
 
Nucleoside-binding protein
M1 M3 M12 M89
H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411
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Hypothetical membrane associated protein
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1 1 1 1
2 2 2 2
3 3 3 3
4 4 4 4
5 5 5 5
6 6 6 6
7 7 7 7
8 8 8 8
9 9 9 9
10 10 10 10
11 11 11 11
12 12 12 12
13 13 13 13
14 14 14 14
15 15 15 15
16 16 16 16
17 17 17 17
18 18 18 18 13 24 38
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159 
 
 
 
Figure 3.24 (Continued): Conserved vaccine candidate antigens were identif ied within 
the immunoprecipitate samples by LC-MS/MS and SEQUEST analysis using an M1-
GAS reference proteome as outlined in section 2.4 of the methods. The distr ibution of 
each identif ied protein within the extracted bands was tabulated with the numbers 
representing the percentage of the protein sequence covered by the identif ied 
peptides. Coverage levels were scaled from highest to lowest using progressively 
darker shades of grey, with cut-off values of >66% (darkest), >33%, >10% and <10% 
respectively. The heat maps that were generated for the immunoprecipitated 
streptococcal antigens that are conserved within all serotypes are displayed. 
 
Cell surface protein
M1 M3 M12 M89
H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411
1 1 1 1
2 2 2 2
3 3 3 2 16 10 3
4 4 4 17 19 19 5 4
5 5 5 5
6 6 6 2 6 5 5 13
7 7 7 7 17 7 16 8 4
8 8 8 8
9 9 9 9
10 6 7 10 10 10
11 23 29 20 30 27 11 3 12 16 14 11 11
12 21 25 24 10 12 8 7 17 3 12 12
13 13 13 13
14 14 14 14
15 15 15 15
16 16 16 16
17 17 17 17
18 18 18 18
19 19 19 19
20 20 20
21 21 21
22 22
23 23
24 24
25 25
26 26
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Putative surface exclusion protein
M1 M3 M12 M89
H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411
1 1 1 1
2 2 2 2
3 3 3 3
4 4 4 5 3 14 3 4
5 5 5 19 17 26 23 19 5
6 6 6 21 30 23 6 6
7 7 7 7
8 8 8 8 28 24 26 17 25
9 9 9 9 17 6
10 10 10 10
11 11 11 11
12 21 23 33 23 23 12 12 12
13 39 34 43 45 37 13 9 6 15 10 13 13
14 31 35 34 30 27 14 26 23 33 32 31 14 14
15 15 17 14 8 10 15 15
16 9 20 21 24 7 16 5 16 5 5 7 9 5 16 13 7 8 8 8
17 17 4 4 6 17 8 9 9 5 17 3
18 18 18 3 18
19 19 19 19 4
20 20 20 3
21 4 9 21 21
22 3 4 3 5 22 5 5 3 6 9
23 11 16 14 15 6 23 8 10 9 8
24 14 15 15 14 10 24
25 5 7 10 9 25
26 26 4 7
27 6 5 8 4
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3.4.3: Comparative immunoprecipitation of streptococcal vaccine candidate 
antigens using Endobulin, Intratect and Privigen E-IVIG 
Having identified eight potential vaccine candidates by E-IVIG immunoprecipitation, the 
frequency with which these antigens are recognised by the humoral immune response, and 
thus their prevalence upon the streptococcal cell surface during in vivo infection, was next 
investigated. To this end, separate preparations of E-IVIG were generated using IVIG from 
different suppliers; and used to produce three new immunoprecipitation columns. These 
columns were used to immunoprecipitate the IVIG-reactive surface antigens from eight 
streptococcal CWEs (prepared using two representative isolates from each serotype) for 
downstream proteomic analysis (Figure 3.25). The ability of all three E-IVIG preparations to 
facilitate purification of the IVIG-reactive antigens identified above suggested that all eight 
are constitutively expressed upon the GAS cell surface during in vivo infection (Figure 3.26). 
Combined with their high degree of conservation amongst the 20 isolates selected to for 
study, this strongly suggests that the eight streptococcal surface antigens identified by E-
IVIG immunoprecipitation may form the basis of an effective, multivalent anti-GAS 
vaccination. 
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Figure 3.25: Comparative immunoprecipitation of streptococcal antigens using 
Endobulin, Intratect and Privigen E-IVIG. The antigenic proteins were purif ied from 6 
of the 20 GAS strains selected for study (2 from each M type) using CNBr agarose 
coated with E-IVIG synthesised from Endobulin (End.), Intratect (Int.) or Privigen 
(Priv.) IVIG as outlined in section 2.11.2 of the methods. Aliquots of each 
immunoprecipitate were separated using 7% tris -acetate gels, stained with InstantBlue 
and sectioned for proteomic analysis.  
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Figure 3.26: Identification of the putative vaccine candidate antigens from the 
Endobulin, Intratect and Privigen immunoprecipitates by proteomic analysis.  
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Figure 3.26 (Continued) 
 
Maltose/maltodextrin-binding protein 
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Figure 3.26 (Continued) 
 
Oligopeptide-binding protein 
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Figure 3.26 (Continued): The proteins present within the gel slices excised in Figure 
3.23A were identif ied by proteomic analysis using the SEQUEST algorithm and an M1-
GAS reference proteome. The distr ibution of the eight conserved antigens identif ied in 
Figure 3.24 was tabulated with numbers representing the percentage of the protein 
sequence covered by the identi f ied peptides. Coverage levels are scaled from highest 
to lowest using progressively l ighter shades of grey, indicating >66% (darkest), >33%, 
>10% and <10%. 
  
Putative pullulanase
H364 H364 H364 H366 H366 H366 H330 H330 H330 H413 H413 H413 H530 H530 H530 H529 H529 H529 H395 H395 H395 98 98 98
End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv.
1 1 1 1
2 2 2 2
3 3 3 2 2 3 3 3 4
4 2 3 4 3 4 15 10 14 13 12 10 4 11 10 10 17 12 12 4 5 7 18 21
5 3 13 13 5 5 3 3 3 4 5 18 14 20 20 21 21
6 3 6 3 5 2 3 5 6 4 3 2 5 6 6 3 3
7 2 3 3 2 7 7 4 3 7 3 5 5 9 12 9
8 8 8 8 2 4 5
9 9 9 9 4
10 10 10 10
11 11 11 11
12 12 12 12 3 3 6
13 13 13 2 13 2
14 14 14 14
15 15 15 15
16 16 16 16
17 17 17 2 2 17
18 18 18 18
19 19
20 20
21
Putative surface exclusion protein 
H364 H364 H364 H366 H366 H366 H330 H330 H330 H413 H413 H413 H530 H530 H530 H529 H529 H529 H395 H395 H395 98 98 98
End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv. End. Int. Priv.
1 1 1 1
2 2 2 2
3 3 3 3
4 4 4 4
5 5 6 3 4 3 3 5 5 6 5 6 7 13 5
6 6 18 16 27 28 32 30 6 31 37 37 45 40 36 6 4
7 16 26 24 28 18 21 7 38 32 31 22 21 12 7 14 17 22 43 40 47 7 18 15 20 24 25 27
8 5 18 14 23 29 25 8 2 3 8 14 5 8 13 10 16 8 36 32 10 27 40 40
9 4 2 9 3 4 9 2 6 13 10 14 9 6 7 5 3
10 3 10 10 5 6 10 10 12 10 3
11 11 11 3 8 10 11 6 6
12 3 3 12 2 3 3 3 3 12 3 4 5 3 4 12 6 5 6 14 14 14
13 13 4 4 3 5 5 6 13 7 3 3 5 3 5 13 4 4 6 6
14 3 14 16 11 13 12 10 13 14 5 4 4 14 7 10 7
15 7 10 8 10 9 7 15 6 7 6 6 8 12 15 4 3 3 3 4 5 15 2 4
16 3 16 2 16 10 12 11 13 16 9 16
17 17 4 17 5 5 8 8 9 13 17 3
18 18 6 18 18
19 19
20 20 4 6 6 4
21
M1 M3 M12 M89
M1 M3 M12 M89
166 
 
3.4.4: Summary of section 3.4 
The data above indicates IVIG recognises a repertoire of serotype independent streptococcal 
surface antigens that can be isolated by E-IVIG immunoprecipitation for downstream 
proteomic analysis. The eight antigens selected for further study (cell surface protein, 
hypothetical membrane associated protein, maltose/maltodextrin-binding protein, nucleoside 
binding protein, oligopeptide binding protein, putative surface exclusion protein, putative 
pullulanase and C5a peptidase) were identified within all 20 CWE preparations suggesting 
that they are highly conserved amongst the four clinically relevant serotypes selected for 
study (M1, M3, M12 and M89). Furthermore, the ability of three distinct preparations of 
IVIG to recognise these antigens (each of which has been prepared using serum from an 
indeterminate number of healthy donors) suggests that they are constitutively expressed 
during in vivo infection. Combined with the reported efficacy of IVIG as an adjunct treatment 
for iGAS infection, this strongly suggests that these antigens may form the basis of an 
effective multivalent vaccine formulation that transcends the antigenic differences between 
the contrasting GAS serotypes.  
 
In addition to highlighting a number of promising vaccine candidate antigens, the E-IVIG 
immunoprecipitation experiments also identified the enigmatic antigens responsible for the 
high molecular weight smearing reported in the preliminary experiments. Indeed the majority 
of the tryptic peptides that were recovered from the HMR mapped to one of several distinct 
proteins, all of which contained sortase dependent cell wall anchor motifs. It is likely that the 
covalent interaction between the cell wall anchor and the peptidoglycan layer remains intact 
following incomplete enzymatic digestion of the gram positive cell wall. Variations in the 
size and shape of the attached peptidoglycan fragments will cause the associated proteins to 
become spread throughout the HMR of the gel, resulting in the characteristic smear reported 
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in the preliminary experiments. Therefore while IVIG may recognise one or more non 
proteinaceous components of the gram positive cell wall, such interactions did not account 
for the intense reactivity of the HMR. 
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3.5: Characterisation of the streptococcal vaccine candidate antigens 
isolated by E-IVIG immunoprecipitation 
3.5.1: Cloning and expression of recombinant streptococcal antigens 
Having identified a number of promising serotype independent vaccine candidate antigens by 
E-IVIG immunoprecipitation, the eight targets selected for further study were cloned into the 
pET-19b overexpression vector (Table 3.8). Primers were designed to exclude the signal 
sequence and cell wall anchor motif from each insert using the SignalP and PSORTb 
algorithms as outlined in section 2.5.2 of the methods. A series of internal restriction sites 
within the pulA sequence prevented BamHI cloning of the target into pET-19b. Accordingly, 
an NdeI digestion site was included within the pulA primer sequences to facilitate cloning of 
the amplified gene (Table 2.4, materials and methods). Despite numerous attempts, malE 
could not be cloned into pET-19b and thus was excluded from downstream analysis 
(discussed in detail below). Similar problems were encountered with the pulA insert however, 
alteration of the reverse primer sequence resulted in the successful integration of a 1.5 kb N 
terminal fragment (pulA-N) into the pET-19b vector. 
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Table 3.8: The eight targets selected for recombinant production by E-IVIG immunoprecipitation and proteomic analysis.  
  
Protein name Gene name M1 ORF Abbreviation Prior reference 
Cell surface protein N/A Spy_0843 CSP (Rodriguez-Ortega et al., 2006) 
Hypothetical membrane associated protein N/A Spy_1037 HMAP (Bensi et al., 2012) 
Maltose/maltodextrin-binding protein malE Spy_1294 MalE (Lei et al., 2004) 
Nucleoside binding protein N/A Spy_1228 NBP (Lei et al., 2004) 
Oligopeptide binding protein oppA M5005_Spy0249 OppA (Bensi et al., 2012) 
Putative surface exclusion protein prgA Spy_0269 PrgA (Bensi et al., 2012) 
Putative pullulanase pulA Spy_1972 PulA (Fritzer et al., 2010) 
C5a peptidase scpA Spy_2010 ScpA (Ji et al., 1997) 
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The scpA primers were initially designed to produce the same C5a peptidase fragment as that 
utilized by Ji and colleagues, and facilitated the amplification of a 2.9 kb gene sequence 
devoid of the signal sequence and a cell wall anchor motif (Ji et al., 1997). However, the 
recombinant product of this primer pair could not be isolated by IMAC purification and 
produced no detectable reactivity when subjected to immunoblot analysis using mouse anti-
his IgG as the primary antibody (Figure 3.27). Routine automated fluorescent sequencing of 
the cloned insert revealed an intact His-tag sequence; suggesting that the affinity purification 
motif was removed following translation of the full length molecule (data not shown).  
 
 
 
Figure 3.27: Recombinant ScpA is not His-tagged. For SDS-PAGE, 5 µl aliquots of the 
crude PrgA and ScpA soluble fractions were separated using 10% bis -tr is gels 
alongside 2.5 µg of purif ied recombinant cell surface protein (CSP) . (A) The gels were 
stained with InstantBlue or (B) subjected to immunoblot analysis using a 1:100,000 
dilution of mouse anti-his IgG as the primary antibody. Molecular mass markers to 
show the migration patterns of the protein bands are given in kilodaltons.  
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The apparent molecular mass of recombinant ScpA was remarkably similar to that predicted 
from the primary amino acid sequence (>97 kDa vs 106 kDa) suggesting that if the His-tag 
had indeed been removed, the cleavage must have occurred at the extreme N terminus of the 
molecule. Furthermore, the successful production of recombinant ScpA using the pGEX-4T-1 
expression vector that was previously reported by Ji and colleagues suggested that the 
purported cleavage domain was located within the plasmid sequence rather than within scpA 
itself (Ji et al., 1997). Together these observations led to the hypothesis that recombinant 
ScpA was catalyzing the hydrolysis of its own His-tag at the specific enterokinase cleavage 
site contained within the pET-19b vector sequence  
 
Enterokinase is an intestinal serine protease that specifically cleaves the acidic DDDDK 
sequence of the zymogen trypsinogen to yield active trypsin (Kitamoto et al., 1994). During 
recombinant protein production, the incorporation of an enterokinase domain within the 
expression vector sequence facilitates removal of the His-tag from the target protein 
following affinity purification. Consistent with the molecules serine protease activity, the 
active site of enterokinase is formed from three invariant residues (His-841, Asp-892 and Ser-
987). Specific trypsinogen cleavage requires the presence of an aspartic acid residue at the 
base of the specificity pocket (Asp-981), along with two subsidiary glycine residues (Gly-
1008 and Gly-1018) located either side of the active site (Kitamoto et al., 1994). When this 
series of invariant residues was mapped onto the ScpA sequence, a potential trypsinogen 
cleavage domain was revealed approximately 700 aa into the transcribed protein (Figure 
3.28).  
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ScpA            RLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLN 600 
Enterokinase    ------------------------------------------------------------ 
                                                                             
 
ScpA            NVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKLFALAPKALYETSWQKITIPANSS 660 
Enterokinase    ------------------------------------------------------------ 
                                                                             
 
ScpA            KQVTIPIDVSQFSKDLLAPMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALE 720 
Enterokinase    ------------------------------------------------------------ 
                                                                             
 
ScpA            KPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVEN 780 
Enterokinase    -----------XXHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 49 
                             *                                               
                             ↑ 
                          His-841 
 
ScpA            IEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLR 840 
Enterokinase    XXXXDXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 109 
                    :                                                        
                    ↑ 
                 Asp-892 
 
ScpA            NAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVAN 900 
Enterokinase    XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXDXXXXXSXXXXXXXXXXXXXXXXXXXX 169 
                                                       *                     
                                                 ↑ 
                                              Asp-981 
                                                       ↑ 
                                                    Ser-987 
 
ScpA            GTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVY 960 
Enterokinase    GXXXXXX----XXXGXX------------------------------------------- 182 
                *             *                                              
                ↑             ↑ 
             Gly-1008      Gly-1018 
 
Figure 3.28: Mapping the putative enterokinase site of C5a peptidase.  The active 
site residues of the enterokinase catalytic domain (His -841, Asp-892, Asp-981, Ser-
987, Gly-1008 and Gly-1018) were mapped onto the ScpA sequence revealing a 
potential trypsinogen cleavage site within the C terminal region of the protein. Numbers 
represent the posit ion of each active site residue within the primary sequence of 
enterokinase while each X denotes an unspecified amino acid.  
 
In an attempt to prevent incongruous removal of the affinity purification tag from the 
recombinant ScpA molecule, a premature stop codon was introduced upstream of this 
potential enterokinase domain by site directed mutagenesis (SDM) as outlined in section 
2.5.5 of the methods. Incorporation of the premature stop codon was confirmed by automated 
fluorescent sequencing of the relevant region using the primer sequences outlined in Table 
2.4 (Figure S3, supplementary information). The resulting scpA fragment (scpA-F) was 
transformed into BL21 cells for recombinant production as outlined in section 2.5.6 of the 
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methods. Following preparation of the soluble and insoluble protein fractions, the crude 
ScpA-F preparation was separated by SDS-PAGE and visualized by InstantBlue staining and 
immunoblot analysis using mouse anti-his IgG as the primary antibody (Figure 3.29). 
Immunoblot analysis revealed that ScpA-F retains an intact His-tag following recombinant 
production, and thus can be isolated by IMAC purification. Furthermore, while the 
identification of a potential trypsinogen cleavage domain within the ScpA sequence is not 
definitive, the experiment suggests that GAS may be capable of cleaving the zymogen 
trypsinogen to activated trypsin via an ScpA enterokinase-like domain.  
 
 
 
Figure 3.29: Removal of the putative ScpA enterokinase-like domain prevents removal of the 
His-tag. For SDS-PAGE, 5 µl aliquots of the crude ScpA and ScpA-F soluble fractions 
were separated using 10% bis-tris gels, and (A) stained with InstantBlue or (B) 
subjected to immunoblot analysis using a 1:100,000 dilution of mouse anti-his IgG as 
the primary antibody. Molecular mass markers to show the migration patterns of the 
protein bands are given in kilodaltons.  
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3.5.2: Purification and analysis of the recombinant streptococcal antigens 
Following successful integration and expression of the seven target genes, the resulting 
recombinant proteins were extracted and purified by IMAC as outlined in section 2.6 of the 
methods. The concentration of the purified recombinant proteins was determined by 
Coomassie protein assay, and 2.5 µg aliquots were separated on adjacent lanes of a 10% bis-
tris gel for InstantBlue staining and immunoblot analysis using mouse anti-his IgG as the 
primary antibody (Figure 3.30A and B). Comparative immunoblot analysis revealed that 
several of the recombinant antigens were partially degraded; possibly as a result of the release 
of one or more intracellular proteases following lysis of the BL21 expression cell, and/or the 
extended period of storage at -20°C following IMAC purification. Regardless of this slight 
degradation, the IVIG-reactivity of the seven recombinant antigens was assessed by dot blot 
analysis as outlined in 2.3.4 of the methods. In order to determine the background signal 
intensity, recombinant NADP-dependent glyceraldehyde-phosphate-dehydrogenase (N-
GAPDH), which demonstrated no IVIG-reactivity in the earlier experiments, was also 
included as a negative control (Figure 3.11). Furthermore, to assess the importance of the 
protein secondary structure for IVIG recognition, 1 µg aliquots of each recombinant sample 
were spotted onto the Hybond membrane in PBS (Figure 3.30C); or following denaturation in 
LDS buffer and DTT (Figure 3.30D). 
 
While the results appeared to confirm that all seven of the recombinant streptococcal antigens 
were IVIG-reactive under native conditions, the negative control protein N-GAPDH also 
produced a detectable signal when applied in PBS. Indeed the signal produced by N-GAPDH 
was equivalent to that produce by HMAP, OppA and NBP; indicating that IVIG bound to 
these vaccine candidate antigens and the purported negative control preparation with equal 
avidity. This finding may suggest that the recombinant N-GAPDH molecule contains certain 
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conformation epitopes that are recognised by IVIG, or alternatively that the purified protein 
preparations contain one or more antigenic E.coli proteins that contribute to the overall signal 
intensity of the applied samples. 
 
When the proteins were denatured, the reactivity of the HMAP, OppA and NBP dropped 
below the limit of detection as did the signal produced by N-GAPDH (mirroring the data 
recovered in Figure 3.10). This suggests that the reactivity of the N-GAPDH preparation (and 
of HMAP, OppA and NBP) is reliant on an intact secondary structure. However, whether the 
causative epitopes are present within the target recombinant proteins or the contaiminating 
E.coli products cannot yet be elucidated. The signal strength of CSP, PrgA, PulA (N) and 
ScpA (F) also appeared to diminish following denaturation suggesting that the reactivity of 
these molecules is due in part to the presence of conformational epitopes within the protein 
secondary structure. Together this data is consistent with the earlier observation that IVIG 
recognizes a wider array of epitopes under native conditions than was immediately apparent 
by denaturing PAGE. However, whether the conformational epitopes recognized by IVIG in 
this experiment are present within the target streptococcal surface antigens or one or more 
E.coli contaminants is yet to be elucidated.  
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Figure 3.30: Purification of recombinant streptococcal antigens:  Recombinant cell 
surface protein (CSP), hypothetical membrane associated protein (HMAP), nucleoside 
binding protein (NBP), oligopeptide binding protein (OppA), putative surface exclusion 
protein (PrgA), putative pullulanase (PulA) and C5a peptidase (ScpA)  were produced 
by overexpression of the target genes in pET-19b in BL21 cells and purif ied by IMAC 
as outlined in section 2.6 of the methods. (A) For SDS-PAGE, 2.5 µg of the purif ied 
recombinant samples were resolved on duplicate 10 % bis-tr is gels and stained using 
InstantBlue or (B) subjected to immunoblot analys is using a 1:100,000 dilution of 
mouse anti-his IgG as the primary antibody. Molecular mass markers to show the 
migration patterns of the protein bands are given in kilodaltons.  For dotblot analysis, 1 
µg aliquots of the recombinant antigens were spotted onto a Hybond membrane(C) in 
PBS or (D) following denaturation in LDS buffer and DTT and probed with 5 µg/ml of 
IVIG as outlined in section 2.3.4 of the methods. Recombinant CEP-5 and NADP-
dependent glyceraldehyde-phosphate-dehydrogenase (N-GAPDH) were included as 
posit ive and negative controls respectively.  
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3.5.3: Summary of section 3.5 
Together the above data confirms that the recombinant streptococcal antigens selected by E-
IVIG immunoprecipitation are IVIG-reactive and thus may form the basis of a multivalent 
GAS vaccination. Of the eight serotype-independent antigens identified, seven were 
successfully cloned into the pET-19b overexpression vector and produced recombinantly by 
IPTG overexpression. Despite numerous attempts, the gene of one of the selected antigens 
(malE) could not be cloned into the E. coli strain used for plasmid propagation (One Shot 
Top10). Whilst on multiple occasions pET-19b (malE) was recovered from transformed cells, 
on each occasion the construct produced contained a number of mutations that resulted in 
either a framing error, or a significant truncation of the cloned target. This suggests that 
mutation of malE exerts positive selective pressure upon the transformed E.coli cells; 
possibly by alleviating the energetic burden imposed by production of the recombinant 
protein, or because the full length molecule is toxic to the organism. 
 
While the current data suggests that the conformation of the target streptococcal surface 
antigens may be important for IVIG-reactivity, the dot blot experiments described above are 
confounded by the potential presence of one or more IVIG-reactive E.coli contaminants. 
These proteins may be contributing to the overall reactivity of the preparations as evidenced 
by the intense signal recovered from the negative control protein N-GAPDH, which had 
previously been shown to elicit no reactivity with IVIG under denaturing conditions. 
Alternatively it is possible the N-GAPDH contains certain IVIG-reactive epitopes that are 
lost upon disruption of the secondary structure. Indeed, the molecule was recovered from a 
single isolate (H656) following E-IVIG immunoprecipitation, suggesting that the protein may 
be weakly immunoreactive in situ.  
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With this in mind, the purified recombinant preparation should ideally be separated by 
polyacrylamide gel electrophoresis under native conditions (native PAGE) for subsequent 
analysis by immunoblotting. Native PAGE would facilitate separation of the recombinant 
preparations without disrupting the protein secondary structure, and thus allow the 
immunoreactivity of the target antigens to be confirmed definitively. It is important to note 
however that the antigens selected for recombinant production were identified following 
isolation by E-IVIG immunoprecipitation, and are thus unambiguously IVIG-reactive in situ. 
A lack of IVIG reactivity under native conditions would therefore indicate that the 
recombinant streptococcal antigens are being improperly folded following expression in 
E.coli, rather than suggesting that the targets selected had been spuriously identified by 
proteomic analysis.  
 
During the course of these experiments, a putative enterokinase like domain was identified 
within the primary ScpA sequence. Removal of this region was sufficient to prevent removal 
of the affinity purification tag, which led to the hypothesis that recombinant ScpA was 
capable of recognising the enterokinase cleavage site that is contained within the pET-19b 
vector sequence. It is possible that ScpA is autocatalytic, and removes a small portion of its 
own N terminus following translation. Indeed the presence of an enterokinase-like domain 
within the primary ScpA sequence could simply result from both enzymes belonging to the 
serine protease superfamily. However, it is also possible that C5a peptidase performs an as 
yet undefined function during GAS pathogenesis that is related to in situ trypsinogen 
activation. In order to explore this hypothesis the full length protein would be re-cloned into 
an overexpression vector that lacks an enterokinase cleavage domain (for example pET-15b), 
allowing the full length protein to be purified by IMAC for downstream characterization. 
Alternatively ScpA could be expressed on the surface of the heterologous host Lactococcus 
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lactis; allowing the purported enterokinase activity of the molecule to be confirmed in situ 
and any downstream effects of the resulting, incongruent trypsin activation to be assessed in 
vivo.  
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3.6: In vivo analysis of E-IVIG and the recombinant streptococcal antigens 
3.6.1: Pre-treatment with E-IVIG prevents GAS dissemination in a murine model 
Having established that E-IVIG contains a concentrated anti-GAS IgG fraction that 
recognises a similar repertoire of streptococcal surface antigens to native IVIG, the protective 
efficacy of the reagent was assessed in a murine model. Mice were pre-treated with 800 µg of 
E-IVIG or IVIG and intramuscularly challenged with 5x 10
6
 CFU of H305 as outlined in 
section 2.12 of the methods. After 24hours the organs were removed, homogenised and 
plated out to assess the bacterial load at the infection site, and the degree of dissemination 
from the nidus of infection. Analysis of the organ homogenates revealed that the bacterial 
load in the thighs of the E-IVIG treated mice was significantly lower than in the PBS control 
group. While a similar trend was reported between the E-IVIG and IVIG thighs, the 
experiment was insufficiently powered to attain a statistically significant difference (Figure 
3.32). In addition, the bacterial load present within the superficial inguinal lymph nodes of 
the E-IVIG treated mice was significantly lower than in the IVIG and PBS treated animals. 
Together these data suggest that pre-treatment of mice with E-IVIG may be sufficient to 
inhibit bacterial dissemination to the lymphatic system, and to promote clearance of the 
organism during iGAS infection of the soft tissues. 
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Figure 3.31: E-IVIG prevents streptococcal dissemination and promotes clearance 
at the site of infection.  Three groups of eight age matched female C57BL/6  mice were 
pre-treated with 800 µg/ml of E-IVIG, IVIG or PBS then challenged with 5x10
6
 
CFU/mouse of H305 as outlined in section 2.12 of the methods. Twenty four hours post 
infection the mice were culled and the blood, spleen, l iver, thigh muscle and superf icial 
inguinal lymph node were removed. The organs were homogenised in PBS and plated 
onto blood agar to determine the number of  CFU/mg of t issue and, in the case of the 
inguinal lymph node, CFU/node. Heparinised blood was plated to determine the CFU 
present per ml. Solid l ines indicate the median CFU recovered from each organ and 
asterisks denote a statistically signif icant difference between the indicated groups 
(P<0.05, One-way ANOVA with Dunn’s multiple comparison test) .  
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3.6.2: Vaccination of mice with recombinant streptococcal antigens 
In order to assess the capability of recombinant streptococcal antigens to stimulate humoral 
immunity under experimental conditions, two groups of six mice were vaccinated with 
aliquots of pooled M1 CWE or pooled M1 immunoprecipitate and subsequently assessed for 
seroconversion by ELISA. In addition, a third group was vaccinated with a combination of 
three recombinant proteins that displayed a range of reactivities in vitro. The highly 
immunostimulatory SpyCEP fragment CEP-5 and non-reactive NADP-dependent 
glyceraldehyde 3 phosphate dehydrogenase were therefore selected along with oligopeptide 
binding protein which demonstrated modest IVIG-reactivity in the previous experiments. The 
final group of mice were sham vaccinated in order to determine the baseline reactivity of 
each group following intraperitoneal administration of PBS and adjuvant alone. 
 
Vaccinations were performed as outlined in section 2.13.1of the methods. Five days after the 
final vaccination (day 40), tail bleeds were performed and the serum recovered was tested for 
the presence of serum antibody to each vaccine formulation by ELISA. The data confirmed 
that each of the vaccine formulations had stimulated seroconversion as evidence by the 
presence of reactive serum antibody in the vaccinated mice that was absent from mice sham 
vaccinated with PBS and adjuvant alone (Figure 3.33).  
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Figure 3.32: Vaccination with the recombinant streptococcal antigens results in 
murine seroconversion.  Three groups of six age matched female BALB/c mice were 
vaccinated with 15 µg of pooled M1 CWE (CWE), 15 µg of pooled M1 
immunoprecipitate (IP) or 50 µg of a 1:1:1 formulation of oligopeptide binding protein , 
NADP-dependent glyceraldehyde-3-phosphate dehydrogenase and CEP-5 (RcP) as 
outlined in section 2.13.1 of the methods. A forth group of mice was subjected to sham 
vaccination with PBS to determine the baseline level of reactivity of each vaccine 
formulation following intraperitoneal administration of adjuvant. Tail bleeds were 
performed on day 40 and the development of detectable serum antibody in response to 
each vaccination was confirmed by ELISA as outlined in section 2.13.2 of the methods. 
Results are expressed as absorbance readings at 450 nm minus background levels of 
absorbance, determined by incubating one set of wells with normal mouse serum . Solid 
l ines indicate the median A450 recorded for each group of mice and asterisks denote a 
statistically signif icant difference between the vaccinated (tr iangles) and sham 
vaccinated (squares) groups (P<0.05, Mann-Whitney U). 
 
In order to determine if the humoral immunity stimulated by the immunoprecipitate 
formulation could provide protection against iGAS infection, the vaccinated mice were 
challenged with 5.6x10
6
 CFU/mouse of H305 as outlined in section 2.13.3 of the methods. 
After 24 hours the mice were culled and the blood, spleen, liver, thigh muscle and superficial 
inguinal lymph node were assessed for bacterial load (Figure 3.34). While the bacterial loads 
in the thigh were comparable across the four groups, dissemination from the nidus of 
infection was only recorded sporadically suggesting that the infectious dose was not high 
enough to stimulate a systemic infection. This hypothesis is supported by the lack of 
dissemination in the PBS control group which contrasts with previous studies conducted by 
our lab that have reported bacterial dissemination under similar conditions, where higher 
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infectious doses were achieved (Turner et al., 2009b). The most pronounced dissemination 
that was recorded occurred within the recombinant protein group, where four out of six mice 
had detectable bacterial counts within the superficial inguinal lymph node at the time of 
dissection. However, the experiment was insufficiently powered to determine if this effect 
was real or merely an extreme example of sporadic dissemination. 
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Figure 3.33: Immunisation of mice with the immunoprecipitated GAS antigens.  
Three groups of six age matched female BALB/c mice were vaccinated with 15 µg of 
pooled M1 CWE (CWE), 15 µg of pooled M1 immunoprecipitate (IP) or 50 µg of a 1:1:1 
formulation of recombinant oligopeptide binding protein , NADP-dependent 
glyceraldehyde-3-phosphate dehydrogenase and CEP-5 (RcP) as outlined in section 
2.13.1 of the methods. A forth group of mice was subjected to sham vaccination with 
PBS as a negative control. Following vaccination the mice were challenged with 
5.6x10
6
 CFU/mouse of H305 as outlined in section 2.13.3 of the methods. Twenty four 
hours post infection the mice were culled and the blood, spleen, l iver, thigh muscle and 
superficial inguinal lymph node were removed. The organs were homogenised in PBS 
and plated onto blood agar to determine the number of  CFU/mg of tissue and, in the 
case of the inguinal lymph node, CFU/node. Heparinised blood was dil uted 1:10 and 
plated to determine the CFU present per ml. Solid l ines indicate the median CFU 
recovered from each organ. Solid l ines indicate the median CFU recovered from each 
organ and asterisks denote a statistically signif icant difference between the i ndicated 
groups (P<0.05, One-way ANOVA with Dunn’s multiple comparison test).  
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3.6.3: Summary of section 3.6 
The preliminary murine experiments conducted to date indicate that pre-treatment with E-
IVIG may provide a level of protection against iGAS infection in a murine model. Previous 
studies addressing the effect of polyclonal IgG administration on murine iGAS infection 
found that the reagent was only effective when transgenic mice expressing human MHC class 
II molecules were utilised (Patel et al., 2000, Sriskandan et al., 2006). Indeed, Patel and 
colleagues failed to show any enhancement of bacterial clearance from the infected tissues 
C57B1/6 background following administration of IVIG. In contrast the current study 
demonstrated that pre-treatment of C57B1/6 mice with E-IVIG resulted in a significant 
reduction in bacterial CFU at the site of intramuscular infection 24 hours after bacterial 
administration. In addition, E-IVIG treatment was sufficient to prevent bacterial 
dissemination from the nidus of infection to the superficial inguinal lymph node which 
occurred readily within the PBS and IVIG control groups.  
 
It is likely that the inability of Patel and colleagues to demonstrate bacterial clearance in a 
wild type background was due to the inherently low anti-GAS IgG titre of the administered 
IVIG preparation. Indeed during the course of this study, the proportion of anti-GAS IgG 
within the starting IVIG preparation was estimated to be only ~0.15 % of the total 
immunoglobulin content. Therefore the dose of 1 g/kg selected by Patel and colleagues would 
amount to a total anti-GAS IgG concentration of approximately 37.5 µg per 25 g mouse. 
During the treatment experiment outlined above the E-IVIG group received over 20-times 
this concentration of anti-GAS IgG (800 µg per mouse). In order to achieve this 
concentration of anti-GAS IgG, Patel and colleagues would have to administer >500 mg of 
IVIG per mouse (20 g/kg). Therefore it is possible that the ability of IVIG to provide 
consistent protection against murine iGAS infection is dependent on the administration of an 
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unfeasibly large dose of the reagent. This may also be true for the treatment of clinical iGAS 
infections where the dose of IVIG administered is typically less than 1 g/kg per patient per 
day (Alejandria et al., 2002). Administration of E-IVIG may therefore represent a more 
feasible and more effective adjunct treatment for iGAS infection than parenteral infusion of 
polyspecific IVIG than is currently employed clinically.  
 
The only murine vaccination experiment conducted to date are very preliminary, and were 
carried out in parallel with recombinant production of the eight pan-serotype vaccine 
candidate antigens identified by E-IVIG immunoprecipitation. That being said, the 
experiment did provide some valuable data regarding the amount of antigen required to 
induce seroconversion, and the importance of administering the correct dose of H305 
(between 1x10
7
 and 1x10
8
 CFU/mouse) to ensure the development of a fulminant iGAS 
infection in a BALB/c background. This data will be invaluable for ensuring that the 
vaccination experiments involving the recombinant, pan serotype vaccine candidate antigens 
are executed successfully.  
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4: Concluding remarks 
The current study aimed to develop a novel serological approach to the identification of 
bacterial vaccine candidate antigens utilising the clinical blood product IVIG in place of 
patient convalescent serum. The reported efficacy of the reagent as an adjunct treatment for 
iGAS infection both clinically and in vivo led to the hypothesis that IVIG recognises a 
repertoire of highly conserved streptococcal surface antigens that may form the basis of an 
effective, multivalent vaccine formulation. In order to explore this hypothesis, the repertoire 
of streptococcal surface antigens recognised by IVIG was characterised by proteomic 
analysis, and the antigens that were conserved across four clinically relevant GAS serotypes 
were identified for subsequent evaluation in a suitable vaccination model. 
 
Several recent attempts to develop a multivalent anti-GAS vaccination have yielded some 
promising results; with many preparations conferring protection against iGAS infection in a 
variety of murine models (Rodriguez-Ortega et al., 2006, Moreland et al., 2014, Bensi et al., 
2012). These approaches typically employ in silico genomic analysis in conjunction with one 
or more high throughput proteomic techniques to rationally identify highly conserved, 
strongly immunogenic surface proteins (Bensi et al., 2012, Rodriguez-Ortega et al., 2006, 
Fritzer et al., 2010). One of the most comprehensive study conducted to date was performed 
by Bensi and colleagues who used three high throughput technologies (surfome analysis, 
protein array and flow cytometry) to identify 40 highly conserved streptococcal surface 
antigens for downstream assessment in a murine vaccination model (Bensi et al., 2012). An 
equally extensive approach was adopted by Fritzer and colleagues who utilised a 
streptococcal antigenome and immunological analysis to identify a total of 32 putative 
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vaccine candidate antigens that were subsequently assessed using a variety of in vivo models 
(Fritzer et al., 2010).  
 
In contrast, the E-IVIG immunoprecipitation approach developed over the course of this 
study represents a rapid and relatively straightforward means of identifying potential vaccine 
candidate antigens from crude bacterial preparations with a limited reliance on specialised 
equipment or technological expertise. Despite its relative simplicity, E-IVIG 
immunoprecipitation successfully identified many of the classical streptococcal vaccine 
candidate antigens including the M protein, C5a peptidase, streptolysin O and SpyCEP. In 
addition, E-IVIG immunoprecipitation isolated many of the streptococcal surface antigens 
that are frequently identified using multiple high throughput technologies; including several 
of those identified by the two studies outlined above (Figure 4.1).  
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Figure 4.1: Identification of vaccine candidate antigens by; multiple high throughput approaches ( blue), antigenome 
technology (green) and E-IVIG immunoprecipitation ( red).  A) Reactive surface antigens were priorit ised based upon their genetic 
conservation, surface exposure and immunogenicity (blue and green) or their presence within at least four of the five M1 
immunoprecipitates (red). The eight antigens selected for further characterisation in this study are h ighlighted in yellow. B) Vaccine 
candidate antigens were subsequently identif ied by a series of high throughput murine experiments ( blue and green) or by 
interrogation of the M3, M12 and M89 immunoprecipitates ( red). Figure produced using data from Fritzer  et al., 2010 and Bensi et al., 
2012. 
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It is interesting to note the overall disparity between the antigens identified in this study, and 
in those performed by Bensi and colleagues and Fritzer et al; despite all three adhering to the 
classical requirements for promising vaccine candidates (highly conserved, surface expressed 
and strongly immunogenic). Indeed 67 of the 117 vaccine candidate antigens identified from 
the preliminary data sets were only identified by one study, indicating how the different 
methodologies and exclusion criteria employed can drastically affect the antigens selected for 
downstream investigation (Figure 4.1A). Following further characterisation of the 
preliminary targets (by high throughput murine experimentation or interrogation of the M3, 
M12 and M89 immunoprecipitates) this disparity became even more pronounced with only 
two targets meeting the outlined criteria for more than one study (Figure 4.1B).  
 
However, of the eight pan serotype vaccine candidate antigens isolated by E-IVIG 
immunoprecipitation, only two (nucleoside binding protein and maltose maltodextrin binding 
protein) were not shortlisted in either of the other studies (Figure 4.1A). Both of these targets 
have previously been assessed by Lei and colleagues, who demonstrated that neither 
molecule was capable of stimulating the production of a functional, opsonophagocytic 
antibody following subcutaneous vaccination (Lei et al., 2004). While this suggests that these 
antigens would be unlikely to provide protection against iGAS infection if administered in 
isolation, this does not discount their usefulness as part of a multivalent formulation. 
 
While initially, the putative secreted protein SibA (Spy_0019) and the putative pullulanase 
PulA (Spy_1972) were investigated by all three studies, these molecules failed to induce 
protection during the subsequent high throughput murine vaccination models employed by 
the other authors (Bensi et al., 2012, Fritzer et al., 2010). In the current study, PulA was 
selected for inclusion in the multi component vaccine, while SibA was excluded as a result of 
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its absence from >90% of the non M1 immunoprecipitates (Figure 4.1B). The in silico 
analysis performed in the other major studies indicates that sibA is highly conserved amongst 
the different GAS serotypes, suggesting that it is expression of the molecule that varies 
between the different GAS serotypes rather than the presence of sibA within the streptococcal 
metagenome (Fritzer et al., 2010, Bensi et al., 2012).  
 
The only protein flagged as a promising target in all three studies was the putative surface 
exclusion protein PrgA (Spy_0269) which now forms part of the patented Novartis Combo 
vaccination (Figure 4.1B). Very recently PrgA been shown to facilitate primary GAS 
colonisation of the skin and oropharynx (Gallotta et al., 2014). Therefore in addition to 
meeting all of the selection criteria laid out in this study, and the two major high throughput 
studies outlined above, PrgA (now denoted the Streptococcus pyogenes Adhesion and 
Division protein; or SpyAD) represents a novel extracellular virulence factor, and thus may 
have been trialled in isolation had the molecule been characterised prior to the advent of 
reverse vaccinology. This further suggests that the novel antigens identified in each of these 
high throughput studies represent promising vaccine candidates. 
 
The other antigen flagged as a promising target in more than one study was the previously 
characterised cell envelope protease SpyCEP (Spy_0416). While the protective effects of 
SpyCEP are well documented (both in isolation and as part of the Combo vaccine) the 
molecule was excluded from this study as it was only recovered from of two of the five M12 
isolates selected for study (Figure 4.1B). SpyCEP has previously been shown to mediate 
GAS invasion of the soft tissues, and it was noted that the molecule was produced by two of 
the three invasive M12 isolates (H529 and H530) but not by the two M12 isolates recovered 
from uncomplicated pharyngitis cases (49 and 67). Similarly the molecule was only absent 
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from one of the M89 isolates examined (98); which was recovered from a case of 
uncomplicated tonsillitis. SpyCEP expression is known to be repressed in non-invasive 
isolates, and this repression is most pronounced during the logarithmic phase of growth 
(Turner et al., 2009a). It is therefore likely that the absence of SpyCEP from the non-invasive 
immunoprecipitates is a result of the starting CWE being purified once the growing culture 
had reached the logarithmic phase of growth. 
 
The third and final antigen to be included in the Combo preparation was the hemolytic 
exotoxin streptolysin O (Spy_0167). This protein was excluded by Fritzer and colleagues as 
streptolysin O has long been known to stimulate a strong humoral immune response, and 
anti-SLO antibody titres (ASO titres) are routinely used as an indicator of recent GAS 
infection (Edwards, 1964). The molecule was excluded from the present study based upon a 
lack of consistent production by the M89 group, with only three of the five isolates selected 
for study testing positive for the molecule. In addition, the inherent toxicity of streptolysin O 
requires that the molecule be detoxified prior to inclusion in any human vaccine formulation 
(Chiarot et al., 2013, Alouf, 1980). Indeed, immediately after publication of the in vivo 
efficacy of Combo, Chiarot and colleagues (under the employ of Novartis R&D) published a 
non-cytotoxic streptolysin O preparation that was capable of conferring constant protection 
against iGAS infection in a murine model (Chiarot et al., 2013). Therefore while native 
streptolysin O was used by Bensi and colleagues during the preliminary in vivo vaccination 
experiments, it is likely that the detoxified derivative develop by Novartis R and D will form 
the basis of the combo vaccination going forward into human trials.  
 
While Combo represents an important step towards an effective, serotype independent GAS 
vaccination, the level of protection afforded against certain serotypes still does not approach 
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that afforded by vaccination with the corresponding M protein isoform (Bensi et al., 2012). 
However, it has been noted that the inclusion of further conserved antigens within the 
preparation would likely improve the protective efficacy of the formulation (Moreland et al., 
2014). Interestingly, the authors chose to exclude a fourth protein (C5a peptidase) which, like 
the three components of Combo, was identified by all three technologies and is known to 
provide protection against murine GAS infection (Ji et al., 1997, Bensi et al., 2012). C5a 
peptidase was excluded on the grounds that it had already been partially characterised. 
However, it is widely accepted that a combination of protein antigens will prove more 
efficacious than any single component would in isolation (Homma et al., 1978, Guss et al., 
2009, Olive et al., 2007, Serruto et al., 2012). Therefore the decision to exclude a promising 
target on the ground that it has previously been evaluated may have been ill advised, and the 
inclusion of C5a peptidase within the Combo preparation may have increased the efficacy of 
the preparation against certain serotypes. 
 
In contrast, the current study has taken a more inclusive approach to vaccine candidate 
identification. Indeed, all of the proteins that met the outlined inclusion criteria were 
investigated, regardless of their previous level of characterisation, with a view to including all 
in a multivalent humoral-derived exoprotein vaccination (HumEV). HumEV is currently 
undergoing assessment in two murine vaccination models designed to mimic either 
superficial nasopharyngeal infection or invasive intramuscular disease (Alam et al., 2013, 
Turner et al., 2009b).  
 
It is interesting to note that neither Combo nor the nine protective antigens identified by 
Fritzer and colleagues have been assessed in an animal model of non-lethal nasopharyngeal 
carriage. Thus while these antigens have a proven efficacy against iGAS infection, their 
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ability to prevent or limit uncomplicated GAS pharyngitis has not yet been established. 
Although the prevention of streptococcal pharyngitis is of secondary importance to the 
prevention of iGAS disease, there is a significant economic cost associated with such self-
limiting infection. Furthermore, many of the most serious streptococcal disease 
manifestations often stem from such occult infections; suggesting that prevention of 
streptococcal pharyngitis may lead to a subsequent decrease in the incidence of iGAS disease. 
With this in mind, the efficacy of HumEV against superficial GAS infections is being 
investigated alongside the formulations ability to provide in vivo protection against iGAS 
disease. 
 
If HumEV indeed shows promise as an anti-GAS vaccination, the described 
immunoprecipitation approach may also be applicable to other gram positive pathogens most 
notably Staphylococcus aureus, which is subject to many of the same humoral clearance 
mechanisms as GAS. Indeed, IVIG has previously been shown to enhanced neutrophil 
mediated killing of S. aureus in a murine model and it has been suggested that the reagent 
may also serve as an adjunct treatment for severe staphylococcal infections (Farag et al., 
2013). In addition, preliminary data collected towards the end of the current study suggests 
that IVIG may be capable of promoting opsonophagocytic uptake of FITC coated S. aureus 
cells by purified human neutrophils (data not shown). E-IVIG immunoprecipitation could 
therefore be utilised for the purification of novel staphylococcal surface antigens that may 
form the basis of an effective, wide ranging vaccination. In light of the continued rise in the 
rates of multi drug resistance amongst nosocomial S. aureus isolates, an effective anti-
staphylococcal vaccination would prove invaluable.  
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In addition to the lack of specialist equipment and training required to purify vaccine 
candidate antigens by E-IVIG immunoprecipitation, one of the major benefits of the 
technique is the reduction in animal numbers that it affords during the rational selection of 
promising targets. In the preliminary murine vaccination experiments Bensi and colleagues 
utilised 80 murine groups of indeterminate size to test the efficacy of the 40 preliminary 
antigens identified in vitro. These high throughput experiments resulted in the identification 
of six protective antigens three of which were subsequently utilised in the Combo preparation 
(Bensi et al., 2012). Similarly, Fritzer and colleagues utilised several different animal models; 
encompassing three GAS serotypes, two immunisation sites, two challenge routes and three 
mouse strains to test the efficacy of the 32 preliminary antigens identified from the 
streptococcal antigenome (Fritzer et al., 2010). From these experiments the authors identified 
nine novel antigens that provided consistent protection against iGAS infection.  
 
In contrast, the current methodology resulted in the identification of eight potential vaccine 
candidate antigens without the need for high throughput murine screening. While the efficacy 
of these targets has not been assessed in isolation, the recent shift towards the investigation of 
multivalent vaccine preparations suggests that the evaluation of individual targets in vivo may 
be an expensive and unnecessary undertaking. Coupled with the obvious ethical implications 
of employing such large scale in vivo assays, this highlights the need for alternative high 
throughput screening methods that allow the rational development of multivalent vaccine 
formulations without the use of large animal numbers. If HumEV proves to be efficacious, 
any subsequent vaccine developed using the E-IVIG immunoprecipitation method could be 
characterised to near completion before the use of animal protection studies is required. 
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In conclusion the E-IVIG immunoprecipitation protocol developed during the course of this 
study is an effective means of isolating the IVIG-reactive antigens present on the 
streptococcal cell surface. Working from the hypothesis that the antigens recognised by IVIG 
may form the basis of an effective anti-GAS vaccination, seven of these proteins have been 
combined to form a novel, multivalent vaccine formulation (HumEV). It is anticipated that 
administration of HumEV will reduce the duration of nasopharyngeal infection and inhibit 
systemic GAS dissemination from an invasive focus of infection in a murine model. 
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5: Supplementary material 
Table S1: Identification of highly conserved IVIG-reactive antigens by immunoblotting and proteomic analysis. 
 
 111 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity R R R R R R NR R R R NR R R R NR R NR R NR R 
60 kDa chaperonin 
   
4 15 
 
27 18 25 21 26 12 21 23 14 
 
7 
   
C5a peptidase 8 8 15 4 5 18 
 
32 17 
    
3 
  
9 10 
  
Chaperone protein DnaK 17 31 24 24 26 22 25 34 39 28 5 28 16 31 13 8 16 8 3 9 
DNA polymerase III polC-type 
   
2 2 
               
DNA-directed RNA polymerase subunit 
beta 
13 20 14 28 36 
 
21 
 
8 
 
38 23 35 
 
17 30 22 21 12 8 
DNA-directed RNA polymerase subunit 
beta' 
15 20 16 24 32 5 13 
 
4 
 
35 18 28 
 
16 28 24 21 14 7 
Elongation factor G 7 15 11 24 32 
 
18 
 
24 7 11 14 8 10 13 9 10 18 3 8 
Elongation factor Ts 30 6 
 
11 
 
11 7 13 11 14 
 
8 
 
8 8 
     
Elongation factor Tu 13 28 19 38 38 8 20 
 
33 7 14 27 17 22 6 19 24 16 14 17 
Enolase 
 
6 
  
6 11 11 11 16 12 
   
18 11 
     
Fibronectin-binding protein 
  
4 7 7 
               
Glyceraldehyde-3-phosphate 
dehydrogenase 
17 16 13 10 12 
 
16 12 21 19 13 17 13 12 15 8 8 
  
15 
Lactocepin 1 
               
8 11 
  
Leucyl-tRNA synthetase 
      
3 
 
5 
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Table S1 (Continued) 
 
 111 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity R R R R R R NR R R R NR R R R NR R NR R NR R 
Lysyl aminopeptidase/alanine 
aminopeptidase       
6 4 13 3 
   
3 
      
M protein type 1 
 
15 
 
11 13 
               
Phosphoenolpyruvate-protein 
phosphotransferase       
5 4 8 
           
Phosphoglycerate kinase  31 28 16 22 18 23 23 24 28 28 
 
7 
 
11 
      
Pilin 
 
15 8 23 9 
               
Putative transketolase 
   
5 5 
   
9 
    
4 
      
Pyruvate kinase 8 18 8 13 15 
 
16 6 12 
 
9 18 9 6 8 9 
 
5 
 
8 
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Table S1 (Continued) 
 
 71 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity R R NR R R NR NR NR R NR NR R NR NR NR R R R R R 
60 kDa chaperonin         7 5 11   7 9 11      N/A 
Alanyl-tRNA synthetase             3 9          N/A  
ATP-dependent clp protease ATP-
binding subunit 
6 7  8 13    3   10 9 4    7 4 20 19  N/A  
Cell division protein 12 18 14 25 20  7  18   14 9 13 12 5 10 5 16 11  N/A  
Chaperone protein DnaK 20 25 27 29 29 25 29 32 32 35 16 28 28 35 23 3 12 21 14  N/A 
Cysteine synthase       9  22 19 6            N/A  
Elongation factor G 49 52 59 53 59 38 56 37 56 41 56 57 59 51 60 57 43 53 56  N/A  
Elongation factor Ts         10 12     7         N/A  
Elongation factor Tu 19 20 15 23 20  22  20   23 19 18 23   11 10 23 23  N/A 
Formate acetyltransferase 22 16 18 21 26 5 22 27 25 31 20 36 37 17 24 26 14 27 25  N/A  
Fructose-bisphosphate aldolase         7  7    10        N/A  
Glyceraldehyde-3-phosphate 
dehydrogenase 
22 24 17 17 22 8 22 21 32 15  25 19 23 15 8  17 11  N/A  
Phosphoenolpyruvate-protein 
phosphotransferase 
       4 9 14              N/A 
Phosphoglycerate kinase 8        16 13 8    10        N/A  
Phosphorylase 4 12 12 12 17 10 18 27 20 27 11 14 18 13 15 5 2 13 12  N/A  
Putative endopeptidase O 5      4  9 5 4   5 5        N/A  
Putative transketolase  7 4 4 6   14 9 20  5 3 11     3 3  N/A  
Pyruvate kinase     4        6          N/A  
Xaa-Pro dipeptidyl-peptidase         3           3 3             4  N/A  
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Table S1 (Continued) 
 
 65 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity NR R R R R R NR R R NR R R R R NR R R R R R 
60 kDa chaperonin 65 61 53 59 62 61 69 59 63 60 35 34 41 34 41 26 19 27 20 28 
67 kDa Myosin-crossreactive 
streptococcal antigen 
20 24 10 18 16 9 14 7 23 22             
ABC transporter ATP-binding protein 4   7 6    7 17             
Arginyl-tRNA synthetase 46 43 45 43 51 9 34 16 54 14  8           
Aspartyl-tRNA synthetase 7 9 4 6 7  7  8             8 
Cell division protein 7   10 21    5               
Chaperone protein DnaK 8  10 7 5 3 5 14 12 12 22 44 46 41 30 40 17 27 30 13 
CTP synthase 13 16 14 15 22    7               
Dextran glucosidase     5     4             
Dihydrolipoamide dehydrogenase             16 22 19  6 11 4 12    
Elongation factor 4             4      4      
Elongation factor G 11 6 8  11    3   14 8 14    3  6    
Elongation factor Ts         8 8 8    8         
Elongation factor Tu 27 18 10 23 31  17  15   5 11  10     9 9 9 
Enolase     14 6  6  13   10          
Formate acetyltransferase             10 9 8 4 8 9 3 9 10 4 
Fructose-bisphosphate aldolase       9    7  10 12 14 9       
Glucosamine--fructose-6-phosphate 
aminotransferase 
            3        3 3 5 
Glyceraldehyde-3-phosphate 
dehydrogenase 
  13  11  13 11 15 8  13 8 7 8 10  11 15 11 
GTP-binding protein              10 3     5  3 7   
Methionyl-tRNA synthetase     4    6               
NADP-dependent glyceraldehyde-3-
phosphate dehydrogenase 
        4  5             
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Table S1 (Continued) 
 
 65 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity NR R R R R R NR R R NR R R R R NR R R R R R 
Oligopeptide-binding protein              25 13 8   4  11    
Peptide chain release factor 3 11 8  13 16                   
Phosphoenolpyruvate-protein 
phosphotransferase 
 3 4 4     18 6 17 17 20 23 18 30 38 34 35 29 35 
Phosphoglucomutase/phosphomannomut
ase 
55 50 59 55 58 48 39 54 53 53  12 3 6 5   5    
Phosphoglycerate kinase   6    6  5  6    9         
Prolyl-tRNA synthetase             26 38 40 12 6 37 14 32 37   
Protein translocase subunit SecA                      3 5   
Putative endopeptidase O         8  7 20 11 15 34 23 32 19 34 27 12 
Putative ribosomal protein S1-like DNA-
binding protein 
5   14 15               5    
Pyruvate kinase 14 14 16 13 12  16  10   4 17 13  6 6 4 16 7   
Trigger factor    6 6                   
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Table S1 (Continued) 
 
 55 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity NR R R R R R NR R R R R R R R R R R R R R 
3-oxoacyl-[acyl-carrier-protein] synthase 
2 
   6 11    6    6     11 6   6 
4-alpha-glucanotransferase                     4 4   
60 kDa chaperonin 15 32 24 25 28 8 34 36 25 18 4 18 30 23 20 6 13 30 15 9 
ABC transporter ATP-binding protein 33 37 28 29 29 22 32 40 37 35 12 24 29 23 28 22 21 33 35 19 
Arginine deiminase        9 14     6  12         
Arginyl-tRNA synthetase  4 4       7           6    
Cell division protein    5 5    9               
Chaperone protein DnaK  5 5 9 5 3 5 9 17 8 14  12 3 13 3 3  3 3 3 
Cysteinyl-tRNA synthetase           13           9 
D-alanine--poly(phosphoribitol) ligase 
subunit 1  
21 17 29 27 33 16 22 30 21 23 20 28 31 24 29 29 23 29 20 24 
Dihydrolipoamide dehydrogenase 6 6 7 9 15 7 8 3 9 10 9 14 12  5 12 9 15 14 10 
Elongation factor G  3 12 15 24 24 9 9 4 26 14 6 28 13 10 13 20 8 15 16 24 
Elongation factor Ts       9 14 10 10 7  6 7 10 10       
Elongation factor Tu 28 36 15 33 18 8 19 8 32   20 23 18 14 7 17 34 34 17 27 
Enolase  25 15 20 25 15 15 24 23 23 8 15 24 22 29 22 18 19 15 17 
Formate--tetrahydrofolate ligase 1              5 9    4   4   
Formate--tetrahydrofolate ligase 2         5    3 12 11 11 7       
Fructose-bisphosphate aldolase         7       7         
Glutamyl-tRNA synthetase 10 21 10 25 30  20  18   18 28 28  14 30 10 29 27 10 
Glyceraldehyde-3-phosphate 
dehydrogenase 
6 11 19 17 15 6 15 19 15 22 7 15 19 15 17 19 13 15 15 19 
GMP synthase [glutamine-hydrolyzing] 34 39 43 36 40 41 45 45 42 41 38 38 45 45 44 31 37 39 44 33 
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Table S1 (Continued):  The proteins present within the gel slices excised in Figure 3.8A were identif ied by proteomic analysis using 
the SEQUEST algorithm and an M1-GAS reference proteome. The identif ied proteins were tabulated with numbers representing the 
percentage of the protein sequence covered by the identif ied peptides.  
 
 55 kDa region 
M type   M1     M3     M12     M89   
Strain H305 H364 H366 H656 H791 H330 H387 H413 H471 H672 49 67 H529 H530 H599 98 H293 H395 H409 H411 
Reactivity NR R R R R R NR R R R R R R R R R R R R R 
Inosine-5'-monophosphate 
dehydrogenase 
17 23 27 27 29  8  12   30 22 35  18 31 18 38 27 5 
Lysyl-tRNA synthetase 11 9  17 14    13    8     15 10 17 14   
NADP-dependent glyceraldehyde-3-
phosphate dehydrogenase 
9 11 15 12 17 10 14 19 14 27 10 25 30 11 18 11 7 12 5 21 
Nicotinate phosphoribosyltransferase 17 31 30 29 29  19  12   16 23 18 13 15 25 16 29 22 23 
Peroxiredoxin reductase (NAD(P)H) 26 22 34 31 28 6 26 10 10   19 27 32 13 25 21 17 24 16 26 
Phosphocarrier protein HPr        24   28    26         
Phosphoenolpyruvate-protein 
phosphotransferase 
             9  4         
Phosphoglucomutase/phosphomannomut
ase 
 4       21 9               
Phosphoglycerate kinase   5    11 16 16 9 21    10         
Putative 42 kDa protein   11    6  12 11 9 5  12 11 12 11 5  6   
Putative dipeptidase    6    8 10 12 10    3     6  6 
Putative phosphomannomutase  6 16 10 12 32 28 47 36 26 16 27 31 42 23 18 16 20 16 15 
Putative ribosomal protein S1-like DNA-
binding protein 
7 7  15 15  11     9      19 9 16 7   
Putative succinic semialdehyde 
dehydrogenase 
10 5 10 12 4 5 13  5 11 17 20 20 11 13       
Pyruvate kinase 47 49 55 50 55 24 51 36 39 23 56 57 55 38 46 51 46 52 49 46 
Streptolysin O         13 25      5         
Trigger factor 34 41 43 43 45 14 45 10 47 36 14  33 35 20 23 31 31 23 33 
tRNA modification GTPase MnmE                      6 8 
Zn-dependent hydrolase                               7   4     
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Figure S1: The proteins present ubiquitously throughout gel slices excised in 
Figure 3.8. The proteins present within the gel slices excised in Figure 3.8A were 
identif ied by proteomic analysis using the SEQUEST algorithm and an M1 -GAS 
reference proteome. Proteins that were present in the regions of conserved reactivity 
(but also found ubiquitously throughout the gel matrix) were tabulated with numbers 
representing the percentage of the protein sequence covered by the identif ied 
peptides. Coverage levels are scaled from highest to lowest using progressively lighter 
shades of grey, indicating >66 % (darkest), >33 %, >10 % and <10 %.  
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ABC transporter ATP-binding protein 
 
Insert         MGHHHHHHHHHHSSGHIDDDDKHMLEDPLLTVSDVSLRFSDRKLFDDVNIKFTAGNTYGL 60 
ABC            ----------------------------MLTVSDVSLRFSDRKLFDDVNIKFTAGNTYGL 32 
                                           :******************************* 
 
Insert         IGANGAGKSTFLKILAGDIEPSTGHISLGPDERLSVLRQNHFDYEEERAIDVVIMGNEQL 120 
ABC            IGANGAGKSTFLKILAGDIEPSTGHISLGPDERLSVLRQNHFDYEEERAIDVVIMGNEQL 92 
               ************************************************************ 
 
Insert         DNIMKEKDAIYMKADFSEEDGVRAAELEGIFAELGGWEAESEASQLX------------- 167 
ABC            YNIMKEKDAIYMKADFSEEDGVRAAELEGIFAELGGWEAESEASQLLQNLNIPEDLHYQN 152 
               :*********************************************               
 
NADP-dependent glyceraldehyde-3-phosphate dehydrogenase 
 
Insert         MGHHHHHHHHHHSSGHIDDDDKHMLEDPLAKQYKNLVNGEWKLSENEITIYAPATGEELG 60 
N-GAPDH        ----------------------------MAKQYKNLVNGEWKLSENEITIYAPATGEELG 32 
                                           :******************************* 
 
Insert        SVPAMTQAEVDAVYASAKKALSDWRALSYVERAAYLHKAADILVRDAEKIGAILSKEVAK 120 
N-GAPDH       SVPAMTQAEVDAVYASAKKALSDWRALSYVERAAYLHKAADILVRDAEKIGAILSKEVAK 92 
              ************************************************************ 
 
Insert        GHKAAVSEVIRTAEIINYAAEEGLRMEGEVLEGGSFEAASKKKIAIVRREPVGLVLAISP 180 
N-GAPDH       GHKAAVSEVIRTAEIINYAAEEGLRMEGEVLEGGSFEAASKKKIAIVRREPVGLVLAISP 152 
              ************************************************************ 
 
GMP-Synthase 
 
Insert        SGHIDDDDKHMLEDPMTEISILNDVQKIIVLDYGSQYNQLIARRIREFGVFSELKSHKIT 60 
GMPS          ---------------MTEISILNDVQKIIVLDYGSQYNQLIARRIREFGVFSELKSHKIT 45 
                             ********************************************* 
 
Insert        AQELREINPIGIVLSGGPNSVYADNAFGIDPEIFELGIPILGICYGMQLITHKLGGKVVP 120 
GMPS          AQELREINPIGIVLSGGPNSVYADNAFGIDPEIFELGIPILGICYGMQLITHKLGGKVVP 105 
              ************************************************************ 
 
Insert        AGQAGNREYGQSTLHLRETSKLFSGTPQEQLVLMSHGDAVTEIPD--------------- 165 
GMPS          AGQAGNREYGQSTLHLRETSKLFSGTPQEQLVLMSHGDAVTEIPEGFHLVGDSNDCPYAA 165 
              ********************************************:                
 
D-alanine--poly (phosphoribitol) ligase subunit 1  
 
Insert        HHHHHHHHHHSSGHIDDDDKHMLEDPMSKFNRIHLVVLDSVGIGAAPDADKFFNAGVADT 60 
PPM           --------------------------MSKFNRIHLVVLDSVGIGAAPDADKFFNAGVADT 34 
                                        ********************************** 
 
Insert        DSDTLGHISEAAGLSVPNMAKIGLGNISRPIPLKTVPTEDNPTGYVTKLEEVSLGKDTMT 120 
PPM           DSDTLGHISEAAGLSVPNMAKIGLGNISRPIPLKTVPTEDNPTGYVTKLEEVSLGKDTMT 94 
              ************************************************************ 
 
Insert        GHWEIMGLNITEPFDTFWNGFPEEILTKIEEFSGRKIIREANKP---------------- 164 
PPM           GHWEIMGLNITEPFDTFWNGFPEEILTKIEEFSGRKIIREANKPYSGTAVIDDFGPRQME 154 
              ********************************************                 
 
Figure S2: Automated fluorescent sequencing and analysis of the cloned target genes.  
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ATP-dependent clp protease ATP-binding subunit (H305) 
 
Insert_H305   HHHHHHHHHHSSGHIDDDDKHMLEDPMLCQNCNLNESTIHLYTSVNGKQRQVDLCQNCYQ 60 
ClpE          --------------------------MLCQNCNLNESTIHLYTSVNGKQRQVDLCQNCYQ 34 
                                        ********************************** 
 
Insert_H305   IMKSDPANSILNGLTPGYRAQDRSTSPFFDDFFGDLNNFRAFGNLPNTPPTQAGQNGNGG 120 
ClpE          IMKSDPANSILNGLTPGYRAQDRSTSPFFDDFFGDLNNFRAFGNLPNTPPTQAGQNGNGG 94 
              ************************************************************ 
 
Insert_H305   GRYGGNYNGQRPAQPQTPNQQAKGLLEEFGINVTDIARNGNIDPVIGRDEEITRV----- 175 
ClpE          GRYGGNYNGQRPAQPQTPNQQAKGLLEEFGINVTDIARNGNIDPVIGRDEEITRVIEILN 154 
              *******************************************************      
 
 
ATP-dependent clp protease ATP-binding subunit (H366) 
 
Insert_H366   MGHHHHHHHHHHSSGHIDDDDKHMLEDPMLCQNCNLNESTIHLYTSVNGKQRQVDLCQNC 60 
ClpE          ----------------------------MLCQNCNLNESTIHLYTSVNGKQRQVDLCQNC 32 
                                          ******************************** 
 
Insert_H366   YQIMKSDPANSILNGLTPGYRAQDRSTSPFFDDFFGDLNNFRAFGNLPNTPPTQAGQNGN 120 
ClpE          YQIMKSDPANSILNGLTPGYRAQDRSTSPFFDDFFGDLNNFRAFGNLPNTPPTQAGQNGN 92 
              ************************************************************ 
 
Insert_H366   GGGRYGGNYNGQRPAQPQTPNQQAKGLLEEFGINVTDIARNGNIDPVIGRDEEITRVIEI 180 
ClpE          GGGRYGGNYNGQRPAQPQTPNQQAKGLLEEFGINVTDIARNGNIDPVIGRDEEITRVIEI 152 
              ************************************************************ 
 
Figure S2 (Continued):  Following successful integration of the target genes into pET-
19b and transformation into Top10 cells, the identity and frame of each insert was 
confirmed by automated fluorescent sequencing of the construct and alignment with the 
target protein sequence using ClustalW. 
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ScpA-F Alignment 
 
ScpA          GKLFALAPKALYETSWQKITIPANSSKQVTIPIDVSQFSKDLLAPMKNGYFLEGFVRFKQ 632 
ScpA_F        GKLFALAPKALYETSWQKITIPANSSKQVTIPIDVSQFSKDLLAPMKNGYFLEGFVRFKQ 660 
              ************************************************************ 
 
ScpA          DPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYAL 692 
ScpA_F        DPTKEELMSIPYIGFRGDFGNLSAL-KPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYAL 719 
              ************************* ********************************** 
                                       ↑ 
                                Mutated amino acid 
 
Figure S3: Automated fluorescent sequencing and analysis of the mutated ScpA 
(ScpA-F) sequence. Following transformation of the amplif ied pET-19b (ScpA-F) plasmid 
into XL-10 gold cells, the presence of the highlighted premature stop codon was 
confirmed by automated fluorescent sequencing of the construct and alignment with the 
target protein sequence using ClustalW. 
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